U.S. patent application number 11/491440 was filed with the patent office on 2007-02-22 for rnai modulation of the rho-a gene in research models.
Invention is credited to Stephane Budel, Anke Geick, Juergen Soutschek, Pamela Tan.
Application Number | 20070044161 11/491440 |
Document ID | / |
Family ID | 37683845 |
Filed Date | 2007-02-22 |
United States Patent
Application |
20070044161 |
Kind Code |
A1 |
Soutschek; Juergen ; et
al. |
February 22, 2007 |
RNAi modulation of the Rho-A gene in research models
Abstract
The invention relates to compositions and methods for modulating
the expression of the RhoA gene, and more particularly to the
downregulation of RhoA by chemically modified oligonucleotides.
Inventors: |
Soutschek; Juergen;
(Kasendorf, DE) ; Tan; Pamela; (Kulmbach, DE)
; Geick; Anke; (Bayreuth, DE) ; Budel;
Stephane; (New Haven, CT) |
Correspondence
Address: |
FISH & RICHARDSON PC
P.O. BOX 1022
MINNEAPOLIS
MN
55440-1022
US
|
Family ID: |
37683845 |
Appl. No.: |
11/491440 |
Filed: |
July 21, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60701470 |
Jul 21, 2005 |
|
|
|
60726838 |
Oct 14, 2005 |
|
|
|
60748316 |
Dec 7, 2005 |
|
|
|
Current U.S.
Class: |
800/3 ;
514/44A |
Current CPC
Class: |
A61P 9/10 20180101; A61P
9/00 20180101; A61P 35/04 20180101; C12N 2310/3521 20130101; A61P
43/00 20180101; A61P 25/00 20180101; A61P 21/00 20180101; C12N
15/113 20130101; A61P 35/00 20180101; C12N 2310/321 20130101; C12N
2310/321 20130101; C12N 2310/3515 20130101; C12N 2310/315 20130101;
A61P 25/18 20180101; A61P 25/28 20180101; C12N 2310/14 20130101;
C12N 2310/346 20130101 |
Class at
Publication: |
800/003 ;
514/044 |
International
Class: |
A01K 67/027 20070101
A01K067/027; A61K 48/00 20070101 A61K048/00 |
Claims
1. A method of stimulating neuronal cell outgrowth in a neural cell
culture comprising contacting the neural cell culture with an iRNA
agent, wherein the iRNA agent comprises (i) a sense strand, wherein
the sense strand comprises at least 15 contiguous nucleotides that
differ by no more than 1, 2, or 3 nucleotides from the sense strand
sequences of any one agent selected from the group consisting of
agents number 5850 to 6177, and (ii) an antisense strand, wherein
the antisense strand comprises at least 15 contiguous nucleotides
that differ by no more than 1, 2, or 3 nucleotides from the
antisense sequences of any one agent selected from the group
consisting of agents number 5850 to 6177.
2. A method of performing an animal study comprising: (a) providing
an animal having a neural disfunction; (b) administering an iRNA
agent wherein the iRNA agent comprises (i) a sense strand, wherein
the sense strand comprises at least 15 contiguous nucleotides that
differ by no more than 1, 2, or 3 nucleotides from the sense strand
sequences of any one agent selected from the group consisting of
agents number 5850 to 6177, and (ii) an antisense strand, wherein
the antisense strand comprises at least 15 contiguous nucleotides
that differ by no more than 1, 2, or 3 nucleotides from the
antisense sequences of any one agent selected from the group
consisting of agents number 5850 to 6177; and (c) monitoring the
animal for an improvement in neural function.
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application No. 60/701,470, filed Jul. 21, 2005, U.S. Provisional
Application No. 60/726,838, filed Oct. 14, 2005, and U.S.
Provisional Application No. 60/748,316, filed Dec. 7, 2005. The
contents of each of these priority applications are incorporated
herein by reference in their entirety.
TECHNICAL FIELD
[0002] The invention relates to compositions and methods for
modulating the expression of RhoA, and more particularly to the
downregulation of RhoA mRNA and RhoA protein levels by
oligonucleotides via RNA interference, e.g., chemically modified
oligonucleotides.
BACKGROUND
[0003] RNA interference or "RNAi" is a term initially coined by
Fire and co-workers to describe the observation that
double-stranded RNA (dsRNA) can block gene expression when it is
introduced into worms (Fire et al., Nature 391:806-811, 1998).
Short dsRNA directs gene-specific, post-transcriptional silencing
in many organisms, including vertebrates, and has provided a new
tool for studying gene function.
[0004] Numerous myelin-derived axon growth inhibitors have been
characterized (see, for review, David et al., WO995394547, 1999;
Bandman et al. U.S. Pat. No. 5,858,708, 1999; Schwab, Neurochem.
Res. 21:755-761, 1996). Several components of CNS white matter,
NI35, NI250 (Nogo) and Myelin-associated glycoprotein (MAG), which
have inhibitory activity for axonal extension, have been described
as well (Schwab et al., WO9005191, 1990; Schwab et al., U.S. Pat.
No. 5,684,133, 1997). In particular, RhoA is a member of the large
family of Rho (Ras homologue) GTPases, itself belonging to the
superfamily of Ras GTPases. All eukaryotes contain at least one Rho
GTPase. During the process of evolution the number of Rho GTPases
increased from 5 to 6 per organism (yeast) to over 20 (mammals)
(Karnoub, A. E., et al., Breast Cancer Res. Treat. 2004, 84:61).
Like other GTPases, RhoA has intrinsic GTPase activity and shuttles
between an inactive GDP-bound state and an active GTP-bound state.
In vitro, the exchange of GDP to GTP occurs very slowly, and is
catalyzed by guanine nucleotide exchange factors (GEFs), which
exchange GDP for GTP. GTPase activating proteins (GAPs) catalyze
hydrolysis of the .gamma.-phosphate of GTP. (Wheeler, A. P.,
Ridley, A. J., Exp. Cell Res. 2004, 301:43). A third set of
regulatory proteins, the guanine nucleotide-dissociation inhibitors
(GDIs), sequester GTPAses in the cytosol in the inactive, GDP-bound
state.
[0005] The N-terminal half of Rho GTPases contains the majority of
the amino acids involved in GTP binding and hydrolysis, together
with the Switch 1 and 2 regions that change conformation between
the GTP-bound and GDP-bound states (Bishop, A. L., Hall, A.,
Biochem. J. 2000, 348 (Pt. 2):241). The C-terminus of Rho family
GTPases is essential for correct localization of the proteins. It
is post-translationally modified by prenylation of a conserved
C-terminal cysteine followed by methylation and proteolytic removal
of the last three amino acids (Shao, F., Dixon, J. E., Adv. Exp.
Med. Biol. 2003, 529:79). The prenyl group anchors the GTPases into
membranes and this modification is essential for cell growth,
transformation, and cytoskeleton organization (Allal, C., et al.,
J. Biol. Chem. 2000, 275:31001). Prenylation of Rho proteins
appears to be important for their stability, inhibitors of enzymes
that synthesize prenyl groups induce a decrease in Rho protein
levels and their function (Stamatakis, K., et al., J. Biol. Chem
2002, 277:49389). In the case of RhoA, prenylation adds a
geranylgeranyl group. RhoA is mainly found in the cytoplasm or at
the plasma membrane (Adamson, P., et al., J. Cell Biol. 1992,
119:617).
[0006] RhoA may bind to the intracellular portion of p75NTR and is
activated by Nogo-R in a p75NTR-dependent manner (Wang, K. C., et
al., Nature 2002, 420:74), which is how MAG, Nogo-66, and
oligodendrocyte-myelin glycoprotein achieve RhoA activation. The
central inhibitory domain of Nogo-A, NiG, distinct from Nogo-66,
and Versican V2, a chondroitin-sulfate proteoglycan and another
component of myelin, are able to activate RhoA in the absence of
p75NTR, by an alternative pathway of RhoA activation remaining to
be elucidated (Schweigreiter, R., et al., Mol. Cell Neurosci. 2004,
27:163). Further pathways of activation may exist.
[0007] RhoA is part of the growth inhibitory machinery present in
the central nervous system (CNS), but not in peripheral nerves,
which prevents the regeneration of CNS tissue after injury. Both
the expression and the activation of RhoA is induced in brain and
spinal cord injury (Mueller, K., et al., Nature Reviews 2005,
4:387). Activation of RhoA leads to neuronal growth cone collapse,
retraction bulb formation and neurite withdrawal. Inactivation of
RhoA leads to neurite outgrowth in primary neurons on otherwise
inhibitory substrates in vitro, and promotes axon regeneration and
functional recovery after spinal cord injury in rats and mice in
vivo (Lehmann, M. A., et al., J. Neurosci. 1999, 19:7537; Hara, M,
et al., J. Neurosurg. 2000, 93:94; Dergham, P., et al., J.
Neurosci. 2002, 22:6570). Furthermore, inactivation of Rho has been
shown to protect endogenous cells of the spinal cord from apoptosis
induced by spinal cord injury (Dubreuil, C. I., et al, J. Cell
Biol. 2003, 162:233). These findings have clinical relevance
because neuroprotective treatments after spinal cord injury lead to
improved functional recovery (Liu, X. Z., et al., J. Neurosci.
1997, 17:5395).
[0008] Evidently, RhoA is a potential target for therapeutic
intervention strategies aimed at diseases and conditions involving,
e.g., the destruction and/or impaired regeneration of cells of the
CNS. The present invention advances the art by providing methods
and medicaments encompassing short dsRNAs leading to the
downregulation of RhoA mRNA and protein levels in cells expressing
the RhoA gene. These methods and medicaments may be used in the
treatment of disorders or pathological processes mediated, at least
in part, by RhoA, e.g., by preventing the RhoA inhibition of axonal
elongation and regeneration, and consequently stimulating nerve
growth and proliferation.
SUMMARY
[0009] The present invention is based, at least in part, on an
investigation of the RhoA gene using iRNA agents and further
testing of the iRNA agents that target the RhoA site. The present
invention provides compositions and methods that are useful in
reducing RhoA mRNA levels, RhoA protein levels and the treatment of
pathological process mediated, at least in part, by RhoA, e.g.
preventing RhoA inhibition of axonal elongation and regeneration,
in a subject, e.g., a mammal, such as a human.
[0010] In one aspect, the invention provides iRNA agents comprising
a sense strand, wherein the sense strand comprises at least 15
contiguous nucleotides that differ by no more than 1, 2, or 3
nucleotides from the sense strand sequences of any one agent
selected from the group consisting of: agents number 6477 to 6836
as given in Table 1 below, and an antisense strand, wherein the
antisense strand comprises at least 15 contiguous nucleotides that
differ by no more than 1, 2, or 3 nucleotides from the antisense
sequences of any one agent selected from the group consisting of:
agents number 6477 to 6836.
[0011] In a further aspect, the invention provides iRNA agents for
inhibiting the expression of a rhoA gene in a cell comprising a
sense strand, wherein the sense strand comprises at least 15
contiguous nucleotides that differ by no more than 1, 2, or 3
nucleotides from the sense strand sequences of any one agent
selected from the group consisting of: agents number 6477 to 6836,
and an antisense strand wherein the antisense strand comprises at
least 15 contiguous nucleotides of the antisense sequences of any
one agent selected from the group consisting of: agents number 6477
to 6836, and wherein the iRNA agent reduces the amount of RhoA MRNA
present in cultured human cells after incubation with these agents
by 40% or more compared to cells which have not been incubated with
the agent.
[0012] In a further aspect, the invention provides iRNA agents for
inhibiting the expression of a rhoA gene in a cell comprising a
sense strand and an antisense strand each comprising a sequence of
at least 16, 17 or 18 nucleotides which is essentially identical to
one of the sequences of any one agent selected from the group
consisting of: agents number 6477 to 6836, except that not more
than 1, 2 or 3 nucleotides per strand, respectively, have been
substituted by other nucleotides (e.g. adenosine replaced by
uracil), while essentially retaining the ability to inhibit RhoA
expression. Preferably, for such agents the sense and/or antisense
strand sequence is chosen from the group consisting of: the sense
and antisense strand sequences of agent numbers 6523, 6524, 6530,
6614, 6650, 6656, 6657, 6661, 6662, 6703, 6712, 6713, 6732, 6751,
6756, 6767, 6769, 6787, 6789, 6790, 6832.
[0013] Evidently, in the above embodiments, the sense strands
and/or antisense strands of the iRNA agents of the invention can
also be identical to the sense strands and antisense strands of the
agents, agent numbers 6477 to 6836.
[0014] The iRNA agents of the invention may comprise a
modification, e.g a modification that causes the iRNA agent to have
increased stability in a biological sample. For example, they may
comprise a phosphorothioate, a 2'-modified nucleotide, a locked
nucleotide, an abasic nucleotide, morpholino nucleotide, a
phosphoramidate, or a non-natural base comprising nucleotide. For
purposes of the above embodiments, an iRNA agent is considered to
comprise one of the sequences of the agents, agent numbers 6477 to
6836, irrespective of the potential presence of nucleotide
modifications, i.e. a 2'-O-methyl guanosine would be considered a
guanosine for such comparison. However, certain patterns of
modifications are particularly preferred embodiments of the present
invention. Consequently, in another embodiment, the invention
provides iRNA agents for inhibiting the expression of a rhoA gene
in a cell wherein the sense and/or antisense strand sequence is
chosen from the group consisting of: the sense and antisense strand
sequences of agent numbers AL-DP-5972, AL-DP-5973, AL-DP-5974,
AL-DP-5975, AL-DP-5976, AL-DP-5978, AL-DP-5979, AL-DP-5981,
AL-DP-5982, AL-DP-5983, AL-DP-5984, AL-DP-5986, AL-DP-5987,
AL-DP-5988, AL-DP-5989, AL-DP-5990, AL-DP-5991, AL-DP-5992,
AL-DP-5993, AL-DP-5994, AL-DP-5995, AL-DP-6176, AL-DP-6 177.
[0015] In the iRNA agents of the present invention, the antisense
RNA strand may be 30 or fewer nucleotides in length, and the duplex
region of the iRNA agent may be 15-30 nucleotide pairs in
length.
[0016] A 2'-modified nucleotide according to the instant invention
may comprise at least one 5'-uridine-adenine-3' (5'-ua-3')
dinucleotide wherein the uridine is a 2'-modified nucleotide; at
least one 5'-uridine-guanine-3' (5'-ug-3') dinucleotide, wherein
the 5'-uridine is a 2'-modified nucleotide; at least one
5'-cytidine-adenine-3' (5'-ca-3') dinucleotide, wherein the
5'-cytidine is a 2'-modified nucleotide; or at least one
5'-uridine-uridine-3' (5'-uu-3') dinucleotide, wherein the
5'-uridine is a 2'-modified nucleotide.
[0017] The iRNA agents of the invention may be designed such
that
[0018] every 5'-nucleotide in 5'-ua-3', 5'-uu-3', 5'-ca-3', and
5'-ug-3' motifs is a 2'-modified in sense strand, and every
5'-nucleotide in 5'-ua-3' and 5'-ca-3' motifs is 2'-modified in
antisense strand, or
[0019] every 5'-nucleotide in 5'-ua-3', 5'-uu-3', 5'-ca-3', and
5'-ug-3' motifs is 2'-modified in the sense and antisense strand,
or
[0020] every pyrimidine nucleotide is 2'-modified in the sense
strand, and every 5'-nucleotide in 5'-ua-3' and 5'-ca-3' motifs is
2'-modified in the antisense strand, or
[0021] every pyrimidine nucleotide is 2'-modified in sense strand,
and every 5'-nucleotide in 5'-ua-3', 5'-uu-3', 5'-ca-3', and
5'-ug-3' motifs is 2'-modified in the antisense strand, or
[0022] every pyrimidine nucleotide in the sense strand is
2'-modified, and no nucleotide is 2'-modified in the antisense
strand.
[0023] The 2'-modification in the iRNA agents of the invention may
be selected from the group consisting of: 2'-deoxy,
2'-deoxy-2'-fluoro, 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE),
2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE),
2'-O-dimethylaminopropyl (2'-O-DMAP),
2'-O-dimethylaminoethyloxyethyl (2'-O-DMAEOE), and
2'-O-N-methylacetamido (2'-O-NMA).
[0024] The iRNA agents of the invention may comprise a nucleotide
overhang having 1 to 4 unpaired nucleotides, preferably 2 or 3
unpaired nucleotides. The nucleotide overhang may be at the 3'-end
of the antisense strand of the iRNA agent. The iRNA agents may
comprise a cholesterol moiety, which is preferably conjugated to
the 3'-end of the sense strand of the iRNA agent. In a preferred
embodiment, the iRNA agent is targeted for uptake by nerve cells or
nerve sheath cells.
[0025] The present invention further provides methods for reducing
the level of RhoA mRNA in a cell. The present methods utilize the
cellular mechanisms involved in RNA interference to selectively
degrade RhoA mRNA in a cell and are comprised of the step of
contacting a cell with one of the iRNA agents of the present
invention. Such methods can be performed directly on a cell or can
be performed on a mammalian subject by administering to a subject
one of the iRNA agents of the present invention. Reduction of RhoA
mRNA in a cell results in a reduction in the amount of RhoA protein
produced, and in an organism, may result in a decrease in RhoA
specific pathological/disease effects, e.g. preventing RhoA
inhibition of axonal elongation and regeneration.
[0026] In another aspect of the invention, a method of treating a
human subject having a pathological process mediated in part by
RhoA is provided, comprising administering an iRNA agent of the
invention, e.g. wherein the iRNA agent comprises a sense strand
wherein the sense strand comprises at least 15 contiguous
nucleotides that differ by no more than 1, 2, or 3 nucleotides from
the sense strand sequences any one of the agents, agent numbers
6477 to 6836, and an antisense strand, wherein the antisense strand
comprises at least 15 contiguous nucleotides that differ by no more
than 1, 2, or 3 nucleotides from the antisense strand sequences of
any one of the agents, agent numbers 6477 to 6836.
[0027] In one embodiment of the above methods of the invention, the
pathological process is the inhibition of nerve growth or
elongation, preferably as a result of nerve injury or damage. In
another preferred embodiment, the iRNA agent is administered in an
amount sufficient to reduce the expression of RhoA in a cell or
tissue of the subject. Preferably, the subject is a human.
[0028] In another aspect, the instant invention provides
pharmaceutical compositions, comprising:
[0029] a.) an iRNA agent of the invention; and
[0030] b.) a pharmaceutically acceptable carrier
[0031] In another embodiment, the invention provides a cell
comprising an iRNA agent of the invention.
[0032] In another embodiment, the invention provides a method for
inhibiting the expression of a RhoA gene in a cell, the method
comprising: [0033] (a) introducing into the cell an iRNA agent of
the invention; and [0034] (b) maintaining the cell produced in step
(a) for a time sufficient to obtain degradation of the mRNA
transcript of the RhoA gene, thereby inhibiting expression of the
RhoA gene in the cell.
[0035] In another embodiment, the invention provides a vector for
inhibiting the expression of a RhoA gene in a cell, said vector
comprising a regulatory sequence operably linked to a nucleotide
sequence that encodes at least one strand of an an iRNA agent of
the invention.
[0036] In another embodiment, the invention provides a cell
comprising the above vector.
[0037] The methods and compositions of the invention, e.g., the
methods and iRNA compositions can be used with any dosage and/or
formulation described herein, as well as with any route of
administration described herein.
[0038] The details of one or more embodiments of the invention are
set forth in the description below. Other features, objects, and
advantages of the invention will be apparent from this description
and from the claims. This application incorporates all cited
references, patents, and patent applications by references in their
entirety for all purposes.
BRIEF DESCRIPTION OF DRAWINGS
[0039] FIG. 1 is a schematic illustrating the synthesis and
structure of cholesterol conjugated RNA strands. The sphere
represents the solid phase (controlled pore glass, CPG).
[0040] FIG. 2 shows the effect of administration of iRNA agents of
the invention, and of a control agent, respectively, to the site of
injury in rats that have undergone partial dissection of the spinal
cord; shown is the improvement in BBB locomotor score from day 10
after spinal cord injury, taking the BBB locomotor score of
individual rats on day 10 as 0.
DETAILED DESCRIPTION
[0041] For ease of exposition the term "nucleotide" or
"ribonucleotide" is sometimes used herein in reference to one or
more monomeric subunits of an RNA agent. It will be understood that
the usage of the term "ribonucleotide" or "nucleotide" herein can,
in the case of a modified RNA or nucleotide surrogate, also refer
to a modified nucleotide, or surrogate replacement moiety, as
further described below, at one or more positions.
[0042] An "RNA agent" as used herein, is an unmodified RNA,
modified RNA, or nucleoside surrogate, each of which is described
herein or is well known in the RNA synthetic art. While numerous
modified RNAs and nucleoside surrogates are described, preferred
examples include those which have greater resistance to nuclease
degradation than do unmodified RNAs. Preferred examples include
those that have a 2' sugar modification, a modification in a single
strand overhang, preferably a 3' single strand overhang, or,
particularly if single stranded, a 5'-modification which includes
one or more phosphate groups or one or more analogs of a phosphate
group.
[0043] An "iRNA agent" (abbreviation for "interfering RNA agent")
as used herein, is an RNA agent, which can downregulate the
expression of a target gene, e.g., RhoA. While not wishing to be
bound by theory, an iRNA agent may act by one or more of a number
of mechanisms, including post-transcriptional cleavage of a target
mRNA sometimes referred to in the art as RNAi, or
pre-transcriptional or pre-translational mechanisms. An iRNA agent
can be a double stranded iRNA agent.
[0044] A "ds iRNA agent" (abbreviation for "double stranded iRNA
agent"), as used herein, is an iRNA agent which includes more than
one, and preferably two, strands in which interstrand hybridization
can form a region of duplex structure. A "strand" herein refers to
a contigouous sequence of nucleotides (including non-naturally
occurring or modified nucleotides). The two or more strands may be,
or each form a part of, separate molecules, or they may be
covalently interconnected, e.g., by a linker, e.g., a
polyethyleneglycol linker, to form one molecule. At least one
strand can include a region which is sufficiently complementary to
a target RNA. Such strand is termed the "antisense strand." A
second strand of the dsRNA agent, which comprises a region
complementary to the antisense strand, is termed the "sense
strand." However, a ds iRNA agent can also be formed from a single
RNA molecule which is at least partly self-complementary, forming,
e.g., a hairpin or panhandle structure, including a duplex region.
In such case, the term "strand" refers to one of the regions of the
RNA molecule that is complementary to another region of the same
RNA molecule.
[0045] Although, in mammalian cells, long ds iRNA agents can induce
the interferon response which is frequently deleterious, short ds
iRNA agents do not trigger the interferon response, at least not to
an extent that is deleterious to the cell and/or host (Manche et
al., Mol. Cell. Biol. 12:5238, 1992; Lee et al., Virology 199:491,
1994; Castelli et al., J. Exp. Med. 186:967, 1997; Zheng et al.,
RNA 10:1934, 2004; Heidel et al., "Lack of interferon response in
animals to naked siRNAs" Nature Biotechn. advance online
publication doi: 10.1038/nbt1038, Nov. 21, 2004). The iRNA agents
of the present invention include molecules which are sufficiently
short that they do not trigger a deleterious non-specific
interferon response in normal mammalian cells. Thus, the
administration of a composition including an iRNA agent (e.g.,
formulated as described herein) to a subject can be used to
decreased expression of the RhoA genes in RhoA expressing cells in
the subject, while circumventing an interferon response. Molecules
that are short enough that they do not trigger a deleterious
interferon response are termed siRNA agents or siRNAs herein.
"siRNA agent" or "siRNA" as used herein, refers to an iRNA agent,
e.g., a ds iRNA agent, that is sufficiently short that it does not
induce a deleterious interferon response in a human cell, e.g., it
has a duplexed region of less than 60 but preferably less than 50,
40, or 30 nucleotide pairs.
[0046] The isolated iRNA agents described herein, including ds iRNA
agents and siRNA agents, can mediate the decreased expression of a
RhoA nucleic acid, e.g., by RNA degradation. For convenience, such
RNA is also referred to herein as the RNA to be silenced. Such a
nucleic acid is also referred to as a target gene. Preferably, the
RNA to be silenced is a gene product of an endogenous RhoA
gene.
[0047] As used herein, the phrase "mediates RNAi" refers to the
ability of an agent to silence, in a sequence specific manner, a
target gene. "Silencing a target gene" means the process whereby a
cell containing and/or expressing a certain product of the target
gene when not in contact with the agent, will contain and/or
express at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, or 90% less of such gene product when
contacted with the agent, as compared to a similar cell which has
not been contacted with the agent. Such product of the target gene
can, for example, be a messenger RNA (mRNA), a protein, or a
regulatory element.
[0048] As used herein, the term "complementary" is used to indicate
a sufficient degree of complementarity such that stable and
specific binding occurs between a compound of the invention and a
target RNA molecule, e.g., a RhoA mRNA. Specific binding requires a
sufficient degree of complementarity to avoid non-specific binding
of the oligomeric compound to non-target sequences under conditions
in which specific binding is desired, i.e., under physiological
conditions in the case of in vivo assays or therapeutic treatment,
or in the case of in vitro assays, under conditions in which the
assays are performed. The non-target sequences typically differ
from the target sequences by at least 4 nucleotides.
[0049] As used herein, an iRNA agent is "sufficiently
complementary" to a target RNA, e.g., a target mRNA (e.g., a target
RhoA mRNA) if the iRNA agent reduces the production of a protein
encoded by the target RNA in a cell. The iRNA agent may also be
"exactly complementary" to the target RNA, e.g., the target RNA and
the iRNA agent anneal, preferably to form a hybrid made exclusively
of Watson-Crick basepairs in the region of exact complementarity. A
"sufficiently complementary" iRNA agent can include an internal
region (e.g., of at least 10 nucleotides) that is exactly
complementary to a target RhoA RNA. Moreover, in some embodiments,
the iRNA agent specifically discriminates a single-nucleotide
difference. In this case, the iRNA agent only mediates RNAi if
exact complementarity is found in the region (e.g., within 7
nucleotides of) the single-nucleotide difference. Preferred iRNA
agents will be based on or consist of or comprise the sense and
antisense sequences provided in Table 1.
[0050] As used herein, "essentially identical" when used referring
to a first nucleotide sequence in comparison to a second nucleotide
sequence means that the first nucleotide sequence is identical to
the second nucleotide sequence except for up to one, two or three
nucleotide substitutions (e.g., adenosine replaced by uracil).
"Essentially retaining the ability to inhibit RhoA expression in
cultured human RhoA expressing cells," as used herein referring to
an iRNA agent not identical to but derived from one of the iRNA
agents of Table 1 by deletion, addition or substitution of
nucleotides, means that the derived iRNA agent possesses an
inhibitory activity not more than 20% (in terms of remaining target
mRNA) different from the inhibitory activity of the iRNA agent of
Table 1 from which it was derived. For example, an iRNA agent
derived from an iRNA agent of Table 1 which lowers the amount of
RhoA mRNA present in cultured human Rho-A expressing cells by 70%
may itself lower the amount of RhoA mRNA present in cultured human
RhoA expressing cells by at least 50% in order to be considered as
essentially retaining the ability to inhibit RhoA expression in
cultured human RhoA expressing cells. Optionally, an iRNA agent of
the invention may lower the amount of RhoA mRNA present in cultured
human RhoA expressing cells by at least 50%, or at least 40%.
[0051] As used herein, a "subject" refers to a mammalian organism
undergoing treatment for a disorder mediated by RhoA protein
expression. The subject can be any mammal, such as a cow, horse,
mouse, rat, dog, pig, goat, or a primate. In the preferred
embodiment, the subject is a human.
[0052] Design and Selection of iRNA Agents
[0053] As used herein, "disorders associated with RhoA expression"
refers to any biological or pathological state that (1) is mediated
in part by the presence of RhoA mRNA and/or protein and (2) whose
outcome can be affected by reducing the level of RhoA mRNA and/or
protein present. Specific disorders associated with RhoA expression
are noted below and are primarily based on the responsibility of
RhoA action in inhibiting axonal elongation and regeneration.
[0054] The present invention is based on the design, synthesis and
generation of iRNA agents that target RhoA and the demonstration of
silencing of a RhoA gene in vitro in cultured cells after
incubation with an iRNA agent, and the resulting RhoA-specific
effect.
[0055] An iRNA agent can be rationally designed based on sequence
information and desired characteristics. For example, an iRNA agent
can be designed according to the relative melting temperature of
the candidate duplex. Generally, the duplex should have a lower
melting temperature at the 5' end of the antisense strand than at
the 3' end of the antisense strand.
[0056] Candidate iRNA agents can also be designed by performing,
for example, a gene walk analysis of the genes that will serve as
the target gene. Overlapping, adjacent, or closely spaced candidate
agents corresponding to all or some of the transcribed region can
be generated and tested. Each of the iRNA agents can be tested and
evaluated for the ability to down regulate the target gene
expression (see below, "Evaluation of Candidate iRNA agents").
[0057] Herein, potential iRNA agents targeting RhoA were designed
using the known sequences of RhoA for human, rat and mouse and
other known RhoA sequences. The target sequences shown in Table 1
hereinabove were selected from those regions of the human RhoA mRNA
sequences that show complete homology with the corresponding
sequences in rat and mouse. Therefore, the siRNA agents, agent
numbers 6477-6836 should show cross reactivity between these three
species. Based on the results provided, the present invention
provides iRNA agents that silence RhoA in cultured human RhoA
expressing cells and in a subject.
[0058] Table 1 provides exemplary iRNA agents targeting RhoA
TABLE-US-00001 TABLE 1 Exemplary iRNA agents for targeting RhoA
mRNA Start duplex sense strand antisense strand pos. SEQ design SEQ
SEQ Agent in ID (over- ID ID number RNA.sup.b NO. target sequence
(5'-3') hang).sup.a NO. sequence (5'-3') NO. sequence (5'-3') 6477
288 1 ccggaagaaacuggugauuguug double 2 ggaagaaacuggugauuguTT 3
acaaucaccaguuucuuccTT 6478 289 4 cggaagaaacuggugauuguugg double 5
gaagaaacuggugauuguuTT 6 aacaaucaccaguuucuucTT 6479 290 7
ggaagaaacuggugauuguuggu double 8 aagaaacuggugauuguugTT 9
caacaaucaccaguuucuuTT 6480 291 10 gaagaaacuggugauuguuggug double 11
agaaacuggugauuguuggTT 12 ccaacaaucaccaguuucuTT 6481 292 13
aagaaacuggugauuguugguga double 14 gaaacuggugauuguugguTT 15
accaacaaucaccaguuucTT 6482 293 16 agaaacuggugauuguuggugau double 17
aaacuggugauuguuggugTT 18 caccaacaaucaccaguuuTT 6483 294 19
gaaacuggugauuguuggugaug double 20 aacuggugauuguuggugaTT 21
ucaccaacaaucaccaguuTT 6484 295 22 aaacuggugauuguuggugaugg double 23
acuggugauuguuggugauTT 24 aucaccaacaaucaccaguTT 6485 296 25
aacuggugauuguuggugaugga double 26 cuggugauuguuggugaugTT 27
caucaccaacaaucaccagTT 6486 297 28 acuggugauuguuggugauggag double 29
uggugauuguuggugauggTT 30 ccaucaccaacaaucaccaTT 6487 298 31
cuggugauuguuggugauggagc double 32 ggugauuguuggugauggaTT 33
uccaucaccaacaaucaccTT 6488 299 34 uggugauuguuggugauggagcc double 35
gugauuguuggugauggagTT 36 cuccaucaccaacaaucacTT 6489 300 37
ggugauuguuggugauggagccu double 38 ugauuguuggugauggagcTT 39
gcuccaucaccaacaaucaTT 6490 326 40 gaaagacaugcuugcucauaguc double 41
aagacaugcuugcucauagTT 42 cuaugagcaagcaugucuuTT 6491 327 43
aaagacaugcuugcucauagucu double 44 agacaugcuugcucauaguTT 45
acuaugagcaagcaugucuTT 6492 328 46 aagacaugcuugcucauagucuu double 47
gacaugcuugcucauagucTT 48 gacuaugagcaagcaugucTT 6493 329 49
agacaugcuugcucauagucuuc double 50 acaugcuugcucauagucuTT SI
agacuaugagcaagcauguTT 6494 330 52 gacaugcuugcucauagucuuca double 53
caugcuugcucauagucuuTT 54 aagacuaugagcaagcaugTT 6495 331 55
acaugcuugcucauagucuucag double 56 augcuugcucauagucuucTT 57
gaagacuaugagcaagcauTT 6496 332 58 caugcuugcucauagucuucagc double 59
ugcuugcucauagucuucaTT 60 ugaagacuaugagcaagcaTT 6497 333 61
augcuugcucauagucuucagca double 62 gcuugcucauagucuucagTT 63
cugaagacuaugagcaagcTT 6498 334 64 ugcuugcucauagucuucagcaa double 65
cuugcucauagucuucagcTT 66 gcugaagacuaugagcaagTT 6499 335 67
gcuugcucauagucuucagcaag double 68 uugcucauagucuucagcaTT 69
ugcugaagacuaugagcaaTT 6500 336 70 cuugcucauagucuucagcaagg double 71
ugcucauagucuucagcaaTT 72 uugcugaagacuaugagcaTT 6501 337 73
uugcucauagucuucagcaagga double 74 gcucauagucuucagcaagTT 75
cuugcugaagacuaugagcTT 6502 338 76 ugcucauagucuucagcaaggac double 77
cucauagucuucagcaaggTT 78 ccuugcugaagacuaugagTT 6503 339 79
gcucauagucuucagcaaggacc double 80 ucauagucuucagcaaggaTT 81
uccuugcugaagacuaugaTT 6504 340 82 cucauagucuucagcaaggacca double 83
cauagucuucagcaaggacTT 84 guccuugcugaagacuaugTT 6505 341 85
ucauagucuucagcaaggaccag double 86 auagucuucagcaaggaccTT 87
gguccuugcugaagacuauTT 6506 342 88 cauagucuucagcaaggaccagu double 89
uagucuucagcaaggaccaTT 90 ugguccuugcugaagacuaTT 6507 343 91
auagucuucagcaaggaccaguu double 92 agucuucagcaaggaccagTT 93
cugguccuugcugaagacuTT 6508 344 94 uagucuucagcaaggaccaguuc double 95
gucuucagcaaggaccaguTT 96 acugguccuugcugaagacTT 6509 345 97
agucuucagcaaggaccaguucc double 98 ucuucagcaaggaccaguuTT 99
aacugguccuugcugaagaTT 6510 346 100 gucuucagcaaggaccaguuccc double
101 cuucagcaaggaccaguucTT 102 gaacugguccuugcugaagTT 6511 347 103
ucuucagcaaggaccaguuccca double 104 uucagcaaggaccaguuccTT 105
ggaacugguccuugcugaaTT 6512 348 106 cuucagcaaggaccaguucccag double
107 ucagcaaggaccaguucccTT 108 gggaacugguccuugcugaTT 6513 349 109
uucagcaaggaccaguucccaga double 110 cagcaaggaccaguucccaTT 111
ugggaacugguccuugcugTT 6514 350 112 ucagcaaggaccaguucccagag double
113 agcaaggaccaguucccagTT 114 cugggaacugguccuugcuTT 6515 351 115
cagcaaggaccaguucccagagg double 116 gcaaggaccaguucccagaTT 117
ucugggaacugguccuugcTT 6516 352 118 agcaaggaccaguucccagaggu double
119 caaggaccaguucccagagTT 120 cucugggaacugguccuugTT 6517 353 121
gcaaggaccaguucccagaggug double 122 aaggaccaguucccagaggTT 123
ccucugggaacugguccuuTT 6518 354 124 caaggaccaguucccagaggugu double
125 aggaccaguucccagagguTT 126 accucugggaacugguccuTT 6519 425 127
gaaagcagguagaguuggcuuug double 128 aagcagguagaguuggcuuTT 129
aagccaacucuaccugcuuTT 6520 426 130 aaagcagguagaguuggcuuugu double
131 agcagguagaguuggcuuuTT 132 aaagccaacucuaccugcuTT 6521 535 133
gacagcccugauaguuuagaaaa double 134 cagcccugauaguuuagaaTT 135
uucuaaacuaucagggcugTT 6522 536 136 acagcccugauaguuuagaaaac double
137 agcccugauaguuuagaaaTT 138 uuucuaaacuaucagggcuTT 6523 537 139
cagcccugauaguuuagaaaaca double 140 gcccugauaguuuagaaaaTT 141
uuuucuaaacuaucagggcTT 6524 538 142 agcccugauaguuuagaaaacau double
143 cccugauaguuuagaaaacTT 144 guuuucuaaacuaucagggTT 6525 539 145
gcccugauaguuuagaaaacauc double 146 ccugauaguuuagaaaacaTT 147
uguuuucuaaacuaucaggTT 6526 540 148 cccugauaguuuagaaaacaucc double
149 cugauaguuuagaaaacauTT 150 auguuuucuaaacuaucagTT 6527 541 151
ccugauaguuuagaaaacauccc double 152 ugauaguuuagaaaacaucTT 153
gauguuuucuaaacuaucaTT 6528 542 154 cugauaguuuagaaaacauccca double
155 gauaguuuagaaaacauccTT 156 ggauguuuucuaaacuaucTT 6529 543 157
ugauaguuuagaaaacaucccag double 158 auaguuuagaaaacaucccTT 159
gggauguuuucuaaacuauTT 6530 544 160 gauaguuuagaaaacaucccaga double
161 uaguuuagaaaacaucccaTT 162 ugggauguuuucuaaacuaTT 6531 545 163
auaguuuagaaaacaucccagaa double 164 aguuuagaaaacaucccagTT 165
cugggauguuuucuaaacuTT 6532 546 166 uaguuuagaaaacaucccagaaa double
167 guuuagaaaacaucccagaTT 168 ucugggauguuuucuaaacTT 6533 547 169
aguuuagaaaacaucccagaaaa double 170 uuuagaaaacaucccagaaTT 171
uucugggauguuuucuaaaTT 6534 548 172 guuuagaaaacaucccagaaaag double
173 uuagaaaacaucccagaaaTT 174 uuucugggauguuuucuaaTT 6535 549 175
uuuagaaaacaucccagaaaagu double 176 uagaaaacaucccagaaaaTT 177
uuuucugggauguuuucuaTT 6536 575 178 ccccagaagucaagcauuucugu double
179 ccagaagucaagcauuucuTT 180 agaaaugcuugacuucuggTT 6537 576 181
cccagaagucaagcauuucuguc double 182 cagaagucaagcauuucugTT 183
cagaaaugcuugacuucugTT 6538 577 184 ccagaagucaagcauuucugucc double
185 agaagucaagcauuucuguTT 186 acagaaaugcuugacuucuTT 6539 578 187
cagaagucaagcauuucuguccc double 188 gaagucaagcauuucugucTT 189
gacagaaaugcuugacuucTT 6540 579 190 agaagucaagcauuucuguccca double
191 aagucaagcauuucuguccTT 192 ggacagaaaugcuugacuuTT 6541 692 193
ugaaaccugaagaaggcagagau double 194 aaaccugaagaaggcagagTT 195
cucugccuucuucagguuuTT 6542 693 196 gaaaccugaagaaggcagagaua double
197 aaccugaagaaggcagagaTT 198 ucucugccuucuucagguuTT 6543 694 199
aaaccugaagaaggcagagauau double 200 accugaagaaggcagagauTT 201
aucucugccuucuucagguTT 6544 695 202 aaccugaagaaggcagagauaug double
203 ccugaagaaggcagagauaTT 204 uaucucugccuucuucaggTT 6545 696 205
accugaagaaggcagagauaugg double 206 cugaagaaggcagagauauTT 207
auaucucugccuucuucagTT 6546 697 208 ccugaagaaggcagagauauggc double
209 ugaagaaggcagagauaugTT 210 cauaucucugccuucuucaTT 6547 698 211
cugaagaaggcagagauauggca double 212 gaagaaggcagagauauggTT 213
ccauaucucugccuucuucTT 6548 699 214 ugaagaaggcagagauauggcaa double
215 aagaaggcagagauauggcTT 216 gccauaucucugccuucuuTT 6549 700 217
gaagaaggcagagauaugycaaa double 218 agaaggcagagauaug9caTT 219
ugccauaucucugccuucuTT 6550 701 220 aagaaggcagagauauggcaaac double
221 gaaggcagagauauggcaaTT 222 uugccauaucucugccuucTT 6551 702 223
agaaggcagagauauggcaaaca double 224 aaggcagagauauggcaaaTT 225
uuugccauaucucugccuuTT 6552 703 226 gaaggcagagauauggcaaacag double
227 aggcagagauauggcaaacTT 228 guuugccauaucucugccuTT 6553 704 229
aaggcagagauauggcaaacagg double 230 ggcagagauauggcaaacaTT 231
uguuugccauaucucugccTT 6554 705 232 aggcagagauauggcaaacagga double
233 gcagagauauggcaaacagTT 234 cuguuugccauaucucugcTT 6555 706 235
ggcagagauauggcaaacaggau double 236 cagagauauggcaaacaggTT 237
ccuguuugccauaucucugTT 6556 707 238 gcagagauauggcaaacaggauu double
239 agagauauggcaaacaggaTT 240 uccuguuugccauaucucuTT
6557 708 241 cagagauauggcaaacaggauug double 242
gagauauggcaaacaggauTT 243 auccuguuugccauaucucTT 6558 709 244
agagauauggcaaacaggauugg double 245 agauauggcaaacaggauuTT 246
aauccuguuugccauaucuTT 6559 710 247 gagauauggcaaacaggauuggc double
248 gauauggcaaacaggauugTT 249 caauccuguuugccauaucTT 6560 711 250
agauauggcaaacaggauuggcg double 251 auauggcaaacaggauuggTT 252
ccaauccuguuugccauauTT 6561 712 253 gauauggcaaacaggauuggcgc double
254 uauggcaaacaggauuggcTT 255 gccaauccuguuugccauaTT 6562 713 256
auauggcaaacaggauuggcgcu double 257 auggcaaacaggauuggcgTT 258
cgccaauccuguuugccauTT 6563 714 259 uauggcaaacaggauuggcgcuu double
260 uggcaaacaggauuggcgcTT 261 gcgccaauccuguuugccaTT 6564 715 262
auggcaaacaggauuggcgcuuu double 263 ggcaaacaggauuggcgcuTT 264
agcgccaauccuguuugccTT 6565 716 265 uggcaaacaggauuggcgcuuuu double
266 gcaaacaggauuggcgcuuTT 267 aagcgccaauccuguuugcTT 6566 717 268
ggcaaacaggauuggcgcuuuug double 269 caaacaggauuggcgcuuuTT 270
aaagcgccaauccuguuugTT 6567 718 271 gcaaacaggauuggcgcuuuugg double
272 aaacaggauuggcgcuuuuTT 273 aaaagcgccaauccuguuuTT 6568 719 274
caaacaggauuggcgcuuuuggg double 275 aacaggauuggcgcuuuugTT 276
caaaagcgccaauccuguuTT 6569 720 277 aaacaggauuggcgcuuuugggu double
278 acaggauuggcgcuuuuggTT 279 ccaaaagcgccaauccuguTT 6570 721 280
aacaggauuggcgcuuuugggua double 281 caggauuggcgcuuuugggTT 282
cccaaaagcgccaauccugTT 6571 722 283 acaggauuggcgcuuuuggguac double
284 aggauuggcgcuuuuggguTT 285 acccaaaagcgccaauccuTT 6572 723 286
caggauuggcgcuuuuggguaca double 287 ggauuggcgcuuuuggguaTT 288
uacccaaaagcgccaauccTT 6573 724 289 aggauuggcgcuuuuggguacau double
290 gauuggcgcuuuuggguacTT 291 guacccaaaagcgccaaucTT 6574 725 292
ggauuggcgcuuuuggguacaug double 293 auuggcgcuuuuggguacaTT 294
uguacccaaaagcgccaauTT 6575 726 295 gauuggcgcuuuuggguacaugg double
296 uuggcgcuuuuggguacauTT 297 auguacccaaaagcgccaaTT 6576 727 298
auuggcgcuuuuggguacaugga double 299 uggcgcuuuuggguacaugTT 300
cauguacccaaaagcgccaTT 6577 728 301 uuggcgcuuuuggguacauggag double
302 ggcgcuuuuggguacauggTT 303 ccauguacccaaaagcgccTT 6578 729 304
uggcgcuuuuggguacauggagu double 305 gcgcuuuuggguacauggaTT 306
uccauguacccaaaagcgcTT 6579 730 307 ggcgcuuuuggguacauggagug double
308 cgcuuuuggguacauggagTT 309 cuccauguacccaaaagcgTT 6580 731 310
gcgcuuuuggguacauggagugu double 311 gcuuuuggguacauggaguTT 312
acuccauguacccaaaagcTT 6581 732 313 cgcuuuuggguacauggaguguu double
314 cuuuuggguacauggagugTT 315 cacuccauguacccaaaagTT 6582 733 316
gcuuuuggguacauggaguguuc double 317 uuuuggguacauggaguguTT 318
acacuccauguacccaaaaTT 6583 734 319 cuuuuggguacauggaguguuca double
320 uuuggguacauggaguguuTT 321 aacacuccauguacccaaaTT 6584 735 322
uuuuggguacauggaguguucag double 323 uuggguacauggaguguucTT 324
gaacacuccauguacccaaTT 6585 736 325 uuuggguacauggaguguucagc double
326 uggguacauggaguguucaTT 327 ugaacacuccauguacccaTT 6586 737 328
uuggguacauggaguguucagca double 329 ggguacauggaguguucagTT 330
cugaacacuccauguacccTT 6587 738 331 uggguacauggaguguucagcaa double
332 gguacauggaguguucagcTT 333 gcugaacacuccauguaccTT 6588 739 334
ggguacauggaguguucagcaaa double 335 guacauggaguguucagcaTT 336
ugcugaacacuccauguacTT 6589 740 337 gguacauggaguguucagcaaag double
338 uacauggaguguucagcaaTT 339 uugcugaacacuccauguaTT 6590 741 340
guacauggaguguucagcaaaga double 341 acauggaguguucagcaaaTT 342
uuugcugaacacuccauguTT 6591 742 343 uacauggaguguucagcaaagac double
344 cauggaguguucagcaaagTT 345 cuuugcugaacacuccaugTT 6592 743 346
acauggaguguucagcaaagacc double 347 auggaguguucagcaaagaTT 348
ucuuugcugaacacuccauTT 6593 744 349 cauggaguguucagcaaagacca double
350 uggaguguucagcaaagacTT 351 gucuuugcugaacacuccaTT 6594 745 352
auggaguguucagcaaagaccaa double 353 ggaguguucagcaaagaccTT 354
ggucuuugcugaacacuccTT 6595 746 355 uggaguguucagcaaagaccaaa double
356 gaguguucagcaaagaccaTT 357 uggucuuugcugaacacucTT 6596 747 358
ggaguguucagcaaagaccaaag double 359 aguguucagcaaagaccaaTT 360
uuggucuuugcugaacacuTT 6597 748 361 gaguguucagcaaagaccaaaga double
362 guguucagcaaagaccaaaTT 363 uuuggucuuugcugaacacTT 6598 749 364
aguguucagcaaagaccaaagau double 365 uguucagcaaagaccaaagTT 366
cuuuggucuuugcugaacaTT 6599 750 367 guguucagcaaagaccaaagaug double
368 guucagcaaagaccaaagaTT 369 ucuuuggucuuugcugaacTT 6600 770 370
auggagugagagagguuuuugaa double 371 ggagugagagagguuuuugTT 372
caaaaaccucucucacuccTT 6601 771 373 uggagugagagagguuuuugaaa double
374 gagugagagagguuuuugaTT 375 ucaaaaaccucucucacucTT 6602 797 376
cuacgagagcugcucugcaagcu double 377 acgagagcugcucugcaagTT 378
cuugcagagcagcucucguTT 6603 798 379 uacgagagcugcucugcaagcua double
380 cgagagcugcucugcaagcTT 381 gcuugcagagcagcucucgTT 6604 799 382
acgagagcugcucugcaagcuag double 383 gagagcugcucugcaagcuTT 384
agcuugcagagcagcucucTT 6605 800 385 cgagagcugcucugcaagcuaga double
386 agagcugcucugcaagcuaTT 387 uagcuugcagagcagcucuTT 6606 801 388
gagagcugcucugcaagcuagac double 389 gagcugcucugcaagcuagTT 390
cuagcuugcagagcagcucTT 6607 802 391 agagcugcucugcaagcuagacg double
392 agcugcucugcaagcuagaTT 393 ucuagcuugcagagcagcuTT 6608 803 394
gagcugcucugcaagcuagacgu double 395 gcugcucugcaagcuagacTT 396
gucuagcuugcagagcagcTT 6609 804 397 agcugcucugcaagcuagacgug double
398 cuyoucugcaagcuagacgTT 399 cgucuagcuugcagagcagTT 6610 895 400
uugaagugcuguuuauuaaucuu double 401 gaagugcuguuuauuaaucTT 402
gauuaauaaacagcacuucTT 6611 896 403 ugaagugcuguuuauuaaucuua double
404 aagugcuguuuauuaaucuTT 405 agauuaauaaacagcacuuTT 6612 897 406
gaagugcuguuuauuaaucuuag double 407 agugcuguuuauuaaucuuTT 408
aagauuaauaaacagcacuTT 6613 898 409 aagugcuguuuauuaaucuuagu double
410 gugcuguuuauuaaucuuaTT 411 uaagauuaauaaacagcacTT 6614 899 412
agugcuguuuauuaaucuuagug double 413 ugcuguuuauuaaucuuagTT 414
cuaagauuaauaaacagcaTT 6615 900 415 gugcuguuuauuaaucuuagugu double
416 gcuguuuauuaaucuuaguTT 417 acuaagauuaauaaacagcTT 6616 901 418
ugcuguuuauuaaucuuagugua double 419 cuguuuauuaaucuuagugTT 420
cacuaagauuaauaaacagTT 6617 902 421 gcuguuuauuaaucuuaguguau double
422 uguuuauuaaucuuaguguTT 423 acacuaagauuaauaaacaTT 6618 903 424
cuguuuauuaaucuuaguguaug double 425 guuuauuaaucuuaguguaTT 426
uacacuaagauuaauaaacTT 6619 904 427 uguuuauuaaucuuaguguauga double
428 uuuauuaaucuuaguguauTT 429 auacacuaagauuaauaaaTT 6620 905 430
guuuauuaaucuuaguguaugau double 431 uuauuaaucuuaguguaugTT 432
cauacacuaagauuaauaaTT 6621 906 433 uuuauuaaucuuaguguaugauu double
434 uauuaaucuuaguguaugaTT 435 ucauacacuaagauuaauaTT 6622 907 436
uuauuaaucuuaguguaugauua double 437 auuaaucuuaguguaugauTT 438
aucauacacuaagauuaauTT 6623 908 439 uauuaaucuuaguguaugauuac double
440 uuaaucuuaguguaugauuTT 441 aaucauacacuaagauuaaTT 6624 909 442
auuaaucuuaguguaugauuacu double 443 uaaucuuaguguaugauuaTT 444
uaaucauacacuaagauuaTT 6625 910 445 uuaaucuuaguguaugauuacug double
446 aaucuuaguguaugauuacTT 447 guaaucauacacuaagauuTT 6626 911 448
uaaucuuaguguauyauuacugg double 449 aucuuaguguaugauuacuTT 450
aguaaucauacacuaagauTT 6627 912 451 aaucuuaguguaugauuacuggc double
452 ucuuaguguaugauuacugTT 453 caguaaucauacacuaagaTT 6628 913 454
aucuuaguguaugauuacuggcc double 455 cuuaguguaugauuacuggTT 456
ccaguaaucauacacuaagTT 6629 914 457 ucuuaguguaugauuacuggccu double
458 uuaguguaugauuacuggcTT 459 gccaguaaucauacacuaaTT 6630 915 460
cuuaguguaugauuacuggccuu double 461 uaguguaugauuacuggccTT 462
ggccaguaaucauacacuaTT 6631 916 463 uuaguguaugauuacuggccuuu double
464 aguguaugauuacuggccuTT 465 aggccaguaaucauacacuTT 6632 917 466
uaguguaugauuacuggccuuuu double 467 guguaugauuacuggccuuTT 468
aaggccaguaaucauacacTT 6633 918 469 aguguaugauuacugyccuuuuu double
470 uguaugauuacuggccuuuTT 471 aaaggccaguaaucauacaTT 6634 919 472
guguaugauuacuggccuuuuuc double 473 guaugauuacuggccuuuuTT 474
aaaaggccaguaaucauacTT 6635 939 475 uucauuuaucuauaauuuaccua double
476 cauuuaucuauaauuuaccTT 477 gguaaauuauagauaaaugTT 6636 940 478
ucauuuaucuauaauuuaccuaa double 479 auuuaucuauaauuuaccuTT 480
agguaaauuauagauaaauTT 6637 941 481 cauuuaucuauaauuuaccuaag double
482 uuuaucuauaauuuaccuaTT 483 uagguaaauuauagauaaaTT 6638 942 484
auuuaucuauaauuuaccuaaga double 485 uuaucuauaauuuaccuaaTT 486
uuagguaaauuauagauaaTT 6639 943 487 uuuaucuauaauuuaccuaagau double
488 uaucuauaauuuaccuaagTT 489 cuuagguaaauuauagauaTT 6640 944 490
uuaucuauaauuuaccuaagauu double 491 aucuauaauuuaccuaagaTT 492
ucuuagguaaauuauagauTT 6641 945 493 uaucuauaauuuaccuaagauua double
494 ucuauaauuuaccuaagauTT 495 aucuuagguaaauuauagaTT 6642 946 496
aucuauaauuuaccuaagauuac double 497 cuauaauuuaccuaagauuTT 498
aaucuuagguaaauuauagTT 6643 947 499 ucuauaauuuaccuaagauuaca double
500 uauaauuuaccuaagauuaTT 501 uaaucuuagguaaauuauaTT 6644 948 502
cuauaauuuaccuaagauuacaa double 503 auaauuuaccuaagauuacTT 504
guaaucuuagguaaauuauTT 6645 949 505 uauaauuuaccuaagauuacaaa double
506 uaauuuaccuaagauuacaTT 507 uguaaucuuagguaaauuaTT 6646 950 508
auaauuuaccuaagauuacaaau double 509 aauuuaccuaagauuacaaTT 510
uuguaaucuuagguaaauuTT 6647 951 511 uaauuuacauaagauuacaaauc double
512 auuuaccuaagauuacaaaTT 513 uuuguaaucuuagguaaauTT 6648 952 514
aauuuaccuaagauuacaaauca double 515 uuuaccuaagauuacaaauTT 516
auuuguaaucuuagguaaaTT 6649 953 517 auuuaccuaagauuacaaaucag double
518 uuaccuaagauuacaaaucTT 519 gauuuguaaucuuagguaaTT 6650 954 520
uuuaccuaagauuacaaaucaga double 521 uaccuaagauuacaaaucaTT 522
ugauuuguaaucuuagguaTT 6651 974 523 agaagucaucuugcuaccaguau double
524 aagucaucuugcuaccaguTT 525 acugguagcaagaugacuuTT 6652 975 526
gaagucaucuugcuaccaguauu double 527 agucaucuugcuaccaguaTT 528
uacugguagcaagaugacuTT 6653 976 529 aagucaucuugcuaccaguauuu double
530 gucaucuugcuaccaguauTT 531 auacugguagcaagaugacTT 6654 977 532
agucaucuugcuaccaguauuua double 533 ucaucuugcuaccaguauuTT 534
aauacugguagcaagaugaTT 6655 978 535 gucaucuugcuaccaguauuuag double
536 caucuugcuaccaguauuuTT 537 aaauacugguagcaagaugTT 6656 979 538
ucaucuugcuaccaguauuuaga double 539 aucuugcuaccaguauuuaTT 540
uaaauacugguagcaagauTT 6657 980 541 caucuugcuaccaguauuuagaa double
542 ucuugcuaccaguauuuagTT 543 cuaaauacugguagcaagaTT 6658 981 544
aucuugcuaccaguauuuagaag double 545 cuugcuaccaguauuuagaTT 546
ucuaaauacugguagcaagTT 6659 982 547 ucuugcuaccaguauuuagaagc double
548 uugcuaccaguauuuagaaTT 549 uucuaaauacugguagcaaTT 6660 983 550
cuugcuaccaguauuuagaagcc double 551 ugcuaccaguauuuagaagTT 552
cuucuaaauacugguagcaTT 6661 984 553 uugcuaccaguauuuagaagcca double
554 gcuaccaguauuuagaagcTT 555 gcuucuaaauacugguagcTT 6662 985 556
ugcuaccaguauuuagaagccaa double 557 cuaccaguauuuagaagccTT 558
ggcuucuaaauacugguagTT 6663 986 559 gcuaccaguauuuagaagccaac double
560 uaccaguauuuagaagccaTT 561 uggcuucuaaauacugguaTT 6664 987 562
cuaccaguauuuagaagccaacu double 563 accaguauuuagaagccaaTT 564
uuggcuucuaaauacugguTT 6665 988 565 uaccaguauuuagaagccaacua double
566 ccaguauuuagaagccaacTT 567 guuggcuucuaaauacuggTT 6666 1131 568
cuugcuucuuucuagaaagagaa double 569 ugcuucuuucuagaaagagTT 570
cucuuucuagaaagaagcaTT 6667 1132 571 uugcuucuuucuagaaagagaaa double
572 gcuucuuucuagaaagagaTT 573 ucucuuucuagaaagaagcTT 6668 1133 574
ugcuucuuucuagaaagagaaac double 575 cuucuuucuagaaagagaaTT 576
uucucuuucuagaaagaagTT 6669 1134 577 gcuucuuucuagaaagagaaaca double
578 uucuuucuagaaagagaaaTT 579 uuucucuuucuagaaagaaTT 6670 1135 580
cuucuuucuagaaagagaaacag double 581 ucuuucuagaaagagaaacTT 582
guuucucuuucuagaaagaTT 6671 1136 583 uucuuucuagaaagagaaacagu double
584 cuuucuagaaagagaaacaTT 585 uguuucucuuucuagaaagTT 6672 1137 586
ucuuucuagaaagagaaacaguu double 587 uuucuagaaagagaaacagTT 588
cuguuucucuuucuagaaaTT 6673 1138 589 cuuucuagaaagagaaacaguug double
590 uucuagaaagagaaacaguTT 591 acuguuucucuuucuagaaTT 6674 1139 592
uuucuagaaagagaaacaguugg double 593 ucuagaaagagaaacaguuTT 594
aacuguuucucuuucuagaTT 6675 1140 595 uucuagaaagagaaacaguuggu double
596 cuagaaagagaaacaguugTT 597 caacuguuucucuuucuagTT 6676 1141 598
ucuagaaagagaaacaguuggua double 599 uagaaagagaaacaguuggTT 600
ccaacuguuucucuuucuaTT 6677 1142 601 cuagaaagagaaacaguugguaa double
602 agaaagagaaacaguugguTT 603 accaacuguuucucuuucuTT 6678 1143 604
uagaaagagaaacaguugguaac double 605 gaaagagaaacaguugguaTT 606
uaccaacuguuucucuuucTT 6679 1144 607 agaaagagaaacaguugguaacu double
608 aaagagaaacaguugguaaTT 609 uuaccaacuguuucucuuuTT 6680 1145 610
gaaagagaaacaguugguaacuu double 611 aagagaaacaguugguaacTT 612
guuaccaacuguuucucuuTT 6681 1146 613 aaagagaaacaguugguaacuuu double
614 agagaaacaguugguaacuTT 615 aguuaccaacuguuucucuTT 6682 1147 616
aagagaaacaguugguaacuuuu double 617 gagaaacaguugguaacuuTT 618
aaguuaccaacuguuucucTT 6683 1148 619 agagaaacaguugguaacuuuug double
620 agaaacaguugguaacuuuTT 621 aaaguuaccaacuguuucuTT 6684 1149 622
gagaaacaguugguaacuuuugu double 623 gaaacaguugguaacuuuuTT 624
aaaaguuaccaacuguuucTT 6685 1150 625 agaaacaguugguaacuuuugug double
626 aaacaguugguaacuuuugTT 627 caaaaguuaccaacuguuuTT 6686 1151 628
gaaacaguugguaacuuuuguga double 629 aacaguugguaacuuuuguTT 630
acaaaaguuaccaacuguuTT 6687 1152 631 aaacaguugguaacuuuugugaa double
632 acaguugguaacuuuugugTT 633 cacaaaaguuaccaacuguTT 6688 1153 634
aacaguugguaacuuuugugaau double 635 caguugguaacuuuugugaTT 636
ucacaaaaguuaccaacugTT 6689 1154 637 acaguugguaacuuuugugaauu double
638 aguugguaacuuuugugaaTT 639 uucacaaaaguuaccaacuTT 6690 1155 640
caguugguaacuuuugugaauua double 641 guugguaacuuuugugaauTT 642
auucacaaaaguuaccaacTT 6691 1156 643 aguugguaacuuuugugaauuag double
644 uugguaacuuuugugaauuTT 645 aauucacaaaaguuaccaaTT 6692 1157 646
guugguaacuuuugugaauuagg double 647 ugguaacuuuugugaauuaTT 648
uaauucacaaaaguuaccaTT 6693 1158 649 uugguaacuuuugugaauuaggc double
650 gguaacuuuugugaauuagTT 651 cuaauucacaaaaguuaccTT 6694 1159 652
ugguaacuuuugugaauuaggcu double 653 guaacuuuugugaauuaggTT 654
ccuaauucacaaaaguuacTT 6695 1160 655 gguaacuuuugugaauuaggcug double
656 uaacuuuugugaauuaggcTT 657 gccuaauucacaaaaguuaTT 6696 1161 658
guaacuuuugugaauuaggcugu double 659 aacuuuugugaauuaggcuTT 660
agccuaauucacaaaaguuTT 6697 1162 661 uaacuuuugugaauuaggcugua double
662 acuuuugugaauuaggcugTT 663 cagccuaauucacaaaaguTT 6698 1163 664
aacuuuugugaauuaggcuguaa double 665 cuuuugugaauuaggcuguTT 666
acagccuaauucacaaaagTT 6699 1164 667 acuuuugugaauuaggcuguaac double
668 uuuugugaauuaggcuguaTT 669 uacagccuaauucacaaaaTT 6700 1165 670
cuuuugugaauuaggcuguaacu double 671 uuugugaauuaggcuguaaTT 672
uuacagccuaauucacaaaTT 6701 1166 673 uuuugugaauuaggcuguaacua double
674 uugugaauuaggcuguaacTT 675 guuacagccuaauucacaaTT 6702 1167 676
uuugugaauuaggcuguaacuac double 677 ugugaauuaggcuguaacuTT 678
aguuacagccuaauucacaTT 6703 1168 679 uugugaauuaggcuguaacuacu double
680 gugaauuaggcuguaacuaTT 681 uaguuacagccuaauucacTT 6704 1169 682
ugugaauuaggcuguaacuacuu double 683 ugaauuaggcuguaacuacTT 684
guaguuacagccuaauucaTT 6705 1170 685 gugaauuaggcuguaacuacuuu double
686 gaauuaggcuguaacuacuTT 687 aguaguuacagccuaauucTT 6706 1171 688
ugaauuaggcuguaacuacuuua double 689 aauuaggcuguaacuacuuTT 690
aaguaguuacagccuaauuTT 6707 1172 691 gaauuaggcuguaacuacuuuau double
692 auuaggcuguaacuacuuuTT 693 aaaguaguuacagccuaauTT 6708 1173 694
aauuaggcuguaacuacuuuaua double 695 uuaggcuguaacuacuuuaTT 696
uaaaguaguuacagccuaaTT 6709 1174 697 auuaggcuguaacuacuuuauaa double
698 uaggcuguaacuacuuuauTT 699 auaaaguaguuacagccuaTT 6710 1175 700
uuaggcuguaacuacuuuauaac double 701 aggcuguaacuacuuuauaTT 702
uauaaaguaguuacagccuTT 6711 1176 703 uaggcuguaacuacuuuauaacu double
704 ggcuguaacuacuuuauaaTT 705 uuauaaaguaguuacagccTT 6712 1177 706
aggcuguaacuacuuuauaacua double 707 gcuguaacuacuuuauaacTT 708
guuauaaaguaguuacagcTT 6713 1178 709 ggcuguaacuacuuuauaacuaa double
710 cuguaacuacuuuauaacuTT 711 aguuauaaaguaguuacagTT 6714 1179 712
gcuguaacuacuuuauaacuaac double 713 uguaacuacuuuauaacuaTT 714
uaguuauaaaguaguuacaTT 6715 1180 715 cuguaacuacuuuauaacuaaca double
716 guaacuacuuuauaacuaaTT 717 uuaguuauaaaguaguuacTT 6716 1181 718
uguaacuacuuuauaacuaacau double 719 uaacuacuuuauaacuaacTT 720
guuaguuauaaaguaguuaTT 6717 1182 721 guaacuacuuuauaacuaacaug double
722 aacuacuuuauaacuaacaTT 723 uguuaguuauaaaguaguuIT 6718 1183 724
uaacuacuuuauaacuaacaugu double 725 acuacuuuauaacuaacauTT 726
auguuaguuauaaaguaguTT 6719 1184 727 aacuacuuuauaacuaacauguc double
728 cuacuuuauaacuaacaugTT 729 cauguuaguuauaaaguagTT 6720 1185 730
acuacuuuauaacuaacaugucc double 731 uacuuuauaacuaacauguTT 732
acauguuaguuauaaaguaTT 6721 1186 733 cuacuuuauaacuaacauguccu double
734 acuuuauaacuaacaugucTT 735 gacauguuaguuauaaaguTT 6722 1187 736
uacuuuauaacuaacauguccug double 737 cuuuauaacuaacauguccTT 738
ggacauguuaguuauaaagTT 6723 1188 739 acuuuauaacuaacauguccugc double
740 uuuauaacuaacauguccuTT 741 aggacauguuaguuauaaaTT
6724 1189 742 cuuuauaacuaacauguccugcc double 743
uuauaacuaacauguccugTT 744 caggacauguuaguuauaaTT 6725 1190 745
uuuauaacuaacauguccugccu double 746 uauaacuaacauguccugcTT 747
gcaggacauguuaguuauaTT 6726 1191 748 uuauaacuaacauguccugccua double
749 auaacuaacauguccugccTT 750 ggcaggacauguuaguuauTT 6727 1192 751
uauaacuaacauguccugccuau double 752 uaacuaacauguccugccuTT 753
aggcaggacauguuaguuaTT 6728 1193 754 auaacuaacauguccugccuauu double
755 aacuaacauguccugccuaTT 756 uaggcaggacauguuaguuTT 6729 1352 757
uggcagaguuacaguucuguggu double 758 gcagaguuacaguucugugTT 759
cacagaacuguaacucugcTT 6730 1353 760 ggcagaguuacaguucugugguu double
761 cagaguuacaguucuguggTT 762 ccacagaacuguaacucugTT 6731 1354 763
gcagaguuacaguucugugguuu double 764 agaguuacaguucugugguTT 765
accacagaacuguaacucuTT 6732 1374 766 uuucauguuaguuaccuuauagu double
767 ucauguuaguuaccuuauaTT 768 uauaagguaacuaacaugaTT 6733 1375 769
uucauguuaguuaccuuauaguu double 770 cauguuaguuaccuuauagTT 771
cuauaagguaacuaacaugTT 6734 1376 772 ucauguuaguuaccuuauaguua double
773 auguuaguuaccuuauaguTT 774 acuauaagguaacuaacauTT 6735 1377 775
cauguuaguuaccuuauaguuac double 776 uguuaguuaccuuauaguuTT 777
aacuauaagguaacuaacaTT 6736 1378 778 auguuaguuaccuuauaguuacu double
779 guuaguuaccuuauaguuaTT 780 uaacuauaagguaacuaacTT 6737 1379 781
uguuaguuaccuuauaguuacug double 782 uuaguuaccuuauaguuacTT 783
guaacuauaagguaacuaaTT 6738 1380 784 guuaguuaccuuauaguuacugu double
785 uaguuaccuuauaguuacuTT 786 aguaacuauaagguaacuaTT 6739 1381 787
uuaguuaccuuauaguuacugug double 788 aguuaccuuauaguuacugTT 789
caguaacuauaagguaacuTT 6740 1382 790 uaguuaccuuauaguuacugugu double
791 guuaccuuauaguuacuguTT 792 acaguaacuauaagguaacTT 6741 1383 793
aguuaccuuauaguuacugugua double 794 uuaccuuauaguuacugugTT 795
cacaguaacuauaagguaaTT 6742 1384 796 guuaccuuauaguuacuguguaa double
797 uaccuuauaguuacuguguTT 798 acacaguaacuauaagguaTT 6743 1385 799
uuaccuuauaguuacuguguaau double 800 accuuauaguuacuguguaTT 801
uacacaguaacuauaagguTT 6744 1386 802 uaccuuauaguuacuguguaauu double
803 ccuuauaguuacuguguaaTT 804 uuacacaguaacuauaaggTT 6745 1387 805
accuuauaguuacuguguaauua double 806 cuuauaguuacuguguaauTT 807
auuacacaguaacuauaagTT 6746 1388 808 ccuuauaguuacuguguaauuag double
809 uuauaguuacuguguaauuTT 810 aauuacacaguaacuauaaTT 6747 1389 811
cuuauaguuacuguguaauuagu double 812 uauaguuacuguguaauuaTT 813
uaauuacacaguaacuauaTT 6748 1390 814 uuauaguuacuguguaauuagug double
815 auaguuacuguguaauuagTT 816 cuaauuacacaguaacuauTT 6749 1391 817
uauaguuacuguguaauuagugc double 818 uaguuacuguguaauuaguTT 819
acuaauuacacaguaacuaTT 6750 1392 820 auaguuacuguguaauuagugcc double
821 aguuacuguguaauuagugTT 822 cacuaauuacacaguaacuTT 6751 1393 823
uaguuacuguguaauuagugcca double 824 guuacuguguaauuagugcTT 825
gcacuaauuacacaguaacTT 6752 1394 826 aguuacuguguaauuagugccac double
827 uuacuguguaauuagugccTT 828 ggcacuaauuacacaguaaTT 6753 1395 829
guuacuguguaauuagugccacu double 830 uacuguguaauuagugccaTT 831
uggcacuaauuacacaguaTT 6754 1396 832 uuacuguguaauuagugccacuu double
833 acuguguaauuagugccacTT 834 guggcacuaauuacacaguTT 6755 1397 835
uacuguguaauuagugccacuua double 836 cuguguaauuagugccacuTT 837
aguggcacuaauuacacagTT 6756 1398 838 acuguguaauuagugccacuuaa double
839 uguguaauuagugccacuuTT 840 aaguggcacuaauuacacaTT 6757 1399 841
cuguguaauuagugccacuuaau double 842 guguaauuagugccacuuaTT 843
uaaguggcacuaauuacacTT 6758 1400 844 uguguaauuagugccacuuaaug double
845 uguaauuagugccacuuaaTT 846 uuaaguggcacuaauuacaTT 6759 1401 847
guguaauuagugccacuuaaugu double 848 guaauuagugccacuuaauTT 849
auuaaguggcacuaauuacTT 6760 1402 850 uguaauuagugccacuuaaugua double
851 uaauuagugccacuuaaugTT 852 cauuaaguggcacuaauuaTT 6761 1403 853
guaauuagugccacuuaauguau double 854 aauuagugccacuuaauguTT 855
acauuaaguggcacuaauuTT 6762 1404 856 uaauuagugccacuuaauguaug double
857 auuagugccacuuaauguaTT 858 uacauuaaguggcacuaauTT 6763 1405 859
aauuagugccacuuaauguaugu double 860 uuagugccacuuaauguauTT 861
auacauuaaguggcacuaaTT 6764 1406 862 auuagugccacuuaauguauguu double
863 uagugccacuuaauguaugTT 864 cauacauuaaguggcacuaTT 6765 1407 865
uuagugccacuuaauguauguua double 866 agugccacuuaauguauguTT 867
acauacauuaaguggcacuTT 6766 1408 868 uagugccacuuaauguauguuac double
869 gugccacuuaauguauguuTT 870 aacauacauuaaguggcacTT 6767 1409 871
agugccacuuaauguauguuacc double 872 ugccacuuaauguauguuaTT 873
uaacauacauuaaguggcaTT 6768 1410 874 gugccacuuaauguauguuacca double
875 gccacuuaauguauguuacTT 876 guaacauacauuaaguggcTT 6769 1411 877
ugccacuuaauguauguuaccaa double 878 ccacuuaauguauguuaccTT 879
gguaacauacauuaaguggTT 6770 1412 880 gccacuuaauguauguuaccaaa double
881 cacuuaauguauguuaccaTT 882 ugguaacauacauuaagugTT 6771 1413 883
ccacuuaauguauguuaccaaaa double 884 acuuaauguauguuaccaaTT 885
uugguaacauacauuaaguTT 6772 1414 886 cacuuaauguauguuaccaaaaa double
887 cuuaauguauguuaccaaaTT 888 uuugguaacauacauuaagTT 6773 1415 889
acuuaauguauguuaccaaaaau double 890 uuaauguauguuaccaaaaTT 891
uuuugguaacauacauuaaTT 6774 1416 892 cuuaauguauguuaccaaaaaua double
893 uaauguauguuaccaaaaaTT 894 uuuuugguaacauacauuaTT 6775 1435 895
aauaaauauaucuaccccagacu double 896 uaaauauaucuaccccagaTT 897
ucugggguagauauauuuaTT 6776 1436 898 auaaauauaucuaccccagacua double
899 aaauauaucuaccccagacTT 900 gucugggguagauauauuuTT 6777 1437 901
uaaauauaucuaccccagacuag double 902 aauauaucuaccccagacuTT 903
agucugggguagauauauuTT 6778 1438 904 aaauauaucuaccccagacuaga double
905 auauaucuaccccagacuaTT 906 uagucugggguagauauauTT 6779 1439 907
aauauaucuaccccagacuagau double 908 uauaucuaccccagacuagTT 909
cuagucugggguagauauaTT 6780 1440 910 auauaucuaccccagacuagaug double
911 auaucuaccccagacuagaTT 912 ucuagucugggguagauauTT 6781 1441 913
uauaucuaccccagacuagaugu double 914 uaucuaccccagacuagauTT 915
aucuagucugggguagauaTT 6782 1442 916 auaucuaccccagacuagaugua double
917 aucuaccccagacuagaugTT 918 caucuagucugggguagauTT 6783 1443 919
uaucuaccccagacuagauguag double 920 ucuaccccagacuagauguTT 921
acaucuagucugggguagaTT 6784 1444 922 aucuaccccagacuagauguagu double
923 cuaccccagacuagauguaTT 924 uacaucuagucugggguagTT 6785 1445 925
ucuaccccagacuagauguagua double 926 uaccccagacuagauguagTT 927
cuacaucuagucugggguaTT 6786 1446 928 cuaccccagacuagauguaguau double
929 accccagacuagauguaguTT 930 acuacaucuagucugggguTT 6787 1447 931
uaccccagacuagauguaguauu double 932 ccccagacuagauguaguaTT 933
uacuacaucuagucuggggTT 6788 1448 934 accccagacuagauguaguauuu double
935 cccagacuagauguaguauTT 936 auacuacaucuagucugggTT 6789 1449 937
ccccagacuagauguaguauuuu double 938 ccagacuagauguaguauuTT 939
aauacuacaucuagucuggTT 6790 1450 940 cccagacuagauguaguauuuuu double
941 cagacuagauguaguauuuTT 942 aaauacuacaucuagucugTT 6791 1451 943
ccagacuagauguaguauuuuuu double 944 agacuagauguaguauuuuTT 945
aaaauacuacaucuagucuTT 6792 1452 946 cagacuagauguaguauuuuuug double
947 gacuagauguaguauuuuuTT 948 aaaaauacuacaucuagucTT 6793 1453 949
agacuagauguaguauuuuuugu double 950 acuagauguaguauuuuuuTT 951
aaaaaauacuacaucuaguTT 6794 1454 952 gacuagauguaguauuuuuugua double
953 cuagauguaguauuuuuugTT 954 caaaaaauacuacaucuagTT 6795 1455 955
acuagauguaguauuuuuuguau double 956 uagauguaguauuuuuuguTT 957
acaaaaaauacuacaucuaTT 6796 1456 958 cuagauguaguauuuuuuguaua double
959 agauguaguauuuuuuguaTT 960 uacaaaaaauacuacaucuTT 6797 1457 961
uagauguaguauuuuuuguauaa double 962 gauguaguauuuuuuguauTT 963
auacaaaaaauacuacaucTT 6798 1458 964 agauguaguauuuuuuguauaau double
965 auguaguauuuuuuguauaTT 966 uauacaaaaaauacuacauTT 6799 1459 967
gauguagauuuuuuuguauaauu double 968 uguaguauuuuuuguauaaTT 969
uuauacaaaaaauacuacaTT 6800 1460 970 auguaguauuuuuuguauaauug double
971 guaguauuuuuuguauaauTT 972 auuauacaaaaaauacuacTT 6801 1461 973
uguaguauuuuuuguauaauugg double 974 uaguauuuuuuguauaauuTT 975
aauuauacaaaaaauacuaTT 6802 1462 976 guaguauuuuuuguauaauugga double
977 aguauuuuuuguauaauugTT 978 caauuauacaaaaaauacuTT 6803 1463 979
uaguauuuuuuguauaauuggau double 980 guauuuuuuguauaauuggTT 981
ccaauuauacaaaaaauacTT 6804 1464 982 aguauuuuuuguauaauuggauu double
983 uauuuuuuguauaauuggaTT 984 uccaauuauacaaaaaauaTT 6805 1465 985
guauuuuuuguauaauuggauuu double 986 auuuuuuguauaauuggauTT 987
auccaauuauacaaaaaauTT 6806 1466 988 uauuuuuuguauaauuggauuuc double
989 uuuuuuguauaauuggauuTT 990 aauccaauuauacaaaaaaTl 6807 1467 991
auuuuuuguauaauuggauuucc double 992 uuuuuguauaauuggauuuTT 993
aaauccaauuauacaaaaaTT
6808 1468 994 uuuuuuguauaauuggauuuccu double 995
uuuuguauaauuggauuucTT 996 gaaauccaauuauacaaaaTT 6809 1469 997
uuuuuguauaauuggauuuccua double 998 uuuguauaauuggauuuccTT 999
ggaaauccaauuauacaaaTT 6810 1470 1000 uuuuguauaauuggauuuccuaa double
1001 uuguauaauuggauuuccuTT 1602 aggaaauccaauuauacaaTT 6811 1471
1003 uuuguauaauuggauuuccuaau double 1004 uguauaauuggauuuccuaTT 1005
uaggaaauccaauuauacaTT 6812 1472 1006 uuguauaauuggauuuccuaaua double
1007 guauaauuggauuuccuaaTT 1008 uuaggaaauccaauuauacTT 6813 1473
1009 uguauaauuggauuuccuaauac double 1010 uauaauuggauuuccuaauTT 1011
auuaggaaauccaauuauaTT 6814 1540 1012 guauuuggaaauaaagucagaug double
1013 auuuggaaauaaagucagaTT 1014 ucugacuuuauuuccaaauTT 6815 1541
lOIS uauuuggaaauaaagucagaugg double 1016 uuuggaaauaaagucagauTT 1017
aucugacuuuauuuccaaaTT 6816 1542 1018 auuuggaaauaaagucagaugga double
1019 uuggaaauaaagucagaugTT 1020 aaucugacuuuauuuccaaTT 6817 1543
1021 uuuggaaauaaagucagauggaa double 1022 uggaaauaaagucagauggTT 1023
ccaucugacuuuauuuccaTT 6818 1544 1024 uuggaaauaaagucagauggaaa double
1025 ggaaauaaagucagauggaTT 1026 uccaucugacuuuauuuccTT 6819 1545
1027 uggaaauaaagucagauggaaaa double 1028 gaaauaaagucagauggaaTT 1029
uuccaucugacuuuauuucTT 6820 1796 1030 ucccucccagaggagccaccagu double
1031 ccucccagaggagccaccaTT 1032 ugguggcuccucugggaggTT 6821 1797
1033 cccucccagaggagccaccaguu double 1034 cucccagaggagccaccagTT 1035
cugguggcuccucugggagTT 6822 1798 1036 ccucccagaggagccaccaguuc double
1037 ucccagaggagccaccaguTT 1038 acugguggcuccucugggaTT 6823 1799
1039 cucccagaggagccaccaguucu double 1040 cccagaggagccaccaguuTT 1041
aacugguggcuccucugggTT 6824 1800 1042 ucccagaggagccaccaguucuc double
1043 ccagaggagccaccaguucTT 1044 gaacugguggcuccucuggTT 6825 1801
1045 cccagaggagccaccaguucuca double 1046 cagaggagccaccaguucuTT 1047
agaacugguggcuccucugTT 6826 1843 1048 cuucucuccagcugacuaaacuu double
1049 ucucuccagcugacuaaacTT 1050 guuuagucagcuggagagaTT 6827 1869
1051 uucuguaccaguuaauuuuucca double 1052 cuguaccaguuaauuuuucTT 1053
gaaaaauuaacugguacagTT 6828 1870 1054 ucuguaccaguuaauuuuuccaa double
1055 uguaccaguuaauuuuuccTT 1056 ggaaaaauuaacugguacaTT 6829 1871
1057 cuguaccaguuaauuuuuccaac double 1058 guaccaguuaauuuuuccaTT 1059
uggaaaaauuaacugguacTT 6830 1872 1060 uguaacaguuaauuuuuccaacu double
1061 uaccaguuaauuuuuccaaTT 1062 uuggaaaaauuaacugguaTT 6831 1873
1063 guaccaguuaauuuuuccaacua double 1064 accaguuaauuuuuccaacTT 1065
guuggaaaaauuaacugguTT 6832 1874 1066 uaccaguuaauuuuuccaacuac double
1067 ccaguuaauuuuuccaacuTT 1068 aguuggaaaaauuaacuggTT 6833 1875
1069 accaguuaauuuuuccaacuacu double 1070 caguuaauuuuuccaacuaTT 1071
uaguuggaaaaauuaacugTT 6834 1897 1072 uaauagaauaaaggcaguuuucu double
1073 auagaauaaaggcaguuuuTT 1074 aaaacugccuuuauucuauTT 6835 1898
1075 aauagaauaaaggcaguuuucua double 1076 uagaauaaaggcaguuuucTT 1077
gaaaacugccuuuauucuaTT 6836 1899 1078 auagaauaaaggcaguuuucuaa double
1079 agaauaaaggcaguuuucuTT 1080 agaaaacugccuuuauucuTT .sup.aSingle:
Single overhang design 21 mer sense, corresponding 23 mer antisense
with 2 nucleotides overhang at 3' end; Double: double overhang
design corresponding 19 mer sense and antisense strand each with 2
dT nucleotide overhang at 3' end .sup.b"Start position" corresponds
to the position within the sequence of human RhoA (Genbank
accession no. NM_001664) mRNA to which the 5'-most nucleotide of
the sense strand corresponds for single overhang designs; for
double overhang designs, the 5'-most ribonucleotide of the sense
strand corresponds to (Start position + 2)
[0059] Based on these results, the invention specifically provides
an iRNA agent that includes a sense strand having at least 15
contiguous nucleotides of the sense strand sequences of the agents
provided in Table 1 under agent numbers 6477-6836, and an antisense
strand having at least 15 contiguous nucleotides of the antisense
sequences of the agents provided in Table 1 under agent numbers
6477 to 6836.
[0060] The iRNA agents shown in Table 1 are composed of two strands
of 19 nucleotides in length which are complementary or identical to
the target sequence, plus a 3'-TT overhang. The present invention
provides agents that comprise 15 contiguous nucleotides from these
agents. However, while these lengths may potentially be optimal,
the iRNA agents are not meant to be limited to these lengths. The
skilled person is well aware that shorter or longer iRNA agents may
be similarly effective, since, within certain length ranges, the
efficacy is rather a finction of the nucleotide sequence than
strand length. For example, Yang, et al., PNAS 99:9942-9947 (2002),
demonstrated similar efficacies for iRNA agents of lengths between
21 and 30 base pairs. Others have shown effective silencing of
genes by iRNA agents down to a length of approx. 15 base pairs
(Byrom, et al., "Inducing RNAi with siRNA Cocktails Generated by
RNase III" Tech Notes 10(1), Ambion, Inc., Austin, Tex.).
[0061] Therefore, it is possible and contemplated by the instant
invention to select from the sequences provided in Table 1 under
agent numbers 6477 to 6836 a partial sequence of between 15 to 22
nucleotides for the generation of an iRNA agent derived from one of
the sequences provided in Table 1 under agent numbers 6477 to 6836.
Alternatively, one may add one or several nucleotides to one of the
sequences provided in Table 1 under agent numbers 6477 to 6836, or
an agent comprising 15 contiguous nucleotides from one of these
agents, preferably, but not necessarily, in such a fashion that the
added nucleotides are complementary to the respective sequence of
the target gene, e.g., RhoA. For example, the first 15 nucleotides
from one of the agents can be combined with the 8 nucleotides found
5' to these sequence in the RhoA mRNA to obtain an agent with 23
nucleotides in the sense and antisense strands. All such derived
iRNA agents are included in the iRNA agents of the present
invention, provided they essentially retain the ability to inhibit
RhoA expression in cultured human RhoA expressing cells.
[0062] The antisense strand of an iRNA agent should be equal to or
at least, 14, 15, 16 17, 18, 19, 25, 29, 40, or 50 nucleotides in
length. It should be equal to or less than 60, 50, 40, or 30,
nucleotides in length. Preferred ranges are 15-30, 17 to 25, 19 to
23, and 19 to 21 nucleotides in length.
[0063] The sense strand of an iRNA agent should be equal to or at
least 14, 15, 16 17, 18, 19, 25, 29, 40, or 50 nucleotides in
length. It should be equal to or less than 60, 50, 40, or 30
nucleotides in length. Preferred ranges are 15-30, 17 to 25, 19 to
23, and 19 to 21 nucleotides in length.
[0064] The double stranded portion of an iRNA agent should be equal
to or at least, 15, 16 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40,
or 50 nucleotide pairs in length. It should be equal to or less
than 60, 50, 40, or 30 nucleotides pairs in length. Preferred
ranges are 15-30, 17 to 25, 19 to 23, and 19 to 21 nucleotides
pairs in length.
[0065] Generally, the iRNA agents of the instant invention include
a region of sufficient complementarity to the respective RhoA gene,
and are of sufficient length in terms of nucleotides, that the iRNA
agent, or a fragment thereof, can mediate down regulation of the
RhoA gene. The ribonucleotide portions of the antisense strands of
the iRNA agents of Table 1 under agent numbers 6477 to 6836 are
fully complementary to the mRNA sequences of the RhoA gene,
respectively, and ribonucleotide portion of their sense strands are
fully complementary to the ribonucleotide portions of the
respective antisense strands, except for the two 3'-terminal
nucleotides on the antisense strand in single overhang design iRNA
agents. However, it is not necessary that there be perfect
complementarity between the iRNA agent and the target, but the
correspondence must be sufficient to enable the iRNA agent, or a
cleavage product thereof, to direct sequence specific silencing,
e.g., by RNAi cleavage of a RhoA mRNA.
[0066] Therefore, the iRNA agents of the instant invention include
agents comprising a sense strand and antisense strand each
comprising a sequence of at least 16, 17 or 18 nucleotides which is
essentially identical, as defined below, to one of the sequences of
Table 1 under agent numbers 6477 to 6836, except that not more than
1, 2 or 3 nucleotides per strand, respectively, have been
substituted by other nucleotides (e.g. adenosine replaced by
uracil), while essentially retaining the ability to inhibit RhoA
expression in cultured human RhoA expressing cells, respectively.
These agents will therefore possess at least 15 nucleotides
identical to one of the sequences of Table 1 under agent numbers
6477 to 6836, but 1, 2 or 3 base mismatches with respect to either
the target RhoA mRNA sequence or between the sense and antisense
strand are introduced. Mismatches to the target RhoA mRNA sequence,
particularly in the antisense strand, are most tolerated in the
terminal regions and if present are preferably in a terminal region
or regions, e.g., within 6, 5, 4, or 3 nucleotides of a 5' and/or
3' terminus, most preferably within 6, 5, 4, or 3 nucleotides of
the 5'-terminus of the sense strand or the 3'-terminus of the
antisense strand. The sense strand need only be sufficiently
complementary with the antisense strand to maintain the overall
double stranded character of the molecule.
[0067] It is preferred that the sense and antisense strands be
chosen such that the iRNA agent includes a single strand or
unpaired region at one or both ends of the molecule. Thus, an iRNA
agent contains sense and antisense strands, preferably paired to
contain an overhang, e.g., one or two 5' or 3' overhangs but
preferably a 3' overhang of 2-3 nucleotides. Most embodiments will
have a 3' overhang. Preferred siRNA agents will have
single-stranded overhangs, preferably 3' overhangs, of 1 to 4, or
preferably 2 or 3 nucleotides, in length, at one or both ends of
the iRNA agent. The overhangs can be the result of one strand being
longer than the other, or the result of two strands of the same
length being staggered. The unpaired nucleotides forming the
overhang can be ribonucleotides, or they can be
deoxyribonucleotides, preferably thymidine. 5'-ends are preferably
phosphorylated.
[0068] Preferred lengths for the duplexed region are between 15 and
30, most preferably 18, 19, 20, 21, 22, and 23 nucleotides in
length, e.g., in the siRNA agent range discussed above. siRNA
agents can resemble in length and structure the natural Dicer
processed products from long dsRNAs. Embodiments in which the two
strands of the siRNA agent are linked, e.g., covalently linked, are
also included. Hairpin, or other single strand structures which
provide the required double stranded region, and preferably a 3'
overhang are also within the invention.
[0069] Evaluation of Candidate iRNA Agents
[0070] A candidate iRNA agent can be evaluated for its ability to
downregulate target gene expression. For example, a candidate iRNA
agent can be provided, and contacted with a cell, that expresses
the target gene, e.g., the RhoA gene, either endogenously or
because it has been transfected with a construct from which a RhoA
protein can be expressed. The level of target gene expression prior
to and following contact with the candidate iRNA agent can be
compared, e.g., on an MRNA or protein level. If it is determined
that the amount of RNA or protein expressed from the target gene is
lower following contact with the iRNA agent, then it can be
concluded that the iRNA agent downregulates target gene expression.
The level of target RhoA RNA or RhoA protein in the cell can be
determined by any method desired. For example, the level of target
RNA can be determined by Northern blot analysis, reverse
transcription coupled with polymerase chain reaction (RT-PCR), or
RNAse protection assay. The level of protein can be determined, for
example, by Western blot analysis or immuno-fluorescence.
Preferably, the assay also tests the ability of the iRNA agent to
inhibit RhoA expression on a functional level, e.g. by assessing
the ability of the iRNA agent to facilitate neuronal growth, e.g.
the restoration of neurite outgrowth on an otherwise inhibitory
substrate, e.g a substrate comprising myelin.
Stability Testing, Modification, and Retesting of iRNA Agents
[0071] A candidate iRNA agent can be evaluated with respect to
stability, e.g., its susceptibility to cleavage by an endonuclease
or exonuclease, such as when the iRNA agent is introduced into the
body of a subject. Methods can be employed to identify sites that
are susceptible to modification, particularly cleavage, e.g.,
cleavage by a component found in the body of a subject.
[0072] When sites susceptible to cleavage are identified, a further
iRNA agent can be designed and/or synthesized wherein the potential
cleavage site is made resistant to cleavage, e.g. by introduction
of a 2'-modification on the site of cleavage, e.g. a 2'-O-methyl
group. This further iRNA agent can be retested for stability, and
this process may be iterated until an iRNA agent is found
exhibiting the desired stability.
In Vivo Testing
[0073] An iRNA agent identified as being capable of inhibiting RhoA
gene expression can be tested for functionality in vivo in an
animal model (e.g., in a mammal, such as in mouse or rat). For
example, the iRNA agent can be administered to an animal, and the
iRNA agent evaluated with respect to its biodistribution,
stability, and its ability to inhibit RhoA gene expression or
reduce a biological or pathological process mediated at least in
part by RhoA.
[0074] The iRNA agent can be administered directly to the target
tissue, e.g. the spinal cord, and, in the case of a spinal cord
injury model, to the site of spinal cord injury, such as by
injection. Preferably, the iRNA agent is administered to the animal
model in the same manner that it would be administered to a
human.
[0075] The iRNA agent can also be evaluated for its intracellular
distribution. The evaluation can include determining whether the
iRNA agent was taken up into the cell. The evaluation can also
include determining the stability (e.g., the half-life) of the iRNA
agent. Evaluation of an iRNA agent in vivo can be facilitated by
use of an iRNA agent conjugated to a traceable marker (e.g., a
fluorescent marker such as fluorescein; a radioactive label, such
as .sup.35S, .sup.32P, .sup.33P, or .sup.3H; gold particles; or
antigen particles for immunohistochemistry).
[0076] The iRNA agent can be evaluated with respect to its ability
to down regulate RhoA gene expression. Levels of RhoA gene
expression in vivo can be measured, for example, by in situ
hybridization, or by the isolation of RNA from tissue prior to and
following exposure to the iRNA agent. Where the animal needs to be
sacrificed in order to harvest the tissue, an untreated control
animal will serve for comparison. RhoA mRNA can be detected by any
desired method, including but not limited to RT-PCR, Northern blot,
branched-DNA assay, or RNAase protection assay. Alternatively, or
additionally, RhoA gene expression can be monitored by performing
Western blot analysis on tissue extracts treated with the iRNA
agent.
[0077] Animal models may be used to establish the concentration
necessary to achieve a certain desired effect (e.g., EC.sub.50 or
ED.sub.50). Such animal models may include transgenic animals that
express a human gene, e.g., a gene that produces a target human
RhoA RNA. In another embodiment, the composition for testing
includes an iRNA agent that is complementary, at least in an
internal region, to a sequence that is conserved between the target
RhoA RNA in the animal model and the target RhoA RNA in a
human.
[0078] iRNA Chemistry
[0079] Described herein are isolated iRNA agents, e.g., ds RNA
agents that mediate RNAi to inhibit expression of a RhoA gene.
[0080] RNA agents discussed herein include otherwise unmodified RNA
as well as RNA which has been modified, e.g., to improve efficacy,
and polymers of nucleoside surrogates. Unmodified RNA refers to a
molecule in which the components of the nucleic acid, namely
sugars, bases, and phosphate moieties, are the same or essentially
the same as that which occur in nature, preferably as occur
naturally in the human body. The art has referred to rare or
unusual, but naturally occurring, RNAs as modified RNAs, see, e.g.,
Limbach et al. Nucleic Acids Res. 22: 2183-2196, 1994. Such rare or
unusual RNAs, often termed modified RNAs (apparently because they
are typically the result of a post-transcriptional modification)
are within the term unmodified RNA, as used herein. Modified RNA as
used herein refers to a molecule in which one or more of the
components of the nucleic acid, namely sugars, bases, and phosphate
moieties, are different from that which occurs in nature,
preferably different from that which occurs in the human body.
While they are referred to as modified "RNAs," they will of course,
because of the modification, include molecules which are not RNAs.
Nucleoside surrogates are molecules in which the ribophosphate
backbone is replaced with a non-ribophosphate construct that allows
the bases to the presented in the correct spatial relationship such
that hybridization is substantially similar to what is seen with a
ribophosphate backbone, e.g., non-charged mimics of the
ribophosphate backbone. Examples of the above are discussed
herein.
[0081] Modifications described herein can be incorporated into any
double-stranded RNA and RNA-like molecule described herein, e.g.,
an iRNA agent. It may be desirable to modify one or both of the
antisense and sense strands of an iRNA agent. As nucleic acids are
polymers of subunits or monomers, many of the modifications
described below occur at a position which is repeated within a
nucleic acid, e.g., a modification of a base, or a phosphate
moiety, or the non-linking O of a phosphate moiety. In some cases
the modification will occur at all of the subject positions in the
nucleic acid but in many, and in fact in most, cases it will not.
By way of example, a modification may only occur at a 3' or 5'
terminal position, may only occur in a terminal region, e.g. at a
position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10
nucleotides of a strand. A modification may occur in a double
strand region, a single strand region, or in both. E.g., a
phosphorothioate modification at a non-linking O position may only
occur at one or both termini, may only occur in a terminal regions,
e.g., at a position on a terminal nucleotide or in the last 2, 3,
4, 5, or 10 nucleotides of a strand, or may occur in double strand
and single strand regions, particularly at termini. Similarly, a
modification may occur on the sense strand, antisense strand, or
both. In some cases, the sense and antisense strand will have the
same modifications or the same class of modifications, but in other
cases the sense and antisense strand will have different
modifications, e.g., in some cases it may be desirable to modify
only one strand, e.g. the sense strand.
[0082] Two prime objectives for the introduction of modifications
into iRNA agents is their stabilization towards degradation in
biological environments and the improvement of pharmacological
properties, e.g. pharmacodynamic properties, which are further
discussed below. Other suitable modifications to a sugar, base, or
backbone of an iRNA agent are described in co-owned PCT Application
No. PCT/US2004/01193, filed Jan. 16, 2004. An iRNA agent can
include a non-naturally occurring base, such as the bases described
in co-owned PCT Application No. PCT/US2004/011822, filed Apr. 16,
2004. An iRNA agent can include a non-naturally occurring sugar,
such as a non-carbohydrate cyclic carrier molecule. Exemplary
features of non-naturally occurring sugars for use in iRNA agents
are described in co-owned PCT Application No. PCT/US2004/11829,
filed Apr. 16, 2003.
[0083] An iRNA agent can include an internucleotide linkage (e.g.,
the chiral phosphorothioate linkage) useful for increasing nuclease
resistance. In addition, or in the alternative, an iRNA agent can
include a ribose mimic for increased nuclease resistance. Exemplary
intemucleotide linkages and ribose mimics for increased nuclease
resistance are described in co-owned PCT Application No.
PCT/US2004/07070, filed on Mar. 8, 2004.
[0084] An iRNA agent can include ligand-conjugated monomer subunits
and monomers for oligonucleotide synthesis. Exemplary monomers are
described in co-owned U.S. application Ser. No. 10/916,185, filed
on Aug. 10, 2004.
[0085] An iRNA agent can have a ZXY structure, such as is described
in co-owned PCT Application No. PCT/US2004/07070, filed on Mar. 8,
2004.
[0086] An iRNA agent can be complexed with an amphipathic moiety.
Exemplary amphipathic moieties for use with iRNA agents are
described in co-owned PCT Application No. PCT/US2004/07070, filed
on Mar. 8, 2004.
[0087] In another embodiment, the iRNA agent can be complexed to a
delivery agent that features a modular complex. The complex can
include a carrier agent linked to one or more of (preferably two or
more, more preferably all three of): (a) a condensing agent (e.g.,
an agent capable of attracting, e.g., binding, a nucleic acid,
e.g., through ionic or electrostatic interactions); (b) a fusogenic
agent (e.g., an agent capable of fusing and/or being transported
through a cell membrane); and (c) a targeting group, e.g., a cell
or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or
protein, e.g., an antibody, that binds to a specified cell type.
iRNA agents complexed to a delivery agent are described in co-owned
PCT Application No. PCT/US2004/07070, filed on Mar. 8, 2004.
[0088] An iRNA agent can have non-canonical pairings, such as
between the sense and antisense sequences of the iRNA duplex.
Exemplary features of non-canonical iRNA agents are described in
co-owned PCT Application No. PCT/US2004/07070, filed on Mar. 8,
2004.
Enhanced Nuclease Resistance
[0089] An iRNA agent, e.g., an iRNA agent that targets RhoA, can
have enhanced resistance to nucleases. Naked RNA is often an easy
prey for nucleolytic enzymes, such as exonucleases and
endonucleases, which are omnipresent in biological media, such as
the cellular cytoplasm, blood, or cerebrospinal fluid (CSF). Quick
degradation can severly hamper the ability of an siRNA to inhibit
the expression of a target gene. The vulnerability towards
nucleolytic degradation can be greatly reduced by chemically
modifying certain nucleotides of an siRNA. However, adding
modifications in order to stabilize an siRNA sometimes represents a
trade-off with its activity, and stabilizing modifications may even
introduce toxic effects. It is therefore desirable to introduce the
minimum number of modifications that still imparts the desired
level of stability. Modifications in the sense strand usually have
less impact on the activity of an siRNA.
[0090] In order to increase the stability of an siRNA towards
nucleolytic degradation by endonucleases, it is therefore
advantageous to modify only a limited number of nucleotides in
particularly degradation prone positions, as described in co-owned
U.S. Application No. 60/559,917, filed on May 4, 2004, co-owned
U.S. Application No. 60/574,744, filed on May 27, 2004, and
co-owned international application PCT/US2005/018931, filed May 27,
2005. We have determined that pyrimidine nucleotides, and
specifically the 5' nucleotide in a 5'-ua-3' sequence context, a
5'-ug-3' sequence context, a 5'-ca-3' sequence context, a 5'-uu-3'
sequence context, or a 5'-cc-3' sequence context are particularly
prone to degradative attack, in that approximate order.
Sufficiently stable and highly active siRNAs have been obtained by
our laboratory when the 5'-most pyrimidines in all occurrences of
the sequence contexts 5'-ua-3' and 5'-ca-3', or in all occurrences
of 5'-ua-3', 5'-ca-3', and 5'-uu-3', or in all occurrences of
5'-ua-3', 5'-ca-3', 5'-uu-3', and 5'-ug-3' were replaced by
2'-modified nucleotides, such as 2'-O-methyl nucleotides, in both
strands. Alternatively, 2'-modifying all pyrimidine nucleotides in
the sense strand and the 5'-most pyrimidines in all occurrences of
the sequence contexts 5'-ua-3' and 5'-ca-3' in the antisense strand
has given good results in terms of activity and stability.
Sometimes, it has been necessary to 2'-modify all pyrimidine
nucleotides in the sense strand and the 5'-most pyrimidines in all
occurrences of the sequence contexts 5'-ua-3', 5'-ca-3', 5'-uu-3',
and 5'-ug-3' in the antisense strand. The iRNA agent can include at
least 2, at least 3, at least 4 or at least 5 of such
dinucleotides.
[0091] Preferably, the 2'-modified nucleotides include, for
example, a 2'-modified ribose unit, e.g., the 2'-hydroxyl group
(OH) can be modified or replaced with a number of different "oxy"
or "deoxy" substituents.
[0092] Examples of "oxy"-2' hydroxyl group modifications include
alkoxy or aryloxy (OR, e.g., R=H, alkyl, cycloalkyl, aryl, aralkyl,
heteroaryl or sugar); polyethyleneglycols (PEG),
O(CH.sub.2CH.sub.2O).sub.nCH.sub.2CH.sub.2OR; "locked" nucleic
acids (LNA) in which the 2' hydroxyl is connected, e.g., by a
methylene bridge, to the 4' carbon of the same ribose sugar;
O-AMINE and aminoalkoxy, O(CH.sub.2).sub.nAMINE, (e.g.,
AMINE=NH.sub.2; alkylamino, dialkylamino, heterocyclyl amino,
arylamino, diaryl amino, heteroaryl amino, or diheteroaryl amino,
ethylene diamine, polyamino). It is noteworthy that
oligonucleotides containing only the methoxyethyl group (MOE),
(OCH.sub.2CH.sub.2OCH.sub.3, a PEG derivative), exhibit nuclease
stabilities comparable to those modified with the robust
phosphorothioate modification.
[0093] "Deoxy" modifications include hydrogen (i.e. deoxyribose
sugars, which are of particular relevance to the overhang portions
of partially ds RNA); halo (e.g., fluoro); amino (e.g. NH.sub.2;
alkylamino, dialkylamino, heterocyclyl, arylamino, diaryl amino,
heteroaryl amino, diheteroaryl amino, or amino acid);
NH(CH.sub.2CH.sub.2NH).sub.nCH.sub.2CH.sub.2-AMINE (AMINE=NH.sub.2;
alkylamino, dialkylamino, heterocyclyl amino, arylamino, diaryl
amino, heteroaryl amino,or diheteroaryl amino), --NHC(O)R (R=alkyl,
cycloalkyl, aryl, aralkyl, heteroaryl or sugar), cyano; mercapto;
alkyl-thio-alkyl; thioalkoxy; and alkyl, cycloalkyl, aryl, alkenyl
and alkynyl, which may be optionally substituted with e.g., an
amino functionality.
[0094] Preferred substitutents are 2'-methoxyethyl, 2'-OCH.sub.3,
2'-O-allyl, 2'-C-allyl, and 2'-fluoro.
[0095] The inclusion of furanose sugars in the oligonucleotide
backbone can also decrease endonucleolytic cleavage. An iRNA agent
can be further modified by including a 3' cationic group, or by
inverting the nucleoside at the 3'-terminus with a 3'-3' linkage.
In another alternative, the 3'-terminus can be blocked with an
aminoalkyl group, e.g., a 3' C5-aminoalkyl dT. Other 3' conjugates
can inhibit 3'-5' exonucleolytic cleavage. While not being bound by
theory, a 3' conjugate, such as naproxen or ibuprofen, may inhibit
exonucleolytic cleavage by sterically blocking the exonuclease from
binding to the 3'-end of oligonucleotide. Even small alkyl chains,
aryl groups, or heterocyclic conjugates or modified sugars
(D-ribose, deoxyribose, glucose etc.) can block
3'-5'-exonucleases.
[0096] Nucleolytic cleavage can also be inhibited by the
introduction of phosphate linker modifications, e.g.,
phosphorothioate linkages. Thus, preferred iRNA agents include
nucleotide dimers enriched or pure for a particular chiral form of
a modified phosphate group containing a heteroatom at a nonbridging
position normally occupied by oxygen. The heteroatom can be S, Se,
Nr.sub.2, or Br.sub.3. When the heteroatom is S, enriched or
chirally pure Sp linkage is preferred. Enriched means at least 70,
80, 90, 95, or 99% of the preferred form. Modified phosphate
linkages are particularly efficient in inhibiting exonucleolytic
cleavage when introduced near the 5'- or 3'-terminal positions, and
preferably the 5'-terminal positions, of an iRNA agent.
[0097] 5' conjugates can also inhibit 5'-3' exonucleolytic
cleavage. While not being bound by theory, a 5' conjugate, such as
naproxen or ibuprofen, may inhibit exonucleolytic cleavage by
sterically blocking the exonuclease from binding to the 5'-end of
oligonucleotide. Even small alkyl chains, aryl groups, or
heterocyclic conjugates or modified sugars (D-ribose, deoxyribose,
glucose etc.) can block 3'-5'-exonucleases.
[0098] An iRNA agent can have increased resistance to nucleases
when a duplexed iRNA agent includes a single-stranded nucleotide
overhang on at least one end. In preferred embodiments, the
nucleotide overhang includes 1 to 4, preferably 2 to 3, unpaired
nucleotides. In a preferred embodiment, the unpaired nucleotide of
the single-stranded overhang that is directly adjacent to the
terminal nucleotide pair contains a purine base, and the terminal
nucleotide pair is a G-C pair, or at least two of the last four
complementary nucleotide pairs are G-C pairs. In further
embodiments, the nucleotide overhang may have 1 or 2 unpaired
nucleotides, and in an exemplary embodiment the nucleotide overhang
is 5'-GC-3'. In preferred embodiments, the nucleotide overhang is
on the 3'-end of the antisense strand. In one embodiment, the iRNA
agent includes the motif 5'-CGC-3' on the 3'-end of the antisense
strand, such that a 2-nt overhang 5'-GC-3' is formed.
[0099] Thus, an iRNA agent can include modifications so as to
inhibit degradation, e.g., by nucleases, e.g., endonucleases or
exonucleases, found in the body of a subject. These monomers are
referred to herein as NRMs, or Nuclease Resistance promoting
Monomers, the corresponding modifications as NRM modifications. In
many cases these modifications will modulate other properties of
the iRNA agent as well, e.g., the ability to interact with a
protein, e.g., a transport protein, e.g., serum albumin, or a
member of the RISC, or the ability of the first and second
sequences to form a duplex with one another or to form a duplex
with another sequence, e.g., a target molecule.
[0100] One or more different NRM modifications can be introduced
into an iRNA agent or into a sequence of an iRNA agent. An NRM
modification can be used more than once in a sequence or in an iRNA
agent.
[0101] NRM modifications include some which can be placed only at
the terminus and others which can go at any position. Some NRM
modifications can inhibit hybridization so it is preferable to use
them only in terminal regions, and preferable to not use them at
the cleavage site or in the cleavage region of a sequence which
targets a subject sequence or gene, particularly on the antisense
strand. They can be used anywhere in a sense strand, provided that
sufficient hybridization between the two strands of the ds iRNA
agent is maintained. In some embodiments it is desirable to put the
NRM at the cleavage site or in the cleavage region of a sense
strand, as it can minimize off-target silencing.
[0102] In most cases, NRM modifications will be distributed
differently depending on whether they are comprised on a sense or
antisense strand. If on an antisense strand, modifications which
interfere with or inhibit endonuclease cleavage should not be
inserted in the region which is subject to RISC mediated cleavage,
e.g., the cleavage site or the cleavage region (As described in
Elbashir et al., 2001, Genes and Dev. 15: 188, hereby incorporated
by reference). Cleavage of the target occurs about in the middle of
a 20 or 21 nt antisense strand, or about 10 or 11 nucleotides
upstream of the first nucleotide on the target mRNA which is
complementary to the antisense strand. As used herein cleavage site
refers to the nucleotides on either side of the cleavage site, on
the target or on the iRNA agent strand which hybridizes to it.
Cleavage region means the nucleotides within 1, 2, or 3 nucleotides
of the cleavagee site, in either direction.
[0103] Such modifications can be introduced into the terminal
regions, e.g., at the terminal position or with 2, 3, 4, or 5
positions of the terminus, of a sense or antisense strand.
Tethered Ligands
[0104] The properties of an iRNA agent, including its
pharmacological properties, can be influenced and tailored, for
example, by the introduction of ligands, e.g. tethered ligands.
[0105] A wide variety of entities, e.g., ligands, can be tethered
to an iRNA agent, e.g., to the carrier of a ligand-conjugated
monomer subunit. Examples are described below in the context of a
ligand-conjugated monomer subunit but that is only preferred,
entities can be coupled at other points to an iRNA agent.
[0106] Preferred moieties are ligands, which are coupled,
preferably covalently, either directly or indirectly via an
intervening tether, to the carrier. In preferred embodiments, the
ligand is attached to the carrier via an intervening tether. The
ligand or tethered ligand may be present on the ligand-conjugated
monomer when the ligand-conjugated monomer is incorporated into the
growing strand. In some embodiments, the ligand may be incorporated
into a "precursor" ligand-conjugated monomer subunit after a
"precursor" ligand-conjugated monomer subunit has been incorporated
into the growing strand. For example, a monomer having, e.g., an
amino-terminated tether, e.g., TAP-(CH.sub.2).sub.nNH.sub.2 may be
incorporated into a growing sense or antisense strand. In a
subsequent operation, i.e., after incorporation of the precursor
monomer subunit into the strand, a ligand having an electrophilic
group, e.g., a pentafluorophenyl ester or aldehyde group, can
subsequently be attached to the precursor ligand-conjugated monomer
by coupling the electrophilic group of the ligand with the terminal
nucleophilic group of the precursor ligand-conjugated monomer
subunit tether.
[0107] In preferred embodiments, a ligand alters the distribution,
targeting or lifetime of an iRNA agent into which it is
incorporated. In preferred embodiments a ligand provides an
enhanced affinity for a selected target, e.g., molecule, cell or
cell type, compartment, e.g., a cellular or organ compartment,
tissue, organ or region of the body, as, e.g., compared to a
species absent such a ligand.
[0108] Preferred ligands can improve transport, hybridization, and
specificity properties and may also improve nuclease resistance of
the resultant natural or modified oligoribonucleotide, or a
polymeric molecule comprising any combination of monomers described
herein and/or natural or modified ribonucleotides.
[0109] Ligands in general can include therapeutic modifiers, e.g.,
for enhancing uptake; diagnostic compounds or reporter groups e.g.,
for monitoring distribution; cross-linking agents;
nuclease-resistance conferring moieties; and natural or unusual
nucleobases. General examples include lipophilic molecules, lipids,
lectins, steroids (e.g.,uvaol, hecigenin, diosgenin), terpenes
(e.g., triterpenes, e.g., sarsasapogenin, Friedelin, epifriedelanol
derivatized lithocholic acid), vitamins, carbohydrates (e.g., a
dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or
hyaluronic acid), proteins, protein binding agents, integrin
targeting molecules, polycationics, peptides, polyamines, and
peptide mimics.
[0110] The ligand may be a naturally occurring or recombinant or
synthetic molecule, such as a synthetic polymer, e.g., a synthetic
polyamino acid. Examples of polyamino acids include polylysine
(PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic
acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer,
divinyl ether-maleic anhydride copolymer,
N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene
glycol (PEG), polyvinyl alcohol (PVA), polyurethane,
poly(2-ethylacrylic acid), N-isopropylacrylamide polymers, or
polyphosphazine. Example of polyamines include: polyethylenimine,
polylysine (PLL), spermine, spermidine, polyamine,
pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer
polyamine, arginine, amidine, protamine, cationic moieties, e.g.,
cationic lipid, cationic porphyrin, quaternary salt of a polyamine,
or an alpha helical peptide.
[0111] Ligands can also include targeting groups, e.g., a cell or
tissue targeting agent, e.g., a thyrotropin, melanotropin,
surfactant protein A, Mucin carbohydrate, a glycosylated
polyaminoacid, transferrin, bisphosphonate, polyglutamate,
polyaspartate, or an RGD peptide or RGD peptide mimetic.
[0112] Ligands can be proteins, e.g., glycoproteins, lipoproteins,
e.g. low density lipoprotein (LDL), or albumins, e.g. human serum
albumin (HSA), or peptides, e.g., molecules having a specific
affinity for a co-ligand, or antibodies e.g., an antibody, that
binds to a specified cell type such as a cancer cell, endothelial
cell, or bone cell. Ligands may also include hormones and hormone
receptors. They can also include non-peptidic species, such as
cofactors, multivalent lactose, multivalent galactose,
N-acetyl-galactosamine, N-acetyl-glucosamine, multivalent mannose,
or multivalent fucose. The ligand can be, for example, a
lipopolysaccharide, an activator of p38 MAP kinase, or an activator
of NF-.kappa.B.
[0113] The ligand can be a substance, e.g, a drug, which can
increase the uptake of the iRNA agent into the cell, for example,
by disrupting the cell's cytoskeleton, e.g., by disrupting the
cell's microtubules, microfilaments, and/or intermediate filaments.
The drug can be, for example, taxon, vincristine, vinblastine,
cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin,
swinholide A, indanocine, or myoservin.
[0114] In one aspect, the ligand is a lipid or lipid-based
molecule. Such a lipid or lipid-based molecule preferably binds a
serum protein, e.g., human serum albumin (HSA). An HSA binding
ligand allows for distribution of the conjugate to a target tissue,
e.g., liver tissue, including parenchymal cells of the liver. Other
molecules that can bind HSA can also be used as ligands. For
example, neproxin or aspirin can be used. A lipid or lipid-based
ligand can (a) increase resistance to degradation of the conjugate,
(b) increase targeting or transport into a target cell or cell
membrane, and/or (c) can be used to adjust binding to a serum
protein, e.g., HSA.
[0115] A lipid based ligand can be used to modulate, e.g., control
the binding of the conjugate to a target tissue. For example, a
lipid or lipid-based ligand that binds to HSA more strongly will be
less likely to be targeted to the kidney and therefore less likely
to be cleared from the body. A lipid or lipid-based ligand that
binds to HSA less strongly can be used to target the conjugate to
the kidney.
[0116] In a preferred embodiment, the lipid based ligand binds HSA.
Preferably, it binds HSA with a sufficient affinity such that the
conjugate will be preferably distributed to a non-kidney tissue.
However, it is preferred that the affinity not be so strong that
the HSA-ligand binding cannot be reversed.
[0117] In another aspect, the ligand is a moiety, e.g., a vitamin
or nutrient, which is taken up by a target cell, e.g., a
proliferating cell. These are particularly useful for treating
disorders characterized by unwanted cell proliferation, e.g., of
the malignant or non-malignant type, e.g., cancer cells. Exemplary
vitamins include vitamin A, E, and K. Other exemplary vitamins
include the B vitamins, e.g., folic acid, B12, riboflavin, biotin,
pyridoxal or other vitamins or nutrients taken up by cancer
cells.
[0118] In another aspect, the ligand is a cell-permeation agent,
preferably a helical cell-permeation agent. Preferably, the agent
is amphipathic. An exemplary agent is a peptide such as tat or
antennapedia. If the agent is a peptide, it can be modified,
including a peptidylmimetic, invertomers, non-peptide or
pseudo-peptide linkages, and use of D-amino acids. The helical
agent is preferably an alpha-helical agent, which preferably has a
lipophilic and a lipophobic phase.
5'-Phosphate Modifications
[0119] In preferred embodiments, iRNA agents are 5' phosphorylated
or include a phosphoryl analog at the 5' prime terminus.
5'-phosphate modifications of the antisense strand include those
which are compatible with RISC mediated gene silencing. Suitable
modifications include: 5'-monophosphate ((HO)2(O)P--O-5');
5'-diphosphate ((HO)2(O)P--O--P(HO)(O)--O-5'); 5'-triphosphate
((HO)2(O)P--O--(HO)(O)P--O--P(HO)(O)--O-5'); 5'-guanosine cap
(7-methylated or non-methylated)
(7m-G-O-5'-(HO)(O)P--O--(HO)(O)P--O--P(HO)(O)--O-5'); 5'-adenosine
cap (Appp), and any modified or unmodified nucleotide cap structure
(N--O-5'-(HO)(O)P--O--(HO)(O)P--O--P(HO)(O)--O-5');
5'-monothiophosphate (phosphorothioate; (HO)2(S)P--O-5');
5'-monodithiophosphate (phosphorodithioate; (HO)(HS)(S)P--O-5'),
5'-phosphorothiolate ((HO)2(O)P--S-5'); any additional combination
of oxygen/sulfur replaced monophosphate, diphosphate and
triphosphates (e.g. 5'-alpha-thiotriphosphate,
5'-gamma-thiotriphosphate, etc.), 5'-phosphoramidates
((HO)2(O)P--NH-5', (HO)(NH2)(O)P--O-5'), 5'-alkylphosphonates
(R=alkyl=methyl, ethyl, isopropyl, propyl, etc., e.g.
RP(OH)(O)--O-5'-, (OH)2(O)P-5'-CH2-), 5'-alkyletherphosphonates
(R=alkylether=methoxymethyl (MeOCH2-), ethoxymethyl, etc., e.g.
RP(OH)(O)--O-5'-).
[0120] The sense strand can be modified in order to inactivate the
sense strand and prevent formation of an active RISC, thereby
potentially reducing off-target effects. This can be accomplished
by a modification which prevents 5'-phosphorylation of the sense
strand, e.g., by modification with a 5'-O-methyl ribonucleotide
(see Nykanen et al., (2001) ATP requirements and small interfering
RNA structure in the RNA interference pathway. Cell 107, 309-321.)
Other modifications which prevent phosphorylation can also be used,
e.g., simply substituting the 5'-OH by H rather than O-Me.
Alternatively, a large bulky group may be added to the 5'-phosphate
turning it into a phosphodiester linkage.
Transport of iRNA Agents into Cells
[0121] Not wishing to be bound by any theory, the chemical
similarity between cholesterol-conjugated iRNA agents and certain
constituents of lipoproteins (e.g. cholesterol, cholesteryl esters,
phospholipids) may lead to the association of iRNA agents with
lipoproteins (e.g. LDL, HDL) in blood and/or the interaction of the
iRNA agent with cellular components having an affinity for
cholesterol, e.g. components of the cholesterol transport pathway.
Lipoproteins as well as their constituents are taken up and
processed by cells by various active and passive transport
mechanisms, for example, without limitation, endocytosis of
LDL-receptor bound LDL, endocytosis of oxidized or otherwise
modified LDLs through interaction with Scavenger receptor A,
Scavenger receptor B1-mediated uptake of HDL cholesterol in the
liver, pinocytosis, or transport of cholesterol across membranes by
ABC (ATP-binding cassette) transporter proteins, e.g. ABC-A1,
ABC-G1 or ABC-G4. Hence, cholesterol-conjugated iRNA agents could
enjoy facilitated uptake by cells possessing such transport
mechanisms, e.g. cells of the liver. As such, the present invention
provides evidence and general methods for targeting iRNA agents to
cells expressing certain cell surface components, e.g. receptors,
by conjugating a natural ligand for such component (e.g.
cholesterol) to the iRNA agent, or by conjugating a chemical moiety
(e.g. cholesterol) to the iRNA agent which associates with or binds
to a natural ligand for the component (e.g. LDL, HDL).
[0122] Other Embodiments
[0123] An RNA, e.g., an iRNA agent, can be produced in a cell in
vivo, e.g., from exogenous DNA templates that are delivered into
the cell. For example, the DNA templates can be inserted into
vectors and used as gene therapy vectors. Gene therapy vectors can
be delivered to a subject by, for example, intravenous injection,
local administration (U.S. Pat. No. 5,328,470), or by stereotactic
injection (see, e.g., Chen et al. Proc. Natl. Acad. Sci. USA
91:3054-3057, 1994). The pharmaceutical preparation of the gene
therapy vector can include the gene therapy vector in an acceptable
diluent, or can comprise a slow release matrix in which the gene
delivery vehicle is imbedded. The DNA templates, for example, can
include two transcription units, one that produces a transcript
that includes the top strand of an iRNA agent and one that produces
a transcript that includes the bottom strand of an iRNA agent. When
the templates are transcribed, the iRNA agent is produced, and
processed into siRNA agent fragments that mediate gene
silencing.
[0124] Formulation
[0125] The iRNA agents described herein can be formulated for
administration to a subject.
[0126] For ease of exposition, the formulations, compositions, and
methods in this section are discussed largely with regard to
unmodified iRNA agents. It should be understood, however, that
these formulations, compositions, and methods can be practiced with
other iRNA agents, e.g., modified iRNA agents, and such practice is
within the invention.
[0127] A formulated iRNA agent composition can assume a variety of
states. In some examples, the composition is at least partially
crystalline, uniformly crystalline, and/or anhydrous (e.g., less
than 80, 50, 30, 20, or 10% water). In another example, the iRNA
agent is in an aqueous phase, e.g., in a solution that includes
water.
[0128] The aqueous phase or the crystalline compositions can, e.g.,
be incorporated into a delivery vehicle, e.g., a liposome
(particularly for the aqueous phase) or a particle (e.g., a
microparticle as can be appropriate for a crystalline composition).
Generally, the iRNA agent composition is formulated in a manner
that is compatible with the intended method of administration.
[0129] An iRNA agent preparation can be formulated in combination
with another agent, e.g., another therapeutic agent or an agent
that stabilizes an iRNA agent, e.g., a protein that complexes with
the iRNA agent to form an iRNP. Still other agents include
chelators, e.g., EDTA (e.g., to remove divalent cations such as
Mg.sup.2+), salts, RNAse inhibitors (e.g., a broad specificity
RNAse inhibitor such as RNAsin) and so forth.
[0130] In one embodiment, the iRNA agent preparation includes two
or more iRNA agent(s), e.g., two or more iRNA agents that can
mediate RNAi with respect to the same gene, or different alleles of
the gene, or with respect to different genes. Such preparations can
include at least three, five, ten, twenty, fifty, or a hundred or
more different iRNA agent species. Such iRNA agents can mediate
RNAi with respect to a similar number of different genes.
[0131] Where the two or more iRNA agents in such preparation target
the same gene, they can have target sequences that are
non-overlapping and non-adjacent, or the target sequences may be
overlapping or adjacent.
[0132] Disorders Associated with RhoA Expression
[0133] An iRNA agent that targets RhoA, e.g., an iRNA agent
described herein, can be used to treat a subject, e.g., a human
having or at risk for developing a disease or disorder associated
with RhoA gene expression or treating a subject where a biological
process mediated by RhoA is unwanted. Since Nogo-L, RhoA, and
Nogo-R participate in inhibiting axonal growth and elongations, the
iRNA agents of the present invention are used to reverse this
inhibition leading to nerve/axonal growth and elongation. Such a
treatment is useful in treating injuries to the nervous system such
as spinal cord injury or peripheral nerve death (caused by, e.g.,
Metastatic cancers of the CNS, e.g., gliomas (such as
glioblastomas, astrocytomas, oligodendrogliomas, ependymomas),
meningiomas, medulloblastomas, neuroblastomas, choroid plexus
papillomas, sarcomas can also be treated by the iRNA agents
described herein. Other indications include diseases of the central
nervous system, including but not limited to encephalomyelitis,
ischemic stroke, Alzheimer's Disease, spongiform encephalopathy,
Amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA),
multiple sclerosis, transverse myelitis, motor neuron disease,
Guillan Barre, Anterior Spinal Artery Syndrome, and
schizophrenia.
[0134] For example, an iRNA agent that targets RhoA mRNA can be
used to treat a subject with a spinal cord injury or a subject
having another pathological state which can be ameliorated, at
least in part, by nerve growth and elongation. In such a use, an
iRNA agent of the present invention is administered preferably
locally at the site of nerve damage or the site at which the
inhibitory effects of RhoA is desired to be reversed.
Administration of the iRNA agent leads to decrease in RhoA protein
resulting in reversing Nogo mediated inhibition of axonal
elongation and growth.
[0135] Treatment Methods and Routes of Delivery
[0136] A composition that includes an iRNA agent, e.g., an iRNA
agent that targets RhoA, can be delivered to a subject by a variety
of routes to achieve either local delivery to the site of action of
systemic delivery to the subject. Exemplary routes include direct
injection to the site of treatment, intrathecal, parenchymal,
intravenous, nasal, oral, and ocular delivery. The preferred means
of administering the iRNA agents of the present invention is
through direct injection or infusion to the site of treatment.
[0137] An iRNA agent can be incorporated into pharmaceutical
compositions suitable for administration. For example, compositions
can include one or more species of an iRNA agent and a
pharmaceutically acceptable carrier. As used herein the language
"pharmaceutically acceptable carrier" is intended to include any
and all solvents, dispersion media, coatings, antibacterial and
antifungal agents, isotonic and absorption delaying agents, and the
like, compatible with pharmaceutical administration. The use of
such media and agents for pharmaceutically active substances is
well known in the art. Except insofar as any conventional media or
agent is incompatible with the active compound, use thereof in the
compositions is contemplated. Supplementary active compounds can
also be incorporated into the compositions.
[0138] The pharmaceutical compositions of the present invention may
be administered in a number of ways depending upon whether local or
systemic treatment is desired and upon the area to be treated.
Administration may be topical (including ophthalmic, intranasal,
transdermal), oral or parenteral. Parenteral administration
includes intravenous drip, subcutaneous, intraperitoneal or
intramuscular injection, or intrathecal or intraventricular
administration.
[0139] The route of delivery can be dependent on the disorder of
the patient. In general, the delivery of the iRNA agents of the
present invention is done to achieve systemic delivery into the
subject. One preferred means of achieving this is through
parenteral administration. In a particularly preferred embodiment,
the application is achieved by direct application of the
pharmaceutical composition to the site of nerve injury, such as the
the site of spinal cord injury. Formulations for parenteral
administration may include sterile aqueous solutions which may also
contain buffers, diluents and other suitable additives. For
intravenous use, the total concentration of solutes should be
controlled to render the preparation isotonic.
[0140] Using the small interfering RNA vectors previously
described, the invention also provides devices, systems, and
methods for delivery of small interfering RNA to target locations
in the nervous system and or/the brain. The envisioned route of
delivery is through the use of implanted, indwelling, intrathecal
or intraparenchymal catheters that provide a means for injecting
small volumes of fluid containing the dsRNA of the invention
directly into local nerves or local brain tissue. The proximal end
of these catheters may be connected to an implanted, intrathecal or
intracerebral access port surgically affixed to the patient's body
or cranium, or to an implanted drug pump located in the patient's
torso.
[0141] Alternatively, implantable delivery devices, such as an
implantable pump may be employed. Examples of the delivery devices
within the scope of the invention include the Model 8506
investigational device (by Medtronic, Inc. of Minneapolis, Minn.),
which can be implanted subcutaneously in the body or on the
cranium, and provides an access port through which therapeutic
agents may be delivered to the nerves or brain. Delivery occurs
through a stereotactically implanted polyurethane catheter. Two
models of catheters that can finction with the Model 8506 access
port include the Model 8770 ventricular catheter by Medtronic,
Inc., for delivery to the intracerebral ventricles, which is
disclosed in U.S. Pat. No. 6,093,180, incorporated herein by
reference, and the IPA1 catheter by Medtronic, Inc., for delivery
to the brain tissue itself (i.e., intraparenchymal delivery),
disclosed in U.S. Ser. Nos. 09/540,444 and 09/625,751, which are
incorporated herein by reference. The latter catheter has multiple
outlets on its distal end to deliver the therapeutic agent to
multiple sites along the catheter path. In addition to the
aforementioned device, the delivery of the small interfering RNA
vectors in accordance with the invention can be accomplished with a
wide variety of devices, including but not limited to U.S. Pat.
Nos. 5,735,814, 5,814,014, and 6,042,579, all of which are
incorporated herein by reference. Using the teachings of the
invention and those of skill in the art will recognize that these
and other devices and systems may be suitable for delivery of small
interfering RNA vectors for the treatment of pain in accordance
with the invention.
[0142] In one such embodiment, the method further comprises the
steps of implanting a pump outside the body or brain, the pump
coupled to a proximal end of the catheter, and operating the pump
to deliver the predetermined dosage of the at least one small
interfering RNA or small interfering RNA vector through the
discharge portion of the catheter. A further embodiment comprises
the further step of periodically refreshing a supply of the at
least one small interfering RNA or small interfering RNA vector to
the pump outside said body or brain.
[0143] Thus, the invention includes the delivery of small
interfering RNA vectors using an implantable pump and catheter,
like that taught in U.S. Pat. Nos. 5,735,814 and 6,042,579, and
further using a sensor as part of the infusion system to regulate
the amount of small interfering RNA vectors delivered to the nerves
or brain, like that taught in U.S. Pat. No. 5,814,014. Other
devices and systems can be used in accordance with the method of
the invention, for example, the devices and systems disclosed in
U.S. Ser. No. 09/872,698 (filed Jun. 1, 2001) and Ser. No.
09/864,646 (filed May 23, 2001), which are incorporated herein by
reference.
[0144] Preferably, the outlet of the pump or catheter is placed in
close proximity of the desired site of action of the pharmaceutical
composition, such as near the site of spinal cord, or other nerve,
injury.
[0145] Administration can be provided by the subject or by another
person, e.g., a caregiver. A caregiver can be any entity involved
with providing care to the human: for example, a hospital, hospice,
doctor's office, outpatient clinic; a healthcare worker such as a
doctor, nurse, or other practitioner; or a spouse or guardian, such
as a parent. The medication can be provided in measured doses or in
a dispenser which delivers a metered dose.
[0146] The term "therapeutically effective amount" is the amount
present in the composition that is needed to provide the desired
level of drug in the subject to be treated to give the anticipated
physiological response.
[0147] The term "physiologically effective amount" is that amount
delivered to a subject to give the desired palliative or curative
effect.
[0148] The term "pharmaceutically acceptable carrier" means that
the carrier can be taken into the lungs with no significant adverse
toxicological effects on the lungs.
[0149] The term "co-administration" refers to administering to a
subject two or more agents, and in particular two or more iRNA
agents. The agents can be contained in a single pharmaceutical
composition and be administered at the same time, or the agents can
be contained in separate formulation and administered serially to a
subject. So long as the two agents can be detected in the subject
at the same time, the two agents are said to be co-administered. In
one embodiment, both Nogo-L, RhoA, and Nogo-R iRNA agents are
co-administered.
[0150] The types of pharmaceutical excipients that are useful as
carrier include stabilizers such as human serum albumin (HSA),
bulking agents such as carbohydrates, amino acids and polypeptides;
pH adjusters or buffers; salts such as sodium chloride; and the
like. These carriers may be in a crystalline or amorphous form or
may be a mixture of the two.
[0151] Bulking agents that are particularly valuable include
compatible carbohydrates, polypeptides, amino acids or combinations
thereof. Suitable carbohydrates include monosaccharides such as
galactose, D-mannose, sorbose, and the like; disaccharides, such as
lactose, trehalose, and the like; cyclodextrins, such as
2-hydroxypropyl-.beta.-cyclodextrin; and polysaccharides, such as
raffmose, maltodextrins, dextrans, and the like; alditols, such as
mannitol, xylitol, and the like. A preferred group of carbohydrates
includes lactose, threhalose, raffinose maltodextrins, and
mannitol. Suitable polypeptides include aspartame. Amino acids
include alanine and glycine, with glycine being preferred.
[0152] Suitable pH adjusters or buffers include organic salts
prepared from organic acids and bases, such as sodium citrate,
sodium ascorbate, and the like; sodium citrate is preferred.
[0153] Dosage. An iRNA agent can be administered at a unit dose
less than about 75 mg per kg of bodyweight, or less than about 70,
60, 50, 40, 30, 20, 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005,
0.001, or 0.0005 mg per kg of bodyweight, and less than 200 nmol of
iRNA agent (e.g., about 4.4.times.1016 copies) per kg of
bodyweight, or less than 1500, 750, 300, 150, 75, 15, 7.5, 1.5,
0.75, 0.15, 0.075, 0.015, 0.0075, 0.0015, 0.00075, 0.00015 nmol of
iRNA agent per kg of bodyweight. The unit dose, for example, can be
administered by injection (e.g., intravenous or intramuscular,
intrathecally, or directly into an organ), an inhaled dose, or a
topical application.
[0154] Delivery of an iRNA agent directly to an organ (e.g.,
directly to the liver) can be at a dosage on the order of about
0.00001 mg to about 3 mg per organ, or preferably about
0.0001-0.001 mg per organ, about 0.03-3.0 mg per organ, about
0.1-3.0 mg per eye or about 0.3-3.0 mg per organ.
[0155] The dosage can be an amount effective to treat or prevent a
disease or disorder.
[0156] In one embodiment, the unit dose is administered less
frequently than once a day, e.g., less than every 2, 4, 8 or 30
days. In another embodiment, the unit dose is not administered with
a frequency (e.g., not a regular frequency). For example, the unit
dose may be administered a single time. Because iRNA agent mediated
silencing can persist for several days after administering the iRNA
agent composition, in many instances, it is possible to administer
the composition with a frequency of less than once per day, or, for
some instances, only once for the entire therapeutic regimen.
[0157] In one embodiment, a subject is administered an initial
dose, and one or more maintenance doses of an iRNA agent, e.g., a
double-stranded iRNA agent, or siRNA agent, (e.g., a precursor,
e.g., a larger iRNA agent which can be processed into an siRNA
agent, or a DNA which encodes an iRNA agent, e.g., a
double-stranded iRNA agent, or siRNA agent, or precursor thereof).
The maintenance dose or doses are generally lower than the initial
dose, e.g., one-half less of the initial dose. A maintenance
regimen can include treating the subject with a dose or doses
ranging from 0.01 to 75 mg/kg of body weight per day, e.g., 70, 60,
50, 40, 30, 20, 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, or
0.0005 mg per kg of body weight per day. The maintenance doses are
preferably administered no more than once every 5, 10, or 30 days.
Further, the treatment regimen may last for a period of time which
will vary depending upon the nature of the particular disease, its
severity and the overall condition of the patient. In preferred
embodiments the dosage may be delivered no more than once per day,
e.g., no more than once per 24, 36, 48, or more hours, e.g., no
more than once every 5 or 8 days. Following treatment, the patient
can be monitored for changes in his condition and for alleviation
of the symptoms of the disease state. The dosage of the compound
may either be increased in the event the patient does not respond
significantly to current dosage levels, or the dose may be
decreased if an alleviation of the symptoms of the disease state is
observed, if the disease state has been ablated, or if undesired
side-effects are observed.
[0158] The effective dose can be administered in a single dose or
in two or more doses, as desired or considered appropriate under
the specific circumstances. If desired to facilitate repeated or
frequent infusions, implantation of a delivery device, e.g., a
pump, semi-permanent stent (e.g., intravenous, intraperitoneal,
intracisternal or intracapsular), or reservoir may be
advisable.
[0159] Following successful treatment, it may be desirable to have
the patient undergo maintenance therapy to prevent the recurrence
of the disease state, wherein the compound of the invention is
administered in maintenance doses, ranging from 0.001 g to 100 g
per kg of body weight (see U.S. Pat. No. 6,107,094).
[0160] The concentration of the iRNA agent composition is an amount
sufficient to be effective in treating or preventing a disorder or
to regulate a physiological condition in humans. The concentration
or amount of iRNA agent administered will depend on the parameters
determined for the agent and the method of administration, e.g.
nasal, buccal, pulmonary, or topical, such as intrathecal or at the
site of nerve injury. For example, topical formulations tend to
require much lower concentrations of some ingredients in order to
avoid irritation or burning.
[0161] Certain factors may influence the dosage required to
effectively treat a subject, including but not limited to the
severity of the disease or disorder, previous treatments, the
general health and/or age of the subject, and other diseases
present. It will also be appreciated that the effective dosage of
an iRNA agent such as an siRNA used for treatment may increase or
decrease over the course of a particular treatment. Changes in
dosage may result and become apparent from the results of
diagnostic assays. For example, the subject can be monitored after
administering an iRNA agent composition. Based on information from
the monitoring, an additional amount of the iRNA agent composition
can be administered.
[0162] Dosing is dependent on severity and responsiveness of the
disease condition to be treated, with the course of treatment
lasting from several days to several months, or until a cure is
effected or a diminution of disease state is achieved. Optimal
dosing schedules can be calculated from measurements of drug
accumulation in the body of the patient, or of drug accumulation at
the site of application when delivering locally, e.g. at the site
of nerve injusry, e.g. at the site of spinal cord injury. Persons
of ordinary skill can easily determine optimum dosages, dosing
methodologies and repetition rates.
[0163] Optimum dosages may vary depending on the relative potency
of individual compounds, and can generally be estimated based on
EC50s found to be effective in in vitro and in vivo animal models
as described above.
[0164] The invention is further illustrated by the following
examples, which should not be construed as further limiting.
EXAMPLES
[0165] Nucleic acid sequences are represented below using standard
nomenclature, and specifically the abbreviations of Table 2.
TABLE-US-00002 TABLE 2 Abbreviations of nucleotide monomers used in
nucleic acid sequence representation. It will be understood that
these monomers, when present in an oligonucleotide, are mutually
linked by 5'-3'-phosphodiester bonds. Abbreviation.sup.a
Nucleotide(s) A, a 2'-deoxy-adenosine-5'-phosphate,
adenosine-5'-phosphate C, c 2'-deoxy-cytidine-5'-phosphate,
cytidine-5'-phosphate G, g 2'-deoxy-guanosine-5'-phosphate,
guanosine-5'-phosphate T, t 2'-deoxy-thymidine-5'-phosphate,
thymidine-5'-phosphate U, u 2'-deoxy-uridine-5'-phosphate,
uridine-5'-phosphate N, n any 2'-deoxy-nucleotide/nucleotide (G, A,
C, or T, g, a, c or u) am 2'-O-methyladenosine-5'-phosphate cm
2'-O-methylcytidine-5'-phosphate gm
2'-O-methylguanosine-5'-phosphate tm
2'-O-methyl-thymidine-5'-phosphate um
2'-O-methyluridine-5'-phosphate A, C, G, T, U, a, underlined:
nucleoside-5'-phosphorothioate c, g, t, u -Chol
1-{6-[cholester-3-yloxycarbonylamino]-
hexanoyl}-4-hydroxy-pyrrolidin-3- phosphorothioate diester
.sup.acapital letters represent 2'-deoxyribonucleotides (DNA),
lower case letters represent ribonucleotides (RNA)
Source of Reagents
[0166] Where the source of a reagent is not specifically given
herein, such reagent may be obtained from any supplier of reagents
for molecular biology at a quality/purity standard for application
in molecular biology.
Example 1
Selection of Sequences
[0167] Sequence alignment was performed to identify regions within
the sequence of human RhoA mRNA with full homology to the
respective sequences in both mouse and rat RhoA mRNA (human RhoA
mRNA: Genbank accession no. NM.sub.--001664; mouse RhoA MRNA:
Genbank accession no. NM.sub.--016802; rat RhoA mRNA: Genbank
accession no. NM.sub.--057132). Within the regions of homology thus
identified, all possible contiguous sequences of 19 nucleotides
were examined by further BLAST comparison for potential
cross-reactivity of an siRNA comprising such sequence to other mRNA
sequences present in humans. Only sequences with 3 or more
mismatches to any other human mRNA or genomic sequence were chosen.
The resulting set of 19 nt sequences is represented in the sense
strand ribonucleotide sequences of the double-overhang iRNA agents
given in Table 1.
[0168] In order to maximise the stability of the siRNAs for testing
in biological media, particularly towards nucleolytic attack by
endo- and exonucleases, the siRNAs were synthesized such that in
the sense strands, all cytidine and uridine nucleotides comprise a
2'-O-methyl group, and in the antisense strand, all cytidines and
uridines appearing in a sequence context of 5'-ca-3' or 5'-ua-3'
comprise a 2'-O-methyl group.
[0169] To the same end, phosphorothioate linkages were introduced
between 3'-terminal 5'-TT-3'-group thymidines. It has been our
experience that the most active exonucleases in serum and other
biological media relevant for the in vivo activity of siRNAs act by
degrading siRNA strands 3'-5'. It has proven advantageous, and
often sufficient, to replace the 2 penultimate nucleotides in the
antisense strand by 2'-O-methyl-5'-phosphorothioate-modified
nucleotides (e.g. the nucleotides in positions 21 and 22, counting
5' to 3', of a 23-nucleotide antisense strand); sometimes it is
sufficient to modify only the penultimate nucleotide, or to use
only 5'-phosphorothioate-modified nucleotides, or both. The sense
strand may be protected in a similar fashion, and/or it may be
3'-conjugated to a tethered ligand via a phosphodiester or a
phosphorothioate diester.
[0170] In addition to the sequences selected as described above,
four siRNAs were synthesized which corresponded to four of those
utilized by the authors of Ahmed, Z.,et al, Mol Cell Neurosci.
2005, 28:509-23. AL-DP-5850 corresponds to RHO-A1 of Ahmed et al.,
supra, AL-DP-5851 to RHO-A2, AL-DP-5852 to RHO-A5 and AL-DP-5853 to
RHO-A4 of Ahmed et al., supra.
Example 2
siRNA Synthesis
[0171] Single-stranded RNAs were produced by solid phase synthesis
on a scale of 1 .mu.mole using an Expedite 8909 synthesizer
(Applied Biosystems, Applera Deutschland GmbH, Darmstadt, Germany)
and controlled pore glass (CPG, 500 .ANG., Glen Research, Sterling
Va.) as solid support. RNA and RNA containing 2'-O-methyl
nucleotides were 30 generated by solid phase synthesis employing
the corresponding phosphoramidites and 2'-O-methyl
phosphoramidites, respectively (Proligo Biochemie GmbH, Hamburg,
Germany). These building blocks were incorporated at selected sites
within the sequence of the oligoribonucleotide chain using standard
nucleoside phosphoramidite chemistry such as described in Current
protocols in nucleic acid chemistry, Beaucage, S. L. et al.
(Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA.
Phosphorothioate linkages were introduced by replacement of the
iodine oxidizer solution with a solution of the Beaucage reagent
(Chruachem Ltd, Glasgow, UK) in acetonitrile (1%). Further
ancillary reagents were obtained from Mallinckrodt Baker
(Griesheim, Germany).
[0172] Deprotection and purification by anion exchange HPLC of the
crude oligoribonucleotides were carried out according to
established procedures. Yields and concentrations were determined
by UV absorption of a solution of the respective RNA at a
wavelength of 260 nm using a spectral photometer (DU 640B, Beckman
Coulter GmbH, Unterschlei.beta.heim, Germany). Double stranded RNA
was generated by mixing an equimolar solution of complementary
strands in annealing buffer (20 mM sodium phosphate, pH 6.8; 100 mM
sodium chloride), heated in a water bath at 85-90.degree. C. for 3
minutes and cooled to room temperature over a period of 3-4 hours.
The purified RNA solution was stored at -20.degree. C. until
use.
[0173] As a result of the synthesis strategy described above, all
oligonucleotides synthesized as described above do not comprise a
phosphate group on their 5'-most nucleotide.
[0174] Cholesterol was 3'-conjugated to siRNA as illustrated in
FIG. 1. For the synthesis of these 3'-cholesterol-conjugated
siRNAs, an appropriately modified solid support was used for RNA
synthesis. The modified solid support was prepared as follows:
Diethyl-2-azabutane-1,4-dicarboxylate AA ##STR1##
[0175] A 4.7 M aqueous solution of sodium hydroxide (50 mL) was
added into a stirred, ice-cooled solution of ethyl glycinate
hydrochloride (32.19 g, 0.23 mole) in water (50 mL). Then, ethyl
acrylate (23.1 g, 0.23 mole) was added and the mixture was stirred
at room temperature until the completion of reaction was
ascertained by TLC (19 h). After 19 h which it was partitioned with
dichloromethane (3.times.100 mL). The organic layer was dried with
anhydrous sodium sulfate, filtered and evaporated. The residue was
distilled to afford AA (28.8 g, 61%).
3-{Ethoxycarbonylmethyl-[6-(9H-fluoren-9-ylmethoxycarbonyl-amino)-hexanoy-
l]-amino}-propionic acid ethyl ester AB ##STR2##
[0176] Fmoc-6-amino-hexanoic acid (9.12 g, 25.83 mmol) was
dissolved in dichloromethane (50 mL) and cooled with ice.
Diisopropylcarbodiimde (3.25 g, 3.99 mL, 25.83 mmol) was added to
the solution at 0.degree. C. It was then followed by the addition
of Diethyl-azabutane-1,4-dicarboxylate (5 g, 24.6 mmol) and
dimethylamino pyridine (0.305 g, 2.5 mmol). The solution was
brought to room temperature and stirred further for 6 h. the
completion of the reaction was ascertained by TLC. The reaction
mixture 1 5 was concentrated in vacuum and to the ethylacetate was
added to precipitate diisopropyl urea. The suspension was filtered.
The filtrate was washed with 5% aqueous hydrochloric acid, 5%
sodium bicarbonate and water. The combined organic layer was dried
over sodium sulfate and concentrated to give the crude product
which was purified by column chromatography (50% EtOAC/Hexanes) to
yield 11.87 g (88%) of AB.
3-[(6-Amino-hexanoyl)-ethoxycarbonylmethyl-amino]-propionic acid
ethyl ester AC ##STR3##
[0177]
3-{Ethoxycarbonylmethyl-[6-(9H-fluoren-9-ylmethoxycarbonylamino)-h-
exanoyl]-amino}-propionic acid ethyl ester AB (11.5 g, 21.3 mmol)
was dissolved in 20% piperidine in dimethylformamide at 0.degree.
C. The solution was continued stirring for 1 h. The reaction
mixture was concentrated in vacuum and the residue water was added
and the product was extracted with ethyl acetate. The crude.
product was purified by converting into hydrochloride salt.
3-({6-[17-(1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,-
15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]--
hexanoyl}ethoxycarbonylmethyl-amino)-propionic acid ethyl ester AD
##STR4##
[0178] The hydrochloride salt of
3-[(6-Amino-hexanoyl)-ethoxycarbonylmethyl-amino]-propionic acid
ethyl ester AC (4.7 g, 14.8 mmol) was taken up in dichloromethane.
The suspension was cooled to 0.degree. C. on ice. To the suspension
diisopropylethylamine (3.87 g, 5.2 mL, 30 mmol) was added. To the
resulting solution cholesteryl chloroformate (6.675 g, 14.8 mmol)
was added. The reaction mixture was stirred overnight. The reaction
mixture was diluted with dichloromethane and washed with 10%
hydrochloric acid. The product was purified by flash chromatography
(10.3 g, 92%).
1-{6-[17-(1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,1-
5,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-h-
exanoyl}-4-oxo-pyrrolidine-3-carboxylic acid ethyl ester AE
##STR5##
[0179] Potassium t-butoxide (1.1 g, 9.8 mmol) was slurried in 30 mL
of dry toluene. The mixture was cooled to 0.degree. C. on ice and 5
g (6.6 mmol) of diester AD was added slowly with stirring within 20
mins. The temperature was kept below 5.degree. C. during the
addition. The stirring was continued for 30 mins at 0.degree. C.
and 1 mL of glacial acetic acid was added, immediately followed by
4 g of NaH.sub.2PO.sub.4.H.sub.2O in 40 mL of water The resultant
mixture was extracted twice with 100 mL of dichloromethane each and
the combined organic extracts were washed twice with 10 mL of
phosphate buffer each, dried, and evaporated to dryness. The
residue was dissolved in 60 mL of toluene, cooled to 0.degree. C.
and extracted with three 50 mL portions of cold pH 9.5 carbonate
buffer. The aqueous extracts were adjusted to pH 3 with phosphoric
acid, and extracted with five 40 mL portions of chloroform which
were combined, dried and evaporated to a residue. The residue was
purified by column chromatography using 25% ethylacetate/hexane to
afford 1.9 g of b-ketoester (39%).
[6-(3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-yl)-6-oxo-hexyl]-carbamic
acid
17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,1-
7-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester AF
##STR6##
[0180] Methanol (2 mL) was added dropwise over a period of 1 h to a
refluxing mixture of b-ketoester AE (1.5 g, 2.2 mmol) and sodium
borohydride (0.226 g, 6 mmol) in tetrahydrofuran (10 mL). Stirring
was continued at reflux temperature for 1 h. After cooling to room
temperature, 1 N HCl (12.5 mL) was added, the mixture was extracted
with ethylacetate (3.times.40 mL). The combined ethylacetate layer
was dried over anhydrous sodium sulfate and concentrated in vacuum
to yield the product which was purified by column chromatography
(10% MeOH/CHCl.sub.3) (89%).
(6-{3-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-py-
rrolidin-1-yl}-6-oxo-hexyl)-carbamic acid
17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,1-
7-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester AG
##STR7##
[0181] Diol AF (1.25 gm 1.994 mmol) was dried by evaporating with
pyridine (2.times.5 mL) in vacuo. Anhydrous pyridine (10 mL) and
4,4'-dimethoxytritylchloride (0.724 g, 2.13 mmol) were added with
stirring. The reaction was carried out at room temperature
overnight. The reaction was quenched by the addition of methanol.
The reaction mixture was concentrated in vacuum and to the residue
dichloromethane (50 mL) was added. The organic layer was washed
with IM aqueous sodium bicarbonate. The organic layer was dried
over anhydrous sodium sulfate, filtered and concentrated. The
residual pyridine was removed by evaporating with toluene. The
crude product was purified by column chromatography (2%
MeOH/Chloroform, Rf=0.5 in 5% MeOH/CHCl.sub.3) (1.75 g, 95%).
Succinic acid
mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5--
dimethyl-hexyl)-10,13-dimethyl
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H
cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl)
ester AH ##STR8##
[0182] Compound AG (1.0 g, 1.05 mmol) was mixed with succinic
anhydride (0.150 g, 1.5 mmol) and DMAP (0.073 g, 0.6 mmol) and
dried in a vacuum at 40.degree. C. overnight. The mixture was
dissolved in anhydrous dichloroethane (3 mL), triethylamine (0.318
g, 0.440 mL, 3.15 mmol) was added and the solution was stirred at
room temperature under argon atmosphere for 16 h. It was then
diluted with dichloromethane (40 mL) and washed with ice cold
aqueous citric acid (5 wt %, 30 mL) and water (2.times.20 mL). The
organic phase was dried over anhydrous sodium sulfate and
concentrated to dryness. The residue was used as such for the next
step. Cholesterol Derivatised CPG AI ##STR9##
[0183] Succinate AH (0.254 g, 0.242 mmol) was dissolved in a
mixture of dichloromethane/acetonitrile (3:2, 3 mL). To that
solution DMAP (0.0296 g, 0.242 mmol) in acetonitrile (1.25 mL),
2,2'-Dithio-bis(5-nitropyridine) (0.075 g, 0.242 mmol) in
acetonitrile/dichloroethane (3:1, 1.25 mL) were added successively
To the resulting solution triphenylphosphine (0.064 g, 0.242 mmol)
in acetonitrile (0.6 ml) was added. The reaction mixture turned
bright orange in color. The solution was agitated briefly using
wrist-action shaker (5 mins). Long chain alkyl amine-CPG (LCAA-CPG)
(1.5 g, 61 mm/g) was added. The suspension was agitated for 2 h.
The CPG was filtered through a sintered finnel and washed with
acetonitrile, dichloromethane and ether successively. Unreacted
amino groups were masked using acetic anhydride/pyridine. The
loading capacity of the CPG was measured by taking UV measurement
(37 mM/g).
[0184] The synthesis and structure of cholesterol conjugated RNA
strands is illustrated in FIG. 1.
[0185] The siRNAs listed Table 3 were synthesized for activity
screening. TABLE-US-00003 TABLE 3 siRNAs specific for RhoA SEQ SEQ
Agent ID ID C. a. number Sense strand NO. Antisense strand NO.
#.sup.1 AL-DP-5850 gauuaugaccgucugaggcTT 1081 gccucagucggucauaaucTT
1082 n.a. AL-DP-5851 ggaucuucggaaugaugagTT 1083
cucaucauuccgaagauccTT 1084 n.a. AL-DP-5852 agaccaaagacggagugagTT
1085 cucacuccgucuuuggucuTT 1086 na. AL-DP-5853
ugaagcaggagccgguaaaTT 1087 uuuaccggcuccugcuucaTT 1088 na.
AL-DP-5972 gcmumacmcmagumaumumumagaagcmTT 1089
gcuucumaaaumacuggumagcTT 1090 6661 AL-DP-5973
cmumacmcmagumaumumumagaagcmcmTT 1091 ggcuucumaaaumacuggumagTT 1092
6662 AL-DP-5974 gcmumgumaacmumacmumumumaumaacmTT 1093
guumaumaaagumaguumacmagcTT 1094 6712 AL-DP-5975
gumumacmumgumgumaaumumagumgcmTT 1095 gcmacumaauumacmacmagumaacTT
1096 6751 AL-DP-5976 cmcmacmumumaaumgumaumgumumacmcmTT 1097
ggumaacmaumacmauumaaguggTT 1098 6769 AL-DP-5977
cmagcmcmcmumgaumagumumumagaaTT 1099 uucumaaacumaucmagggcugTT 1100
6521 AL-DP-5978 gcmcmcmumgaumagumumumagaaaaTT 1101
uuuucumaaacumaucmagggcTT 1102 6523 AL-DP-5979
cmcmcmumgaumagumumumagaaaacmTT 1103 guuuucumaaacumaucmagggTT 1104
6524 AL-DP-5980 gaumagumumumagaaaacmaumcmcmTT 1105
ggauguuuucumaaacumaucTT 1106 6528 AL-DP-5981
umagumumumagaaaacmaumcmcmcmaTT 1107 ugggauguuuucumaaacumaTT 1108
6530 AL-DP-5982 cmagacmumagaumgumagumaumumumTT 1109
aaaumacumacmaucumagucugTT 1110 6790 AL-DP-5983
cmcmcmcmagacmumagaumgumagumaTT 1111 umacumacmaucumagucuggggTT 1112
6787 AL-DP-5984 cmcmagacmumagaumgumagumaumumTT 1113
aaumacumacmaucumagucuggTT 1114 6789 AL-DP-5985
cmcmcmagacmumagaumgumagumaumTT 1115 aumacumacmaucumagucugggTT 1116
6788 AL-DP-5986 umgcmacmumumaaumgumaumgumumaTT 1117
umaacmaumacmauumaaguggcmaTT 1118 6767 AL-DP-5987
umgcmumgumumumaumumaaumcmumumagTT 1119 cumaagauumaaumaaacmagcmaTT
1120 6614 AL-DP-5988 umcmaumgumumagumumacmcmumumaumaTT 1121
umaumaaggumaacumaacmaugaTT 1122 6732 AL-DP-5989
cmcmagumumaaumumumumumcmcmaacmumTT 1123 aguuggaaaaauumaacuggTT 1124
6832 AL-DP-5990 umacmcmumaagaumumacmaaaumcmaTT 1125
ugauuugumaaucuumaggumaTT 1126 6650 AL-DP-5991
umcmumumgcmumacmcmagumaumumumagTT 1127 cumaaaumacuggumagcmaagaTT
1128 6657 AL-DP-5992 umgumgumaaumumagumgcmcmacmumumTT 1129
aaguggcmacumaauumacmacmaTT 1130 6756 AL-DP-5993
aumcmumumgcmumacmcmagumaumumumaTT 1131 umaaaumacuggumagcmaagauTT
1132 6656 AL-DP-5994 cmumgumaacmumacmumumumaumaacmumTT 1133
aguumaumaaagumaguumacmagTT 1134 6713 AL-DP-5995
gumgaaumumaggcmumgumaacmumaTT 1135 umaguumacmagccumaauucmacTT 1136
6703 AL-DP-6176 cmumacmcmagumaumumumagaagcmcmTT-Chol 1137
ggcuucumaaaumacuggumagTT 1138 6662 AL-DP-6177
umgcmumgumumumaumumaaumcmumumagTT-Chol 1139
cumaagauumaaumaaacmagcmaTT 1140 6614 .sup.1C. a. # = corresponding
agent # in Table 2. The agent given under this agent number in
Table 3 possesses the same core nucleotide sequence when nucleotide
modifications, e.g. 2'-O-methyl modifications and phosphorothioate
linkages, are disregarded
Example 3
siRNA Activity Testing
[0186] The ability of the iRNA agents represented in Table 3 to
inhibit the expression of human RhoA was tested in human cell lines
expressing the respective gene product from an expression
construct, or in cell lines constitutively expressing the
respective gene product. The iRNA agent is transfected into the
cells, e.g., by transfection or electroporation, allowed to act on
the cells for a certain time, e.g., 24 hours, and levels of RhoA
expression were determined by measurement of RhoA mRNA
concentrations in cell lysates. These expression levels were then
compared to RhoA expression levels in cells treated equivalently
but without addition of the iRNA agent, or to expression levels of
housekeeping genes (e.g. GAPDH), and the ability of the iRNA agents
representend in Table 3 to inhibit the expression of human RhoA
thereby assessed.
Screening for Inhibition of RhoA Expression
[0187] One day before transfection, Neuroscreen-1 cells (Cellomics
Inc., Pittsburgh, USA) were seeded at 1.5.times.10.sup.4 cells/well
on 96-well collagen-coated plates (Greiner Bio-One GmbH,
Frickenhausen, Germany) in 100 .mu.l of growth medium (RPMI 1640,
10% horse serum, 5% fetal calf serum, 100 u penicillin/100 .mu.g/ml
streptomycin, 2 mM L-glutamine, Biochrom AG, Berlin, Germany).
Transfections were performed in triplicates. For each well 0.5
.mu.l Lipofectamine2000 (Invitrogen GmbH, Karlsruhe, Germany) were
mixed with 12 .mu.l Opti-MEM (Invitrogen) and incubated for 15 min
at room temperature. 2 .mu.l of a 5 .mu.M solution of siRNA in
annealing buffer (20 mM sodium phosphate, pH 6.8; 100 mM sodium
chloride) were mixed with 10.5 .mu.l Opti-MEM per well, combined
with the Lipofectamine2000-Opti-MEM mixture and again incubated for
15 minutes at room temperature. During this incubation, growth
medium was removed from cells and replaced by 75 .mu.l/well of
fresh medium. The 25 .mu.l solution of
siRNA-Lipofectamine2000-complex were added, resulting in an overall
100 nM siRNA concentration in the 100 .mu.l incubation volume, and
the cells were incubated for 24 h at 37.degree. C. and 5% CO.sub.2
in a humidified incubator (Heraeus GmbH, Hanau).
[0188] mRNA levels in cell lysates were quantitated by a
commercially available branched DNA hybridization assay (QuantiGene
bDNA-kit, Genospectra, Fremont, USA). Cells were harvested by
applying 50 .mu.l additional growth medium and 75 .mu.l of Lysis
Mixture (from QuantiGene bDNA-kit) to each well and were lysed at
53.degree. C. for 30 min. 50 .mu.l of the lysates were incubated
with probes specific to rat RhoA and rGAPDH (sequence of probes
given in Table 4 and Table 5) according to the manufacturer's
protocol for the QuantiGene bDNA kit assay. Finally,
chemoluminescence was measured in a Victor2-Light (Perkin Elmer,
Wiesbaden, Germany) as RLUs (relative light units) and values
obtained with RhoA probes were normalized to the respective GAPDH
values for each well. Mock transfected cells (following the same
protocol except that no siRNA was added) served as controls and
forcomparison of mRNA levels.
[0189] Effective siRNAs from the screen were further characterized
by establishment of dose response curves and calculation of
IC.sub.50 concentrations (the concentration at which 50% inhibition
of gene expression would be observed). For dose response
assessment, transfections were performed at the following
concentrations: 100 nM, 33.3 nM, 11.1 nM, 3.7 nM, 1.2 nM, 0.4 nM,
137 pM, 46 pM, 15 pM, 5 pM and mock (no siRNA) by serially diluting
the 5 .mu.M siRNA stock solution with annealing buffer and using 2
.mu.l of the diluted stock according to the above protocol. The
IC.sub.50 was determined by curve fitting using the computer
software Xlfit using the following parameters: Dose Response One
Site, 4 Parameter Logistic Model, fit=(A+((B-A)/(1+(((10 AC)/x)
D)))), inv=((10 C)/((((B-A)/(y-A))-1) (1/D))), res=(y-fit).
TABLE-US-00004 TABLE 4 Rat RhoA probes SEQ Probe ID type.sup.1
Nucleotide sequence NO. CE CCATTTTTCTGGGATGTTTTCTAAATTTTTCTCTTGGAA
1141 AGAAAGT CE ACAGAAATGCTTGACTTCTGGAGTTTTTTCTCTTGGAAA 1142 GAAAGT
CE CTTCAGGTTTTACCGGCTCCTTTTTCTCTTGGAAAGAAA 1143 GT CE
CTGTTTGCCATATCTCTGCCTTTTTTTCTCTTGGAAAGA 1144 AAGT CE
TTGGTCTTTGCTGAACACTCCATTTTTCTCTTGGAAAGA 1145 AAGT CE
CCCGCGTCTAGCTTGCAGATTTTTCTCTTGGAAAGAAAG 1146 T LE
AGGATGATGGGCACATTTGGTTTTTAGGCATAGGACCCG 1147 TGTCT LE
GCCTTGTGTGCTCATCATTCCTTTTTAGGCATAGGACCC 1148 GTGTCT LE
TGCTTCATTTTGGCTAACTCCCTTTTTAGGCATAGGACC 1149 CGTGTCT LE
TGTACCCAAAAGCGCCAATCTTTTTAGGCATAGGACCCG 1150 TGTCT LE
GCAGCTCTCGTGGCCATCTTTTTTAGGCATAGGACCCGT 1151 GTCT LE
AGGCACCCCGACTTTTTCTTTTTTTAGGCATAGGACCCG 1152 TGTCT BL
CTATCAGGGCTGTCGATGGAA 1153 BL GAAGATCCTTCTTGTTCCCAACT 1154 BL
CAAAAACCTCTCTCACTCCGTCT 1155 .sup.1CE = Capture Extender probe; LE
= Label Extender probe; BL = blocking probe
[0190] TABLE-US-00005 TABLE 5 Rat GAPDH probes SEQ Probe ID
type.sup.1 Nucleotide sequence NO. CE
CCAGCTTCCCATTCTCAGCCTTTTTCTCTTGGAAAGAAA 1156 GT CE
TCTCGCTCCTGGAAGATGGTTTTTTCTCTTGGAAAGAAA 1157 GT CE
CCCATTTGATGTTAGCGGGATTTTTCTCTTGGAAAGAAA 1158 GT CE
CGGAGATGATGACCCTTTTGGTTTTTCTCTTGGAAAGAA 1159 AGT LE
GATGGGTTTCCCGTTGATGATTTTTAGGCATAGGACCCG 1160 TGTCT LE
GACATACTCAGCACCAGCATCACTTTTTAGGCATAGGAC 1161 CCGTGTCT LE
CCCAGCCTTCTCCATGGTGGTTTTTAGGCATAGGACCCG 1162 TGTCT BL
TTGACTGTGCCGTTGAACTTG 1163 BL CCCCACCCTTCAGGTGAGC 1164 BL
GGCATCAGCGGAAGGGG 1165 .sup.1CE = Capture Extender probe; LE =
Label Extender probe; BL = blocking probe
[0191] Table 6 lists the agent number, the position of the
nucleotide within the human RhoA mRNA sequence (Genbank accession
number NM.sub.--001664) corresponding to the 5'-most nucleotide of
the sense strand of the agent, the amount of total RhoA mRNA
remaining in cells treated with the agent at 100 nM concentration
in % of controls, and the IC.sub.50 value for selected agents.
TABLE-US-00006 TABLE 6 Ability of siRNAs specific for RhoA to
reduce RhoA mRNA levels in cultured cells Rem. RhoA mRNA at Rem.
RhoA 100 nM mRNA at 100 nM Agent Pos. in agent, agent, second
IC.sub.50 RhoA number mRNA.sup.1 first screen screen [nM]
AL-DP-5850 73 .+-. 8% 142 AL-DP-5852 17 .+-. 4% 3.1 AL-DP-5853 18
.+-. 3% 2.8 AL-DP-5854 17 .+-. 1% 4.2 AL-DP-5972 986 30 .+-. 9% 17
.+-. 2% AL-DP-5973 987 21 .+-. 2% 15 .+-. 1% 0.003 AL-DP-5974 1179
44 .+-. 12% 48 .+-. 2% AL-DP-5975 1395 33 .+-. 4% 27 .+-. 10%
AL-DP-5976 1413 26 .+-. 3% 17 .+-. 2% AL-DP-5977 537 n.d. 30 .+-.
1% AL-DP-5978 539 58 .+-. 4% 51 .+-. 1% AL-DP-5979 540 12 .+-. 2%
15 .+-. 2% 0.06 AL-DP-5980 544 75 .+-. 3% 95 .+-. 3% AL-DP-5981 546
17 .+-. 2% 16 .+-. 1% 0.13 AL-DP-5982 1452 18 .+-. 2% 22 .+-. 2%
0.13 AL-DP-5983 1449 37 .+-. 4% 29 .+-. 3% AL-DP-5984 1451 26 .+-.
1% 33 .+-. 4% AL-DP-5985 1450 n.d. 33 .+-. 1% 0.37 AL-DP-5986 1411
18 .+-. 1% 22 .+-. 1% 0.4 AL-DP-5987 901 22 .+-. 5% 10 .+-. 0% 0.01
AL-DP-5988 1376 17 .+-. 1% 16 .+-. 1% 0.34 AL-DP-5989 1876 20 .+-.
1% 25 .+-. 3% 3.1 AL-DP-5990 956 16 .+-. 2% 17 .+-. 1% 0.36
AL-DP-5991 982 55 .+-. 5% 33 .+-. 5% AL-DP-5992 1400 55 .+-. 6% 55
.+-. 6% AL-DP-5993 981 32 .+-. 2% 33 .+-. 3% AL-DP-5994 1180 23
.+-. 2% 20 .+-. 1% 0.24 AL-DP-5995 1170 25 .+-. 2% 26 .+-. 2% 6.0
AL-DP-6176 987 14 .+-. 2% 1.17 AL-DP-6177 901 19 .+-. 5% 0.005
.sup.1Position of nucleotide within human Nogo-R mRNA corresponding
to the 5'-most nucleotide of the sense strand of the agent
[0192] In summary, agents AL-DP-5979, AL-DP-5990, AL-DP-5988,
AL-DP-5981, AL-DP-5982, AL-DP-5986, AL-DP-5989 AL-DP-6176, and
AL-DP-6177 were able to reduce the expression of RhoA mRNA by 80%
or more, AL-DP-5973, AL-DP-5987, AL-DP-5994, AL-DP-5995,
AL-DP-5976, AL-DP-5984, and AL-DP-5972 were able to reduce the
expression of RhoA mRNA by 70% or more, AL-DP-5993, AL-DP-5975, and
AL-DP-5983 were able to reduce the expression of RhoA mRNA by 60%
or more, AL-DP-5974 was able to reduce the expression of RhoA mRNA
by 50% or more, and AL-DP-5991, AL-DP-5992, and AL-DP-5978 were
able to reduce the expression of RhoA mRNA by 40% or more. The high
activity of AL-DP-6176 and AL-DP-6177 shwos that a cholesteryl
moiety may be conjugated to the 3'-end of the sense strand of an
siRNA without significant loss of activity. AL-DP-6176 and
AL-DP-6177 are identical to AL-DP-5973 and AL-DP-5987,
respectively, except for the 3'-conjugated cholesteryl moiety on
the sense strand.
Example 4
Stability Testing
[0193] In order to verify the stability of siRNAs in the biological
matrix most relevant to their intended physiological application,
cerebrospinal fluid (CSF), we established a method for determining
the degradation half life of siRNAs in this medium. This method
comprises the incubation of siRNAs with CSF followed by Proteinase
K treatment of the CSF sample and the separation of CSF sample
constituents on an HPLC.
[0194] The example below shows the analyses of CSF samples which
were contacted with siRNAs in vitro. However, this method can
equally be applied to biological samples ex vivo, i.e. obtained
from a subject which was contacted with an siRNA in vivo.
[0195] Bovine CSF was obtained from a calf (Bos bovis), age 6
months (Prof. Dr. J. Rehage, University of Veterinary Medicine
Hannover, Foundation, Hannover, Germany). Porcine CSF was pooled
from 3 healthy weaner pigs (Sus scrofa domesticus), age 3-4 months
(Prof. Dr. M. Wendt, University of Veterinary Medicine Hannover,
Foundation, Hannover, Germany). Rat CSF was pooled from 20 male
Sprague Dawley rats (Rattus norvegicus), 175-200 g in weight
(Charles River Laboratories, L'Arbresle Cedex, France). Proteinase
K (20 mg/ml) was obtained from peQLab (Erlangen, Germany; Cat.-No.
04-1075) and diluted 1:1 with deionized water (18.2 m.OMEGA.) to a
final concentration of 10 mg/ml Proteinase K. Proteinase K Buffer
(4.0 ml TRIS-HCl 1M pH 7.5, 1.0 ml EDTA 0.5M, 1.2 ml NaCl 5M, 4.0
ml SDS 10%) was prepared fresh and kept at 50.degree. C. until use
to avoid precipitation.
[0196] A 40 mer of poly(L-dT), (L-dT).sub.40 was obtained from
Noxxon Pharma AG (Berlin, Germany) and used as an internal
standard. Polymers of the L-enantiomers of nucleic acids show an
extraordinary stability towards nucleolytic degradation (Klussman
S, et al., Nature Biotechn. 1996, 14:1112) but otherwise very
similar properties when compared to naturally occuring nucleic
acids consisting of R-enantiomers.
Proteinase K Treatment of siRNA Incubation Samples
[0197] 6 .mu.l of a 50 .mu.M solution of the respective siRNA in
phosphate buffered saline (PBS, Sigma-Aldrich Chemie GmbH,
Taufkirchen, Germany) was incubated with 54 .mu.l CSF at 37.degree.
C. for 30 min, 1, 2, 4, 8, 16, 24 or 48 hours. To terminate the
siRNA-degradation, 25 .mu.l of Proteinase K buffer were added to
incubation samples immediately after expiry of the respective
incubation period, the mixture vortexed at highest speed for 5 s
(Vortex Genie 2, Scientific Industries, Inc., Bohemia, N.Y., USA,
cat. no. SI 0256), 8 .mu.l Proteinase K (10 mg/ml) were added
followed by vortexing for 5 s, and finally the mixture was
incubated for 20 min in a thermomixer at 42.degree. C. and 1050
rpm.
[0198] 5 .mu.l of a 50 .mu.M solution (250 pmole) of (L-dT).sub.40
were added as an internal standard to each well, the solution was
vortexed for 5 s, and the tube centrifuged for 1 min in a tabletop
centrifuge to collect all droplets clinging to the inner surfaces
of the wells at the bottom. The solution was transferred to a 96
well Captiva 0.2 .mu.m filter plate (Varian, Germany, Cat. No.
A5960002) and filtered by centrifugation at 21900 rcf for 45
min.
[0199] The incubation wells were washed with 47.5 .mu.l deionized
water (18.2 m.OMEGA.), the wash filtered through the Captiva Filter
Unit at 21900 rcf for 15 min, and the wash step repeated.
Approximately 180 .mu.l of the theoretical total volume of 200
.mu.l are on average recovered after the second washing step.
Ion exchange chromatographic separation of siRNA single strands
from each other and from degradation products:
[0200] A Dionex BioLC HPLC-system equipped with inline-degasser,
autosampler, column oven and fixed wavelength UV-detector (Dionex
GmbH, Idstein, Germany) was used under denaturing conditions.
Standard run parameters were: TABLE-US-00007 Column: Dionex
DNA-Pac100; 4 .times. 250 mm Temperature: 75.degree. C. Eluent A:
10 mM NaClO.sub.4, 20 mM TRIS-HCl, 1 mM EDTA; 10% acetonitrile, pH
= 8.0 Eluent B: 800 mM NaClO.sub.4, 20 mM TRIS-HCl, 1 mM EDTA; 10%
acetonitrile, pH = 8.0 Detection: @ 260 nm Gradient: 0-1 min: 10% B
1-11 min: 10% -> 35% B 11-12 min: 35% B -> 100% B 12-14 min:
100% B -> 10% B 14-16 min: 10% B for column reequilibration
Injection volume: 20 .mu.l
[0201] Where separation between the two strands of an siRNA was not
satisfactory or a degradation fragment co-eluted with one strand,
the chromatographic parameters were adjusted by changing
temperature, pH, replacement of NaClO.sub.4 by NaBr, the
concentration of acetonitrile, and/or adjusting the slope of the
eluent gradient until separation was achieved which allowed
separate quantitation of the peaks from sense and antisense
strand.
[0202] Peak areas for full length strands were obtained by
integration of the UV detector signal using software supplied by
the manufacturer of the instrument (Chromeleon 6.6; Dionex GmbH,
Idstein, Germany).
Data Analysis:
[0203] Integrated sense strand, antisense strand, and internal
standard peak areas were obtained for all samples and the
normalization control.
[0204] A correction factor CF, accounting for liquid losses in the
filtration and washing steps, was determined for every sample by
calculating the ratio of experimental to theoretical internal
standard peak area. The theoretical internal standard peak area is
obtained, e.g. from a calibration curve of the internal standard
obtained by injecting 50 .mu.l each of a serial dilution of the 50
.mu.M solution of (L-dT).sub.40 onto the HPLC column, and
calculation of the theoretical peak area corresponding to 25 pmole
(L-dT).sub.40 with the equation obtained by linear least square fit
to the peak areas from the dilution series. The correction factor
CF to be applied to the peak areas of the sense and antisense
strand is the obtained as:
CF=PeakArea.sub.intStd(theoretical)/PeakArea.sub.intStd(Sample)
[0205] This treatment assumes that, by virtue of washing the filter
twice, virtually complete recovery is achieved in the combined
filtrates, and corrects for the variable volume of wash water
retained in the filter, such that peak areas from different samples
can be compared.
[0206] The peak areas obtained for the sense and antisense strand
peaks for each time point are then multiplied with the correction
factor CF to obtain Normalized Peak Areas (NPA.sub.sense,t,
NPA.sub.antisense,t): NPA.sub.sense or antisense,t=(Peak
Area.sub.sense or antisense,t).times.CF
[0207] To obtain the relative amount of remaining Full Length
Product (% FLP) for the sense and antisense strands at time t, the
Normalized Peak Area for each strand at time t=0 min
(NPA.sub.sense,t=0, NPA.sub.antisense,t=0) is set as 100%, and the
NPAs from other time points are divided by these values. %
FLP.sub.t=1, 2, 3 . . . n=(NPA.sub.t=1, 2, 3 . . .
n/NPA.sub.t=0)*100
[0208] The value obtained from the control sample, where the siRNA
was incubated with annealing buffer only, may serve as a control of
the accuracy of the method. The % FLP for both strands should lie
near 100%, within error margins, regardless of time of
incubation.
[0209] The degradation half life t.sub.1/2 may then be calculated
for each strand, assuming first order kinetics, from the slope of a
linear least square fit to a plot of ln(% FLP) versus time as:
t.sub.1/2=ln(0,5)/slope Stability of siRNAs Specific for NogoL and
RhoA in Rat, Bovine and Porcine CSF
[0210] Table 7 shows the results for select siRNAs of the
determination of the relative amount of full length dsRNA present
in porcine, rat, and bovine CSF, and PBS, after 48 h of incubation
in the respective medium. In addition, the degradation half life
was determined for the sense and antisense strands separately for
some siRNAs. TABLE-US-00008 TABLE 7 Stability of various siRNAs
specific for NogoL and RhoA in rat, bovine and porcine CSF % full
length duplex present after 48 h in Agent Porcine Rat Bovine
Specific Modifi- C.a. number CSF CSF CSF PBS for cation.sup.1
#.sup.2 AL-DP-5973 95 3 95 100 RhoA 3/TTs 6662 AL-DP-5979 99 108
RhoA 3/TTs 6524 AL-DP-5981 96 103 RhoA 3/TTs 6530 AL-DP-5982 56 98
RhoA 3/TTs 6790 AL-DP-5986 100 105 RhoA 3/TTs 6767 AL-DP-5987 87 97
RhoA 3/TTs 6614 AL-DP-5988 41 99 RhoA 3/TTs 6732 AL-DP-5989 87 101
RhoA 3/TTs 6832 AL-DP-5990 76 92 RhoA 3/TTs 6650 .sup.10 = no
2'-modifications; 1 = 5'-nucleotide in 5'-ua-3', 5'-uu-3',
5'-ca-3', and 5'-ug-3' motifs is 2'-modified in sense strand,
5'-nucleotide in 5'-ua-3' and 5'-ca-3' motifs is 2'-modified in
antisense strand; 2 = 5'-nucleotide in 5'-ua-3', 5'-uu-3',
5'-ca-3', and 5'-ug-3' motifs is # 2'-modified in sense and
antisense strand, 3 = all pyrmidine nucleotides are 2'-modified in
sense strand, 5'-nucleotide in 5'-ua-3' and 5'-ca-3' motifs is
2'-modified in antisense strand; 4 = all pyrimidine nucleotides are
2'-modified in sense strand, # 5'-nucleotide in 5'-ua-3', 5'-uu-3',
5'-ca-3', and 5'-ug-3' motifs is 2'-modified in antisense strand; 5
= all pyrimidine nucleotides are 2'-modified in sense strand, no
2'-modifications in antisense strand; TT = 21 nucleotides and
3'-terminal TT single strand overhangs in sense and antisense
strands; TTs = 21 nucleotides and 3'-terminal # TT single strand
overhangs in sense and antisense strands; 23 = 21 nucleotide sense,
23 nucleotide antisense strand, 2 nucleotide single strand overhang
on 3'-end of antisense strand; 23s = 21 nucleotide sense, 23
nucleotide antisense strand, 2 nucleotide single strand overhang on
3'-end of antisense strand, nucleotides comprise
5'-phosphorothioate groups in positions 21 and 22 of antisense
strand .sup.2C.a. # = corresponding agent # in Table 2. The agent
given under this agent number in Table 2 possesses the same core
nucleotide sequence when nucleotide modifications, e.g. 2'-O-methyl
modifications and phosphorothioate linkages, are disregarded
[0211] As is evident from Table 7, the modification of siRNAs in
select sites vulnerable to degradation can lead to agents with
excellent properties in terms of activity and stability. For
example, AL-DP-5871, AL-DP-5938, AL-DP-5963, AL-DP-5973,
AL-DP-5979, AL-DP-5981, AL-DP-5986, AL-DP-5987, AL-DP-5989, and
AL-DP-5990 all inhibit their respective target gene by more than
70% in the in vitro assays described above, and more than 70% full
length duplex remain after incubation with porcine CSF for 48 h.
However, there is some indication that rat CSF is more aggressive
towards siRNAs than porcine or bovine CSF.
Example 5
Inhibition of RhoA Expression in Rat Primary Dorsal Root Ganglia
(DRG) Cells in Culture
[0212] The inhibition of RhoA expression was assessed in rat
primary dorsal root ganglia (DRG) cells in culture in order to
validate results obtained using Neuroscreen 1 cells as described
above.
[0213] DRG cells were isolated from Sprague-Dawley rats at
postnatal day 3 to 6. Rats were dissected and cells dissociated
into single cells by addition of 1.3 ml (0.28 Wunsch units/ml)
Liberase Blendzyme (Roche) in S-MEM (Invitrogen Gibco, Carlsbad
Calif., USA) and incubated for 35 min at 37.degree. C. The cell
suspension was pre-plated on tissue-culture plates to remove
non-neuronal cells. Neurons were then plated onto tissue-culture
Biocoat.TM. PDL Poly-D-Lysine/Laminin 96 well plates (BD
Biosciences, Bedford Mass., USA) in F12-HAM's Medium containing
glutamine (Invitrogen Gibco, Carlsbad Calif., USA) with 5% fetal
bovine serum (FBS, heat inactivated) and 5% horse serum (heat
inactivated) (both Invitrogen Gibco, Carlsbad Calif., USA)
supplemented with 50 ng/ml mouse nerve growth factor 2.5S (NGF;
Promega Corp., Madison Wis., USA) and kept at 37.degree. C., 5%
CO.sub.2 in a humidified incubator until transfection.
[0214] A rhoA-specific siRNA, agent number AL-DP-5987, was tested
in DRG cultures at 200 nM concentration using TransMessenger.TM.
Transfection reagent (Qiagen GmbH, Hilden, Germany, cat. no.
301525) which is based on a lipid formulation, specific
RNA-condensing reagent (Enhancer R.TM.) and an RNA-condensing
buffer (Buffer EC-R.TM.) keeping siRNA:Enhancer R.TM. ratio
(.mu.g:.mu.l) constant at 1:2, and siRNA:TransMessenger.TM. ratio
(.mu.g:.mu.l) constant at 1:12.
[0215] DRG neurons were transfected 24 h post-plating. For each
well 0.52 .mu.l Enhancer R.TM. were first mixed with 13.68 .mu.l
Buffer EC-R.TM.. 0.8 .mu.l of a 25 .mu.M solution of AL-DP-5987
(0.26 .mu.g) in annealing buffer (20 mM sodium phosphate, pH 6.8;
100 mM sodium chloride), or 0.8 .mu.l of annealing buffer
(siRNA-free control) were added and the mixture incubated for 5 min
at RT. 3.12 .mu.l TransMesssenger.TM. Transfection Reagent were
diluted with 6.88 .mu.l Buffer EC-R.TM., added to the mixture, and
the mixture incubated for another 10 min at room temperature to
allow transfection-complex formation. 75 .mu.l serum free F12-HAM's
Medium containing glutamine (Invitrogen Gibco, Carlsbad Calif.,
USA) supplemented with 50 ng/ml NGF 2.5S (Promega Corp., Madison
Wis., USA) and 1:50 B27 supplement (Invitrogen Gibco, Carlsbad
Calif., USA) were added to the transfection complexes and complete
mixing achieved by gently pipetting up and down. The growth medium
was removed from the DRG cells, and 90 .mu.l of the above
transfection complex mixture were added onto the cells. After 8 h
of incubation at 37.degree. C., 5% CO.sub.2 in a humidified
incubator supernatant was removed from the cells, fresh F12-HAM's
medium containing glutamine supplemented with 5% FBS, 5% horse
serum (both Invitrogen Gibco, Carlsbad Calif., USA), 50 ng/ml mouse
NGF 2.5S (Promega Corp., Madison Wis., USA) and 1:100
Penicillin/Streptomycin (Invitrogen Gibco, Carlsbad Calif., USA)
was added, the cells were incubated for another 16 h at 37.degree.
C., 5% CO.sub.2 in a humidified incubator, and rhoA mRNA was
quantified.
[0216] RhoA mRNA levels were measured using the QuantiGene.TM. bDNA
kit (Genospectra, Fremont, USA) according to manufacturer's
protocol. Briefly, the supernatant was removed from the DRG cells,
and the cells were lysed by addition of 150 .mu.l of Lysis Working
Reagent (1 volume of Lysis Mixture plus 2 volumes of medium) and
incubation at 52.degree. C. for 30min. 40 .mu.l of the lysates were
incubated at 52.degree. C. for 40 min with the probe sets specific
to rat RhoA and rat GAPDH given above in Table 4 and Table 5.
Chemoluminescence was read on a Victor.sup.2-Light.TM. (PerkinElmer
Life And Analytical Sciences, Inc., Boston Mass., USA) as Relative
Light Units (RLU). RLU for RhoA were normalized to GAPDH RLU for
each well. Normalized RhoA/GAPDH ratios were then compared to the
siRNA-free control, which was set as 100%.
[0217] In several independent experiments, rhoA mRNA was reduced in
primary DRG cells treated with AL-DP-5987 in culture consistently
to 20-25% of rhoA mRNA levels found in the siRNA free controls.
Example 6
Neurite Outgrowth Assessment in Primary DRG Transfected with
Selected iRNA Agents of the Invention
Neuron Dissection
[0218] Dorsal root ganglia (DRG) were isolated from Sprague-Dawley
rats at postnatal day 7-12. DRG were dissected into the culture
medium (Neurobasal-A supplemented with 1:50 B27, Glutamine, and
Pen/Strep; Invitrogen Gibco, Carlsbad Calif., USA), blood was
rinsed off with PBS and neurons were dissociated by incubation with
1 mL DMEM/collagenase (0.5%) for 90 minutes at 37.degree. C.,
inverting the tube every 30 minutes. The collagenase was washed off
by serial dilution and the isolated DRG were resuspended in 500
.mu.l of culture medium. The suspension was then triturated 15-20
times with a fire-polished pipette until a homogeneous cell
suspension was achieved. Cells were spun down three times for 3
minutes at 1500 RPM, and the cell debris aspirated off. Cells were
then resuspended in 500 .mu.l of culture media and passed through a
70 .mu.m strainer (Falcon, 352350). The cell suspension was
pre-plated on a 24 well tissue-culture plate in 300 .mu.l of
culture media for 24 hours at 37.degree. C., 5% CO2 in a humidified
incubator. Neurons were then transfected with appropriate siRNA as
follows:
Transfection of siRNA
[0219] For each well, Lipofectamine.TM. 2000 was used and
transfections were performed according to the manufacturer's
protocol. The appropriate amount of siRNA was diluted into Opti-MEM
I Reduced Serum Medium and mixed gently. The Lipofectamine.TM. 2000
was vortexed before use. For each well of a 24 well plate, 1.5
.mu.l was diluted in 25 .mu.l of Opti-MEM I Reduced Serum Medium,
mixed gently and incubated for 5 minutes at room temperature. After
the 5 minute incubation, 3 .mu.l of the diluted siRNA was combined
with the diluted Lipofectamine.TM. 2000 (total volume is 29.5
.mu.l). The complex was mixed gently and incubated for 20 minutes
at room temperature to allow the siRNA: Lipofectamine.TM. 2000
complexes to form. 300 .mu.l of Media were added to the
transfection complexes and complete mixing was achieved by gently
pipetting up and down (total volume: 600 .mu.l). The cells were
incubated for another 20-24 h at 37.degree. C., 5% CO2 in a
humidified incubator
Outgrowth Assay Plate Preparation
[0220] Chondroitin sulfate proteoglycan (CSPG) or myelin was dried
down overnight in 50 .mu.l in individual wells of a biocoat
Poly-D-Lysine plate (BD Biosciences, Bedford Mass., USA). The plate
was rinsed once with water to remove salt deposits. laminin
(Invitrogen, CA; 1 .mu.g/ml) was then coated for 1 h at room
temperature.
Replating of the Neurons
[0221] Neurons were resuspended from the 24 well plate by gently
pipetting up and down, spun down at 1500 RPM for 3 minutes and
resuspended in the appropriate volume. Neurons were replated at a
concentration of 3000 neurons/well onto the prepared
Poly-D-Lysine/Laminin 96-well plates in culture medium. The neurons
were allowed to grow for 16-24 hours at 37.degree. C., 5% CO2 in a
humidified incubator and subjected to neurite quantification as
follows.
Neurite Quantification
[0222] The cells were fixed in 4% formaldehyde, 20% sucrose in PBS
for 15 minutes. The cells were rinsed once with PBS, permeabilized
and blocked for an hour at room temperature using 0.1% Triton, 10%
Goat serum in PBS. The cells were stained with a beta-III tubulin,
polyclonal rabbit antibody (Covance, 1:500) diluted in PBS and
incubated overnight at 4.degree. C. After three 5 minutes rinses in
PBS, the secondary Alexa-Fluor 488 goat anti-rabbit IgG antibody
(Molecular Probes, 1:500 filtered through 0.22 um) was incubated
overnight at 4.degree. C. Following 3 rinses in PBS, neurite
outgrowth was quantified using an automated cellular imaging and
analysis system (Axon Instrument, Union City, Calif.).
Results
[0223] Two iRNA agents specific for the green fluorescent protein
gene (AL-DP 5549, AL-DP 5266; nucleic acid sequences in Table 8)
were used as controls. TABLE-US-00009 TABLE 8 Nucleic acid
sequences of control iRNA agents specific for the green fluorescent
protein gene SEQ SEQ Agent ID ID number Sense strand NO. Antisense
strand NO. AL-DP-5549 ccacaugaagcagcacgacuu-Chol 1166
aagucgugcugcuucauguggmumc 1167 AL-DP-5266 ccacaugaagcagcacgacuu
1168 aagucgugcugcuucauguggmumc 1169
[0224] The iRNA agent of the invention AL-DP-6176 was tested at a
concentration of 250 nM at transfection for its effect on neurite
outgrowth on growth substrate supplemented with 0, 40, or 200 ng
myelin, and compared to the effect of AL-DP-5266. In Table 9,
neurite outgrowth is expressed as percent of neurite outgrowth seen
without myelin. Evidently, the green fluorescent protein-specific
iRNA agent has no effect on neunte outgrowth of DRG on the
inhibitory substrate, while the RhoA-specific iRNA agent strongly
counters the growth inhibitory effect of myelin. TABLE-US-00010
TABLE 9 Inhibition of neurite outgrowth by myelin in DRG in the
absence or presence of iRNA agents specific for green fluorescent
protein (GFP) or RhoA Myelin (ng) no siRNA AL-DP 5266 (GFP) AL-DP
6176 (RhoA) 0 100% 100% 100% 40 82% 75% 183% 200 3% 6% 19%
[0225] Furthermore, the iRNA agents of the invention AL-DP 5973,
AL-DP 5987, AL-DP 6176, and AL-DP 6177 were tested at a
concentration of 250 nM at transfection for its effect on neurite
outgrowth on growth substrate supplemented with 30 ng CSPG, and
compared to the effect of AL-DP-5549 and AL-DP-5266. In Table 10,
neurite outgrowth is expressed as percent of neurite outgrowth seen
without CSPG. Evidently, the green fluorescent protein-specific
iRNA agent has no effect on neurite outgrowth of DRG on the
inhibitory substrate, while the RhoA-specific iRNA agents counter
the growth inhibitory effect of CSPG. TABLE-US-00011 TABLE 10
Inhibition of neurite outgrowth by CSPG in DRG in the absence or
presence of iRNA agents specific for green fluorescent protein
(GFP) or RhoA Relative outgrowth AL-DP-5549 3 .+-. 2% AL-DP-5266 2
.+-. 1% AL-DP 5266 6 .+-. 2% AL-DP 5973 5 .+-. 2% AL-DP 6176 8 .+-.
4% AL-DP 5987 10 .+-. 5%
Example 7
Assessing Behavioural Improvement by Intrathecal Administration of
iRNA Agents of the Invention Following Hemisection Injury
Animals and iRNA Agent Adminstration
[0226] Thirty adult female Sprague-Dawley rats (Charles River
Laboratories, Wilmington, Mass., USA; weight 200-230 grams) were
randomly divided into 3 groups. One day before the spinal cord
lesion surgery, all the animals were trained for locomotor BBB
score in an open field. 3 iRNA agents were administered in blinded
fashion to the three different groups. Group A being administered a
first rhoA-specific iRNA agent (AL-DP-6177), group B receiving a
second rhoA-specific iRNA agent (AL-DP-6176), group C as a control
group getting the unrelated control iRNA agent, directed against
Luciferase (AL-DP-1956, for nucleic acid sequence see Table 11).
The iRNA agents were delivered through an osmotic minipump (Alzet
2004, 0.25 .mu.l/hr, 28 day delivery), which was filled with
appropriate drug for the groups A, B, C, and pre-incubated
overnight at 37.degree. C. before implantation to the animals
(described below). The siRNA was released at a dose of 0.4 mg per
day for 28 days. TABLE-US-00012 TABLE 11 Nucleic acid sequences of
control iRNA agent specific for luciferase SEQ SEQ Agent ID ID
number Sense strand NO. Antisense strand NO. AL-DP-5549
cmumumacmgcmumgagumacmumumcmgaTT-Chol 1170 ucgaagumacucmagcgumaagTT
1171
Microsurgery
[0227] For the microsurgery procedure generating the hemisection
injury the rats were deeply anesthetized with ketamine (60 mg/kg)
and xylazine (10 mg/kg). A complete laminectomy was conducted at
spinal level T6-7 under a surgical microscope. The dorsal part of
spinal cord was transected with the sharp tip of a 30 gauge needle
and a pair of microscissors. The depth of transection (1.85 mm) was
confirmed by passing the sharp part of number 11 blade across the
dorsal spinal cord for several times with the aid of a stereotaxic
(David Kopf Instruments, Tujunga, Calif.). Routinely, the spinal
cord was severed past the central canal area (GrandPre, T., et al.,
Nature 2002, 417:547-551; Li, S., et al., J Neurosci 2004,
24:10511-10520). Rats with an incomplete lesion documented by
uninjured dorsal or dorsolateral corticospinal fibers in caudal
spinal cord or a less degree of disability (BBB score .gtoreq.5) at
two days after injury were excluded.
[0228] For intrathecal administration of the siRNA solutions with
the osmotic pumps the dura over the dorsal spinal cord was gently
lifted with a pair of microforceps and a small hole was made in the
midline with a pair of microscissors at T7 level. The minipump was
sutured to the muscles under the skin on the back of the animals.
The outlet of the minipump was connected to one end of an
intrathecal catheter (PE-60, MS-0040, Marsil Scientific). The other
end of the catheter with a small diameter of PE-5 was inserted into
the subdura space of spinal cord at T7 level through the small
opening made for drug infusion. After pump and catheter
implantation, muscle and connective tissue layers were sutured with
4.0 silk. The skin incision was closed with sterile animal clips.
The animals received a subcutaneous injection of lactated Ringer's
solutions (5% of body weight) immediately after surgery and two
times per day for the first two days after injury. Postoperative
antibiotics and analgesics were given during the first two days
post injury. Bladder expression was performed manually three times
per day during the survival period of the animal.
Behavioral Tests
[0229] To monitor the recovery of locomotor functions during and
after siRNA treatment after spinal cord hemisection, we used a
standard behavioral test, the Basso, Beattie, and Bresnahan (BBB)
locomotor rating scale (GrandPre, T., et al., Nature 2002,
417:547-551; Li, S., et al., J Neurosci 2004, 24:10511-10520;
Basso, D. M., et al., J Neurotrauma 1995, 12:1-21) to analyze
individual components of limp movements, weight support, plantar
and dorsal stepping, forelimb-hindlimp coordination, paw rotation,
toe clearance, trunk stability, and tail placement. Scores from
0-21 were given based on these observations. The BBB score was
evaluated by two individuals unaware of experimental treatments at
several time points (Li, S., et al., J Neurosci 2004,
24:10511-10520). In particular, the locomotion was analyzed on day
3, 10, 17, 24, 31 and 45 post hemisection of the spinal cord.
Results
[0230] The obtained BBB score data were plotted by normalizing all
the single day score data of the animals to the score at day 10.
The group averages of those normalized scores were charted
including the error representing the calculated standard error. By
this procedure improvements in locomotion from day 10 onwards are
shown in FIG. 2. As evident, a significant improvement was obtained
by virtue of the treatment with the inventive RhoA-specific iRNA
agents over the unrelatred control iRNA agent.
Sequence CWU 1
1
1171 1 23 RNA Artificial Sequence Exemplary iRNA agents 1
ccggaagaaa cuggugauug uug 23 2 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 2 ggaagaaacu
ggugauugun n 21 3 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 3 acaaucacca guuucuuccn
n 21 4 23 RNA Artificial Sequence Exemplary iRNA agents 4
cggaagaaac uggugauugu ugg 23 5 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 5 gaagaaacug
gugauuguun n 21 6 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 6 aacaaucacc aguuucuucn
n 21 7 23 RNA Artificial Sequence Exemplary iRNA agents 7
ggaagaaacu ggugauuguu ggu 23 8 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 8 aagaaacugg
ugauuguugn n 21 9 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 9 caacaaucac caguuucuun
n 21 10 23 RNA Artificial Sequence Exemplary iRNA agents 10
gaagaaacug gugauuguug gug 23 11 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 11
agaaacuggu gauuguuggn n 21 12 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 12
ccaacaauca ccaguuucun n 21 13 23 RNA Artificial Sequence Exemplary
iRNA agents 13 aagaaacugg ugauuguugg uga 23 14 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 14 gaaacuggug auuguuggun n 21 15 21 DNA
Artificial Sequence misc_feature 20, 21 n = 2'-deoxy-thymidine
Exemplary iRNA agents 15 accaacaauc accaguuucn n 21 16 23 RNA
Artificial Sequence Exemplary iRNA agents 16 agaaacuggu gauuguuggu
gau 23 17 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 17 aaacugguga uuguuggugn
n 21 18 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 18 caccaacaau caccaguuun
n 21 19 23 RNA Artificial Sequence Exemplary iRNA agents 19
gaaacuggug auuguuggug aug 23 20 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 20
aacuggugau uguuggugan n 21 21 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 21
ucaccaacaa ucaccaguun n 21 22 23 RNA Artificial Sequence Exemplary
iRNA agents 22 aaacugguga uuguugguga ugg 23 23 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 23 acuggugauu guuggugaun n 21 24 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 24 aucaccaaca aucaccagun n 21 25 23 RNA
Artificial Sequence Exemplary iRNA agents 25 aacuggugau uguuggugau
gga 23 26 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 26 cuggugauug uuggugaugn
n 21 27 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 27 caucaccaac aaucaccagn
n 21 28 23 RNA Artificial Sequence Exemplary iRNA agents 28
acuggugauu guuggugaug gag 23 29 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 29
uggugauugu uggugauggn n 21 30 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 30
ccaucaccaa caaucaccan n 21 31 23 RNA Artificial Sequence Exemplary
iRNA agents 31 cuggugauug uuggugaugg agc 23 32 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 32 ggugauuguu ggugauggan n 21 33 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 33 uccaucacca acaaucaccn n 21 34 23 RNA
Artificial Sequence Exemplary iRNA agents 34 uggugauugu uggugaugga
gcc 23 35 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 35 gugauuguug gugauggagn
n 21 36 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 36 cuccaucacc aacaaucacn
n 21 37 23 RNA Artificial Sequence Exemplary iRNA agents 37
ggugauuguu ggugauggag ccu 23 38 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 38
ugauuguugg ugauggagcn n 21 39 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 39
gcuccaucac caacaaucan n 21 40 23 RNA Artificial Sequence Exemplary
iRNA agents 40 gaaagacaug cuugcucaua guc 23 41 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 41 aagacaugcu ugcucauagn n 21 42 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 42 cuaugagcaa gcaugucuun n 21 43 23 RNA
Artificial Sequence Exemplary iRNA agents 43 aaagacaugc uugcucauag
ucu 23 44 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 44 agacaugcuu gcucauagun
n 21 45 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 45 acuaugagca agcaugucun
n 21 46 23 RNA Artificial Sequence Exemplary iRNA agents 46
aagacaugcu ugcucauagu cuu 23 47 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 47
gacaugcuug cucauagucn n 21 48 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 48
gacuaugagc aagcaugucn n 21 49 23 RNA Artificial Sequence Exemplary
iRNA agents 49 agacaugcuu gcucauaguc uuc 23 50 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 50 acaugcuugc ucauagucun n 21 51 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 51 agacuaugag caagcaugun n 21 52 23 RNA
Artificial Sequence Exemplary iRNA agents 52 gacaugcuug cucauagucu
uca 23 53 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine misc_feature 20, 21 n =
2'-deoxy-thymidine 53 caugcuugcu cauagucuun n 21 54 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 54 aagacuauga gcaagcaugn n 21 55 23 RNA
Artificial Sequence Exemplary iRNA agents 55 acaugcuugc ucauagucuu
cag 23 56 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 56 augcuugcuc auagucuucn
n 21 57 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 57 gaagacuaug agcaagcaun
n 21 58 23 RNA Artificial Sequence Exemplary iRNA agents 58
caugcuugcu cauagucuuc agc 23 59 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 59
ugcuugcuca uagucuucan n 21 60 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 60
ugaagacuau gagcaagcan n 21 61 23 RNA Artificial Sequence Exemplary
iRNA agents 61 augcuugcuc auagucuuca gca 23 62 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 62 gcuugcucau agucuucagn n 21 63 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 63 cugaagacua ugagcaagcn n 21 64 23 RNA
Artificial Sequence Exemplary iRNA agents 64 ugcuugcuca uagucuucag
caa 23 65 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 65 cuugcucaua gucuucagcn
n 21 66 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 66 gcugaagacu augagcaagn
n 21 67 23 RNA Artificial Sequence Exemplary iRNA agents 67
gcuugcucau agucuucagc aag 23 68 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 68
uugcucauag ucuucagcan n 21 69 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 69
ugcugaagac uaugagcaan n 21 70 23 RNA Artificial Sequence Exemplary
iRNA agents 70 cuugcucaua gucuucagca agg 23 71 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 71 ugcucauagu cuucagcaan n 21 72 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 72 uugcugaaga cuaugagcan n 21 73 23 RNA
Artificial Sequence Exemplary iRNA agents 73 uugcucauag ucuucagcaa
gga 23 74 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 74 gcucauaguc uucagcaagn
n 21 75 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 75 cuugcugaag acuaugagcn
n 21 76 23 RNA Artificial Sequence Exemplary iRNA agents 76
ugcucauagu cuucagcaag gac 23 77 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 77
cucauagucu ucagcaaggn n 21 78 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 78
ccuugcugaa gacuaugagn n 21 79 23 RNA Artificial Sequence Exemplary
iRNA agents 79 gcucauaguc uucagcaagg acc 23 80 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 80 ucauagucuu cagcaaggan n 21 81 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 81 uccuugcuga agacuaugan n 21 82 23 RNA
Artificial Sequence Exemplary iRNA agents 82 cucauagucu ucagcaagga
cca 23 83 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 83 cauagucuuc agcaaggacn
n 21 84 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 84 guccuugcug aagacuaugn
n 21 85 23 RNA Artificial Sequence Exemplary iRNA agents 85
ucauagucuu cagcaaggac cag 23 86 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 86
auagucuuca gcaaggaccn n 21 87 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 87
gguccuugcu gaagacuaun n 21 88 23 RNA Artificial Sequence Exemplary
iRNA agents 88 cauagucuuc agcaaggacc agu 23 89 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 89 uagucuucag caaggaccan n 21 90 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 90 ugguccuugc ugaagacuan n 21 91 23 RNA
Artificial Sequence Exemplary iRNA agents 91 auagucuuca gcaaggacca
guu 23 92 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 92 agucuucagc aaggaccagn
n 21 93 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 93 cugguccuug cugaagacun
n 21 94 23 RNA Artificial Sequence Exemplary iRNA agents 94
uagucuucag caaggaccag uuc 23 95 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 95
gucuucagca aggaccagun n 21 96 21 DNA Artificial Sequence Exemplary
iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine 96
acugguccuu gcugaagacn n 21 97 23 RNA Artificial Sequence Exemplary
iRNA agents 97 agucuucagc aaggaccagu ucc 23 98 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 98 ucuucagcaa ggaccaguun n 21 99 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 99 aacugguccu ugcugaagan n 21 100 23 RNA
Artificial Sequence Exemplary iRNA agents 100 gucuucagca aggaccaguu
ccc 23 101 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 101 cuucagcaag
gaccaguucn n 21 102 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 102 gaacuggucc
uugcugaagn n 21 103 23 RNA Artificial Sequence Exemplary iRNA
agents 103 ucuucagcaa ggaccaguuc cca 23 104 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 104 uucagcaagg accaguuccn n 21 105 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 105 ggaacugguc cuugcugaan n 21 106 23 RNA
Artificial Sequence Exemplary iRNA agents 106 cuucagcaag gaccaguucc
cag 23 107 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 107 ucagcaagga
ccaguucccn n 21 108 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 108 gggaacuggu
ccuugcugan n 21 109 23 RNA Artificial Sequence Exemplary iRNA
agents 109 uucagcaagg accaguuccc aga 23 110 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 110 cagcaaggac caguucccan n 21 111 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 111 ugggaacugg uccuugcugn n 21 112 23 RNA
Artificial Sequence Exemplary iRNA agents 112 ucagcaagga ccaguuccca
gag 23 113 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 113 agcaaggacc
aguucccagn n 21 114 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 114
cugggaacug
guccuugcun n 21 115 23 RNA Artificial Sequence Exemplary iRNA
agents 115 cagcaaggac caguucccag agg 23 116 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 116 gcaaggacca guucccagan n 21 117 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 117 ucugggaacu gguccuugcn n 21 118 23 RNA
Artificial Sequence Exemplary iRNA agents 118 agcaaggacc aguucccaga
ggu 23 119 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 119 caaggaccag
uucccagagn n 21 120 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 120 cucugggaac
ugguccuugn n 21 121 23 RNA Artificial Sequence Exemplary iRNA
agents 121 gcaaggacca guucccagag gug 23 122 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 122 aaggaccagu ucccagaggn n 21 123 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 123 ccucugggaa cugguccuun n 21 124 23 RNA
Artificial Sequence Exemplary iRNA agents 124 caaggaccag uucccagagg
ugu 23 125 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 125 aggaccaguu
cccagaggun n 21 126 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 126 accucuggga
acugguccun n 21 127 23 RNA Artificial Sequence Exemplary iRNA
agents 127 gaaagcaggu agaguuggcu uug 23 128 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 128 aagcagguag aguuggcuun n 21 129 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 129 aagccaacuc uaccugcuun n 21 130 23 RNA
Artificial Sequence Exemplary iRNA agents 130 aaagcaggua gaguuggcuu
ugu 23 131 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 131 agcagguaga
guuggcuuun n 21 132 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 132 aaagccaacu
cuaccugcun n 21 133 23 RNA Artificial Sequence Exemplary iRNA
agents 133 gacagcccug auaguuuaga aaa 23 134 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 134 cagcccugau aguuuagaan n 21 135 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 135 uucuaaacua ucagggcugn n 21 136 23 RNA
Artificial Sequence Exemplary iRNA agents 136 acagcccuga uaguuuagaa
aac 23 137 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 137 agcccugaua
guuuagaaan n 21 138 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 138 uuucuaaacu
aucagggcun n 21 139 23 RNA Artificial Sequence Exemplary iRNA
agents 139 cagcccugau aguuuagaaa aca 23 140 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 140 gcccugauag uuuagaaaan n 21 141 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 141 uuuucuaaac uaucagggcn n 21 142 23 RNA
Artificial Sequence Exemplary iRNA agents 142 agcccugaua guuuagaaaa
cau 23 143 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 143 cccugauagu
uuagaaaacn n 21 144 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 144 guuuucuaaa
cuaucagggn n 21 145 23 RNA Artificial Sequence Exemplary iRNA
agents 145 gcccugauag uuuagaaaac auc 23 146 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 146 ccugauaguu uagaaaacan n 21 147 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 147 uguuuucuaa acuaucaggn n 21 148 23 RNA
Artificial Sequence Exemplary iRNA agents 148 cccugauagu uuagaaaaca
ucc 23 149 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 149 cugauaguuu
agaaaacaun n 21 150 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 150 auguuuucua
aacuaucagn n 21 151 23 RNA Artificial Sequence Exemplary iRNA
agents 151 ccugauaguu uagaaaacau ccc 23 152 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 152 ugauaguuua gaaaacaucn n 21 153 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 153 gauguuuucu aaacuaucan n 21 154 23 RNA
Artificial Sequence Exemplary iRNA agents 154 cugauaguuu agaaaacauc
cca 23 155 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 155 gauaguuuag
aaaacauccn n 21 156 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 156 ggauguuuuc
uaaacuaucn n 21 157 23 RNA Artificial Sequence Exemplary iRNA
agents 157 ugauaguuua gaaaacaucc cag 23 158 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 158 auaguuuaga aaacaucccn n 21 159 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 159 gggauguuuu cuaaacuaun n 21 160 23 RNA
Artificial Sequence Exemplary iRNA agents 160 gauaguuuag aaaacauccc
aga 23 161 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 161 uaguuuagaa
aacaucccan n 21 162 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 162 ugggauguuu
ucuaaacuan n 21 163 23 RNA Artificial Sequence Exemplary iRNA
agents 163 auaguuuaga aaacauccca gaa 23 164 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 164 aguuuagaaa acaucccagn n 21 165 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 165 cugggauguu uucuaaacun n 21 166 23 RNA
Artificial Sequence Exemplary iRNA agents 166 uaguuuagaa aacaucccag
aaa 23 167 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 167 guuuagaaaa
caucccagan n 21 168 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 168 ucugggaugu
uuucuaaacn n 21 169 23 RNA Artificial Sequence Exemplary iRNA
agents 169 aguuuagaaa acaucccaga aaa 23 170 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 170 uuuagaaaac aucccagaan n 21 171 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 171 uucugggaug uuuucuaaan n 21 172 23 RNA
Artificial Sequence Exemplary iRNA agents 172 guuuagaaaa caucccagaa
aag 23 173 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 173 uuagaaaaca
ucccagaaan n 21 174 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 174 uuucugggau
guuuucuaan n 21 175 23 RNA Artificial Sequence Exemplary iRNA
agents 175 uuuagaaaac aucccagaaa agu 23 176 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 176 uagaaaacau cccagaaaan n 21 177 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 177 uuuucuggga uguuuucuan n 21 178 23 RNA
Artificial Sequence Exemplary iRNA agents 178 ccccagaagu caagcauuuc
ugu 23 179 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 179 ccagaaguca
agcauuucun n 21 180 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 180 agaaaugcuu
gacuucuggn n 21 181 23 RNA Artificial Sequence Exemplary iRNA
agents 181 cccagaaguc aagcauuucu guc 23 182 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 182 cagaagucaa gcauuucugn n 21 183 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 183 cagaaaugcu ugacuucugn n 21 184 23 RNA
Artificial Sequence Exemplary iRNA agents 184 ccagaaguca agcauuucug
ucc 23 185 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 185 agaagucaag
cauuucugun n 21 186 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 186 acagaaaugc
uugacuucun n 21 187 23 RNA Artificial Sequence Exemplary iRNA
agents 187 cagaagucaa gcauuucugu ccc 23 188 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 188 gaagucaagc auuucugucn n 21 189 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 189 gacagaaaug cuugacuucn n 21 190 23 RNA
Artificial Sequence Exemplary iRNA agents 190 agaagucaag cauuucuguc
cca 23 191 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 191 aagucaagca
uuucuguccn n 21 192 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 192 ggacagaaau
gcuugacuun n 21 193 23 RNA Artificial Sequence Exemplary iRNA
agents 193 ugaaaccuga agaaggcaga gau 23 194 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 194 aaaccugaag aaggcagagn n 21 195 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 195 cucugccuuc uucagguuun n 21 196 23 RNA
Artificial Sequence Exemplary iRNA agents 196 gaaaccugaa gaaggcagag
aua 23 197 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 197 aaccugaaga
aggcagagan n 21 198 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 198 ucucugccuu
cuucagguun n 21 199 23 RNA Artificial Sequence Exemplary iRNA
agents 199 aaaccugaag aaggcagaga uau 23 200 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 200 accugaagaa ggcagagaun n 21 201 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 201 aucucugccu ucuucaggun n 21 202 23 RNA
Artificial Sequence Exemplary iRNA agents 202 aaccugaaga aggcagagau
aug 23 203 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 203 ccugaagaag
gcagagauan n 21 204 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 204 uaucucugcc
uucuucaggn n 21 205 23 RNA Artificial Sequence Exemplary iRNA
agents 205 accugaagaa ggcagagaua ugg 23 206 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 206 cugaagaagg cagagauaun n 21 207 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 207 auaucucugc cuucuucagn n 21 208 23 RNA
Artificial Sequence Exemplary iRNA agents 208 ccugaagaag gcagagauau
ggc 23 209 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 209 ugaagaaggc
agagauaugn n 21 210 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 210 cauaucucug
ccuucuucan n 21 211 23 RNA Artificial Sequence Exemplary iRNA
agents 211 cugaagaagg cagagauaug gca 23 212 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 212 gaagaaggca gagauauggn n 21 213 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 213 ccauaucucu gccuucuucn n 21 214 23 RNA
Artificial Sequence Exemplary iRNA agents 214 ugaagaaggc agagauaugg
caa 23 215 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 215 aagaaggcag
agauauggcn n 21 216 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 216 gccauaucuc
ugccuucuun n 21 217 23 RNA Artificial Sequence Exemplary iRNA
agents 217 gaagaaggca gagauauggc aaa 23 218 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 218 agaaggcaga gauauggcan n 21 219 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 219 ugccauaucu cugccuucun n 21 220 23 RNA
Artificial Sequence Exemplary iRNA agents 220 aagaaggcag agauauggca
aac 23 221 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 221 gaaggcagag
auauggcaan n 21 222 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 222 uugccauauc
ucugccuucn n 21 223 23 RNA Artificial Sequence Exemplary iRNA
agents 223 agaaggcaga gauauggcaa aca 23 224 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 224 aaggcagaga uauggcaaan n 21 225 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 225 uuugccauau cucugccuun n 21 226 23 RNA
Artificial Sequence Exemplary iRNA agents 226 gaaggcagag auauggcaaa
cag 23 227 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 227 aggcagagau
auggcaaacn n
21 228 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 228 guuugccaua
ucucugccun n 21 229 23 RNA Artificial Sequence Exemplary iRNA
agents 229 aaggcagaga uauggcaaac agg 23 230 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 230 ggcagagaua uggcaaacan n 21 231 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 231 uguuugccau aucucugccn n 21 232 23 RNA
Artificial Sequence Exemplary iRNA agents 232 aggcagagau auggcaaaca
gga 23 233 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 233 gcagagauau
ggcaaacagn n 21 234 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 234 cuguuugcca
uaucucugcn n 21 235 23 RNA Artificial Sequence Exemplary iRNA
agents 235 ggcagagaua uggcaaacag gau 23 236 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 236 cagagauaug gcaaacaggn n 21 237 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 237 ccuguuugcc auaucucugn n 21 238 23 RNA
Artificial Sequence Exemplary iRNA agents 238 gcagagauau ggcaaacagg
auu 23 239 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 239 agagauaugg
caaacaggan n 21 240 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 240 uccuguuugc
cauaucucun n 21 241 23 RNA Artificial Sequence Exemplary iRNA
agents 241 cagagauaug gcaaacagga uug 23 242 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 242 gagauauggc aaacaggaun n 21 243 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 243 auccuguuug ccauaucucn n 21 244 23 RNA
Artificial Sequence Exemplary iRNA agents 244 agagauaugg caaacaggau
ugg 23 245 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 245 agauauggca
aacaggauun n 21 246 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 246 aauccuguuu
gccauaucun n 21 247 23 RNA Artificial Sequence Exemplary iRNA
agents 247 gagauauggc aaacaggauu ggc 23 248 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 248 gauauggcaa acaggauugn n 21 249 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 249 caauccuguu ugccauaucn n 21 250 23 RNA
Artificial Sequence Exemplary iRNA agents 250 agauauggca aacaggauug
gcg 23 251 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 251 auauggcaaa
caggauuggn n 21 252 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 252 ccaauccugu
uugccauaun n 21 253 23 RNA Artificial Sequence Exemplary iRNA
agents 253 gauauggcaa acaggauugg cgc 23 254 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 254 uauggcaaac aggauuggcn n 21 255 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 255 gccaauccug uuugccauan n 21 256 23 RNA
Artificial Sequence Exemplary iRNA agents 256 auauggcaaa caggauuggc
gcu 23 257 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 257 auggcaaaca
ggauuggcgn n 21 258 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 258 cgccaauccu
guuugccaun n 21 259 23 RNA Artificial Sequence Exemplary iRNA
agents 259 uauggcaaac aggauuggcg cuu 23 260 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 260 uggcaaacag gauuggcgcn n 21 261 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 261 gcgccaaucc uguuugccan n 21 262 23 RNA
Artificial Sequence Exemplary iRNA agents 262 auggcaaaca ggauuggcgc
uuu 23 263 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 263 ggcaaacagg
auuggcgcun n 21 264 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 264 agcgccaauc
cuguuugccn n 21 265 23 RNA Artificial Sequence Exemplary iRNA
agents 265 uggcaaacag gauuggcgcu uuu 23 266 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 266 gcaaacagga uuggcgcuun n 21 267 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 267 aagcgccaau ccuguuugcn n 21 268 23 RNA
Artificial Sequence Exemplary iRNA agents 268 ggcaaacagg auuggcgcuu
uug 23 269 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 269 caaacaggau
uggcgcuuun n 21 270 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 270 aaagcgccaa
uccuguuugn n 21 271 23 RNA Artificial Sequence Exemplary iRNA
agents 271 gcaaacagga uuggcgcuuu ugg 23 272 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 272 aaacaggauu ggcgcuuuun n 21 273 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 273 aaaagcgcca auccuguuun n 21 274 23 RNA
Artificial Sequence Exemplary iRNA agents 274 caaacaggau uggcgcuuuu
ggg 23 275 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 275 aacaggauug
gcgcuuuugn n 21 276 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 276 caaaagcgcc
aauccuguun n 21 277 23 RNA Artificial Sequence Exemplary iRNA
agents 277 aaacaggauu ggcgcuuuug ggu 23 278 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 278 acaggauugg cgcuuuuggn n 21 279 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 279 ccaaaagcgc caauccugun n 21 280 23 RNA
Artificial Sequence Exemplary iRNA agents 280 aacaggauug gcgcuuuugg
gua 23 281 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 281 caggauuggc
gcuuuugggn n 21 282 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 282 cccaaaagcg
ccaauccugn n 21 283 23 RNA Artificial Sequence Exemplary iRNA
agents 283 acaggauugg cgcuuuuggg uac 23 284 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 284 aggauuggcg cuuuugggun n 21 285 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 285 acccaaaagc gccaauccun n 21 286 23 RNA
Artificial Sequence Exemplary iRNA agents 286 caggauuggc gcuuuugggu
aca 23 287 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 287 ggauuggcgc
uuuuggguan n 21 288 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 288 uacccaaaag
cgccaauccn n 21 289 23 RNA Artificial Sequence Exemplary iRNA
agents 289 aggauuggcg cuuuugggua cau 23 290 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 290 gauuggcgcu uuuggguacn n 21 291 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 291 guacccaaaa gcgccaaucn n 21 292 23 RNA
Artificial Sequence Exemplary iRNA agents 292 ggauuggcgc uuuuggguac
aug 23 293 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 293 auuggcgcuu
uuggguacan n 21 294 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 294 uguacccaaa
agcgccaaun n 21 295 23 RNA Artificial Sequence Exemplary iRNA
agents 295 gauuggcgcu uuuggguaca ugg 23 296 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 296 uuggcgcuuu uggguacaun n 21 297 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 297 auguacccaa aagcgccaan n 21 298 23 RNA
Artificial Sequence Exemplary iRNA agents 298 auuggcgcuu uuggguacau
gga 23 299 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 299 uggcgcuuuu
ggguacaugn n 21 300 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 300 cauguaccca
aaagcgccan n 21 301 23 RNA Artificial Sequence Exemplary iRNA
agents 301 uuggcgcuuu uggguacaug gag 23 302 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 302 ggcgcuuuug gguacauggn n 21 303 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 303 ccauguaccc aaaagcgccn n 21 304 23 RNA
Artificial Sequence Exemplary iRNA agents 304 uggcgcuuuu ggguacaugg
agu 23 305 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 305 gcgcuuuugg
guacauggan n 21 306 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 306 uccauguacc
caaaagcgcn n 21 307 23 RNA Artificial Sequence Exemplary iRNA
agents 307 ggcgcuuuug gguacaugga gug 23 308 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 308 cgcuuuuggg uacauggagn n 21 309 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 309 cuccauguac ccaaaagcgn n 21 310 23 RNA
Artificial Sequence Exemplary iRNA agents 310 gcgcuuuugg guacauggag
ugu 23 311 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 311 gcuuuugggu
acauggagun n 21 312 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 312 acuccaugua
cccaaaagcn n 21 313 23 RNA Artificial Sequence Exemplary iRNA
agents 313 cgcuuuuggg uacauggagu guu 23 314 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 314 cuuuugggua cauggagugn n 21 315 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 315 cacuccaugu acccaaaagn n 21 316 23 RNA
Artificial Sequence Exemplary iRNA agents 316 gcuuuugggu acauggagug
uuc 23 317 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 317 uuuuggguac
auggagugun n 21 318 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 318 acacuccaug
uacccaaaan n 21 319 23 RNA Artificial Sequence Exemplary iRNA
agents 319 cuuuugggua cauggagugu uca 23 320 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 320 uuuggguaca uggaguguun n 21 321 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 321 aacacuccau guacccaaan n 21 322 23 RNA
Artificial Sequence Exemplary iRNA agents 322 uuuuggguac auggaguguu
cag 23 323 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 323 uuggguacau
ggaguguucn n 21 324 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 324 gaacacucca
uguacccaan n 21 325 23 RNA Artificial Sequence Exemplary iRNA
agents 325 uuuggguaca uggaguguuc agc 23 326 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 326 uggguacaug gaguguucan n 21 327 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 327 ugaacacucc auguacccan n 21 328 23 RNA
Artificial Sequence Exemplary iRNA agents 328 uuggguacau ggaguguuca
gca 23 329 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 329 ggguacaugg
aguguucagn n 21 330 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 330 cugaacacuc
cauguacccn n 21 331 23 RNA Artificial Sequence Exemplary iRNA
agents 331 uggguacaug gaguguucag caa 23 332 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 332 gguacaugga guguucagcn n 21 333 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 333 gcugaacacu ccauguaccn n 21 334 23 RNA
Artificial Sequence Exemplary iRNA agents 334 ggguacaugg aguguucagc
aaa 23 335 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 335 guacauggag
uguucagcan n 21 336 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 336 ugcugaacac
uccauguacn n 21 337 23 RNA Artificial Sequence Exemplary iRNA
agents 337 gguacaugga guguucagca aag 23 338 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 338 uacauggagu guucagcaan n 21 339 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 339 uugcugaaca cuccauguan n 21 340 23 RNA
Artificial Sequence Exemplary iRNA agents 340 guacauggag uguucagcaa
aga
23 341 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 341 acauggagug
uucagcaaan n 21 342 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 342 uuugcugaac
acuccaugun n 21 343 23 RNA Artificial Sequence Exemplary iRNA
agents 343 uacauggagu guucagcaaa gac 23 344 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 344 cauggagugu ucagcaaagn n 21 345 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 345 cuuugcugaa cacuccaugn n 21 346 23 RNA
Artificial Sequence Exemplary iRNA agents 346 acauggagug uucagcaaag
acc 23 347 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 347 auggaguguu
cagcaaagan n 21 348 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 348 ucuuugcuga
acacuccaun n 21 349 23 RNA Artificial Sequence Exemplary iRNA
agents 349 cauggagugu ucagcaaaga cca 23 350 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 350 uggaguguuc agcaaagacn n 21 351 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 351 gucuuugcug aacacuccan n 21 352 23 RNA
Artificial Sequence Exemplary iRNA agents 352 auggaguguu cagcaaagac
caa 23 353 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 353 ggaguguuca
gcaaagaccn n 21 354 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 354 ggucuuugcu
gaacacuccn n 21 355 23 RNA Artificial Sequence Exemplary iRNA
agents 355 uggaguguuc agcaaagacc aaa 23 356 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 356 gaguguucag caaagaccan n 21 357 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 357 uggucuuugc ugaacacucn n 21 358 23 RNA
Artificial Sequence Exemplary iRNA agents 358 ggaguguuca gcaaagacca
aag 23 359 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 359 aguguucagc
aaagaccaan n 21 360 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 360 uuggucuuug
cugaacacun n 21 361 23 RNA Artificial Sequence Exemplary iRNA
agents 361 gaguguucag caaagaccaa aga 23 362 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 362 guguucagca aagaccaaan n 21 363 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 363 uuuggucuuu gcugaacacn n 21 364 23 RNA
Artificial Sequence Exemplary iRNA agents 364 aguguucagc aaagaccaaa
gau 23 365 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 365 uguucagcaa
agaccaaagn n 21 366 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 366 cuuuggucuu
ugcugaacan n 21 367 23 RNA Artificial Sequence Exemplary iRNA
agents 367 guguucagca aagaccaaag aug 23 368 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 368 guucagcaaa gaccaaagan n 21 369 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 369 ucuuuggucu uugcugaacn n 21 370 23 RNA
Artificial Sequence Exemplary iRNA agents 370 auggagugag agagguuuuu
gaa 23 371 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 371 ggagugagag
agguuuuugn n 21 372 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 372 caaaaaccuc
ucucacuccn n 21 373 23 RNA Artificial Sequence Exemplary iRNA
agents 373 uggagugaga gagguuuuug aaa 23 374 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 374 gagugagaga gguuuuugan n 21 375 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 375 ucaaaaaccu cucucacucn n 21 376 23 RNA
Artificial Sequence Exemplary iRNA agents 376 cuacgagagc ugcucugcaa
gcu 23 377 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 377 acgagagcug
cucugcaagn n 21 378 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 378 cuugcagagc
agcucucgun n 21 379 23 RNA Artificial Sequence Exemplary iRNA
agents 379 uacgagagcu gcucugcaag cua 23 380 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 380 cgagagcugc ucugcaagcn n 21 381 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 381 gcuugcagag cagcucucgn n 21 382 23 RNA
Artificial Sequence Exemplary iRNA agents 382 acgagagcug cucugcaagc
uag 23 383 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 383 gagagcugcu
cugcaagcun n 21 384 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 384 agcuugcaga
gcagcucucn n 21 385 23 RNA Artificial Sequence Exemplary iRNA
agents 385 cgagagcugc ucugcaagcu aga 23 386 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 386 agagcugcuc ugcaagcuan n 21 387 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 387 uagcuugcag agcagcucun n 21 388 23 RNA
Artificial Sequence Exemplary iRNA agents 388 gagagcugcu cugcaagcua
gac 23 389 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 389 gagcugcucu
gcaagcuagn n 21 390 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 390 cuagcuugca
gagcagcucn n 21 391 23 RNA Artificial Sequence Exemplary iRNA
agents 391 agagcugcuc ugcaagcuag acg 23 392 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 392 agcugcucug caagcuagan n 21 393 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 393 ucuagcuugc agagcagcun n 21 394 23 RNA
Artificial Sequence Exemplary iRNA agents 394 gagcugcucu gcaagcuaga
cgu 23 395 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 395 gcugcucugc
aagcuagacn n 21 396 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 396 gucuagcuug
cagagcagcn n 21 397 23 RNA Artificial Sequence Exemplary iRNA
agents 397 agcugcucug caagcuagac gug 23 398 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 398 cugcucugca agcuagacgn n 21 399 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 399 cgucuagcuu gcagagcagn n 21 400 23 RNA
Artificial Sequence Exemplary iRNA agents 400 uugaagugcu guuuauuaau
cuu 23 401 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 401 gaagugcugu
uuauuaaucn n 21 402 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 402 gauuaauaaa
cagcacuucn n 21 403 23 RNA Artificial Sequence Exemplary iRNA
agents 403 ugaagugcug uuuauuaauc uua 23 404 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 404 aagugcuguu uauuaaucun n 21 405 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 405 agauuaauaa acagcacuun n 21 406 23 RNA
Artificial Sequence Exemplary iRNA agents 406 gaagugcugu uuauuaaucu
uag 23 407 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 407 agugcuguuu
auuaaucuun n 21 408 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 408 aagauuaaua
aacagcacun n 21 409 23 RNA Artificial Sequence Exemplary iRNA
agents 409 aagugcuguu uauuaaucuu agu 23 410 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 410 gugcuguuua uuaaucuuan n 21 411 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 411 uaagauuaau aaacagcacn n 21 412 23 RNA
Artificial Sequence Exemplary iRNA agents 412 agugcuguuu auuaaucuua
gug 23 413 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 413 ugcuguuuau
uaaucuuagn n 21 414 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 414 cuaagauuaa
uaaacagcan n 21 415 23 RNA Artificial Sequence Exemplary iRNA
agents 415 gugcuguuua uuaaucuuag ugu 23 416 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 416 gcuguuuauu aaucuuagun n 21 417 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 417 acuaagauua auaaacagcn n 21 418 23 RNA
Artificial Sequence Exemplary iRNA agents 418 ugcuguuuau uaaucuuagu
gua 23 419 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 419 cuguuuauua
aucuuagugn n 21 420 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 420 cacuaagauu
aauaaacagn n 21 421 23 RNA Artificial Sequence Exemplary iRNA
agents 421 gcuguuuauu aaucuuagug uau 23 422 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 422 uguuuauuaa ucuuagugun n 21 423 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 423 acacuaagau uaauaaacan n 21 424 23 RNA
Artificial Sequence Exemplary iRNA agents 424 cuguuuauua aucuuagugu
aug 23 425 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 425 guuuauuaau
cuuaguguan n 21 426 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 426 uacacuaaga
uuaauaaacn n 21 427 23 RNA Artificial Sequence Exemplary iRNA
agents 427 uguuuauuaa ucuuagugua uga 23 428 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 428 uuuauuaauc uuaguguaun n 21 429 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 429 auacacuaag auuaauaaan n 21 430 23 RNA
Artificial Sequence Exemplary iRNA agents 430 guuuauuaau cuuaguguau
gau 23 431 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 431 uuauuaaucu
uaguguaugn n 21 432 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 432 cauacacuaa
gauuaauaan n 21 433 23 RNA Artificial Sequence Exemplary iRNA
agents 433 uuuauuaauc uuaguguaug auu 23 434 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 434 uauuaaucuu aguguaugan n 21 435 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 435 ucauacacua agauuaauan n 21 436 23 RNA
Artificial Sequence Exemplary iRNA agents 436 uuauuaaucu uaguguauga
uua 23 437 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 437 auuaaucuua
guguaugaun n 21 438 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 438 aucauacacu
aagauuaaun n 21 439 23 RNA Artificial Sequence Exemplary iRNA
agents 439 uauuaaucuu aguguaugau uac 23 440 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 440 uuaaucuuag uguaugauun n 21 441 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 441 aaucauacac uaagauuaan n 21 442 23 RNA
Artificial Sequence Exemplary iRNA agents 442 auuaaucuua guguaugauu
acu 23 443 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 443 uaaucuuagu
guaugauuan n 21 444 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 444 uaaucauaca
cuaagauuan n 21 445 23 RNA Artificial Sequence Exemplary iRNA
agents 445 uuaaucuuag uguaugauua cug 23 446 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 446 aaucuuagug uaugauuacn n 21 447 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 447 guaaucauac acuaagauun n 21 448 23 RNA
Artificial Sequence Exemplary iRNA agents 448 uaaucuuagu guaugauuac
ugg 23 449 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 449 aucuuagugu
augauuacun n 21 450 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 450 aguaaucaua
cacuaagaun n 21 451 23 RNA Artificial Sequence Exemplary iRNA
agents 451 aaucuuagug uaugauuacu ggc 23 452 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 452 ucuuagugua ugauuacugn n 21 453 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine
453 caguaaucau acacuaagan n 21 454 23 RNA Artificial Sequence
Exemplary iRNA agents 454 aucuuagugu augauuacug gcc 23 455 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 455 cuuaguguau gauuacuggn n 21 456 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 456 ccaguaauca uacacuaagn n 21 457 23 RNA
Artificial Sequence Exemplary iRNA agents 457 ucuuagugua ugauuacugg
ccu 23 458 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 458 uuaguguaug
auuacuggcn n 21 459 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 459 gccaguaauc
auacacuaan n 21 460 23 RNA Artificial Sequence Exemplary iRNA
agents 460 cuuaguguau gauuacuggc cuu 23 461 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 461 uaguguauga uuacuggccn n 21 462 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 462 ggccaguaau cauacacuan n 21 463 23 RNA
Artificial Sequence Exemplary iRNA agents 463 uuaguguaug auuacuggcc
uuu 23 464 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 464 aguguaugau
uacuggccun n 21 465 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 465 aggccaguaa
ucauacacun n 21 466 23 RNA Artificial Sequence Exemplary iRNA
agents 466 uaguguauga uuacuggccu uuu 23 467 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 467 guguaugauu acuggccuun n 21 468 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 468 aaggccagua aucauacacn n 21 469 23 RNA
Artificial Sequence Exemplary iRNA agents 469 aguguaugau uacuggccuu
uuu 23 470 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 470 uguaugauua
cuggccuuun n 21 471 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 471 aaaggccagu
aaucauacan n 21 472 23 RNA Artificial Sequence Exemplary iRNA
agents 472 guguaugauu acuggccuuu uuc 23 473 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 473 guaugauuac uggccuuuun n 21 474 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 474 aaaaggccag uaaucauacn n 21 475 23 RNA
Artificial Sequence Exemplary iRNA agents 475 uucauuuauc uauaauuuac
cua 23 476 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 476 cauuuaucua
uaauuuaccn n 21 477 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 477 gguaaauuau
agauaaaugn n 21 478 23 RNA Artificial Sequence Exemplary iRNA
agents 478 ucauuuaucu auaauuuacc uaa 23 479 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 479 auuuaucuau aauuuaccun n 21 480 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 480 agguaaauua uagauaaaun n 21 481 23 RNA
Artificial Sequence Exemplary iRNA agents 481 cauuuaucua uaauuuaccu
aag 23 482 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 482 uuuaucuaua
auuuaccuan n 21 483 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 483 uagguaaauu
auagauaaan n 21 484 23 RNA Artificial Sequence Exemplary iRNA
agents 484 auuuaucuau aauuuaccua aga 23 485 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 485 uuaucuauaa uuuaccuaan n 21 486 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 486 uuagguaaau uauagauaan n 21 487 23 RNA
Artificial Sequence Exemplary iRNA agents 487 uuuaucuaua auuuaccuaa
gau 23 488 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 488 uaucuauaau
uuaccuaagn n 21 489 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 489 cuuagguaaa
uuauagauan n 21 490 23 RNA Artificial Sequence Exemplary iRNA
agents 490 uuaucuauaa uuuaccuaag auu 23 491 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 491 aucuauaauu uaccuaagan n 21 492 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 492 ucuuagguaa auuauagaun n 21 493 23 RNA
Artificial Sequence Exemplary iRNA agents 493 uaucuauaau uuaccuaaga
uua 23 494 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 494 ucuauaauuu
accuaagaun n 21 495 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 495 aucuuaggua
aauuauagan n 21 496 23 RNA Artificial Sequence Exemplary iRNA
agents 496 aucuauaauu uaccuaagau uac 23 497 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 497 cuauaauuua ccuaagauun n 21 498 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 498 aaucuuaggu aaauuauagn n 21 499 23 RNA
Artificial Sequence Exemplary iRNA agents 499 ucuauaauuu accuaagauu
aca 23 500 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 500 uauaauuuac
cuaagauuan n 21 501 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 501 uaaucuuagg
uaaauuauan n 21 502 23 RNA Artificial Sequence Exemplary iRNA
agents 502 cuauaauuua ccuaagauua caa 23 503 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 503 auaauuuacc uaagauuacn n 21 504 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 504 guaaucuuag guaaauuaun n 21 505 23 RNA
Artificial Sequence Exemplary iRNA agents 505 uauaauuuac cuaagauuac
aaa 23 506 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 506 uaauuuaccu
aagauuacan n 21 507 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 507 uguaaucuua
gguaaauuan n 21 508 23 RNA Artificial Sequence Exemplary iRNA
agents 508 auaauuuacc uaagauuaca aau 23 509 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 509 aauuuaccua agauuacaan n 21 510 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 510 uuguaaucuu agguaaauun n 21 511 23 RNA
Artificial Sequence Exemplary iRNA agents 511 uaauuuaccu aagauuacaa
auc 23 512 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 512 auuuaccuaa
gauuacaaan n 21 513 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 513 uuuguaaucu
uagguaaaun n 21 514 23 RNA Artificial Sequence Exemplary iRNA
agents 514 aauuuaccua agauuacaaa uca 23 515 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 515 uuuaccuaag auuacaaaun n 21 516 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 516 auuuguaauc uuagguaaan n 21 517 23 RNA
Artificial Sequence Exemplary iRNA agents 517 auuuaccuaa gauuacaaau
cag 23 518 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 518 uuaccuaaga
uuacaaaucn n 21 519 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 519 gauuuguaau
cuuagguaan n 21 520 23 RNA Artificial Sequence Exemplary iRNA
agents 520 uuuaccuaag auuacaaauc aga 23 521 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 521 uaccuaagau uacaaaucan n 21 522 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 522 ugauuuguaa ucuuagguan n 21 523 23 RNA
Artificial Sequence Exemplary iRNA agents 523 agaagucauc uugcuaccag
uau 23 524 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 524 aagucaucuu
gcuaccagun n 21 525 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 525 acugguagca
agaugacuun n 21 526 23 RNA Artificial Sequence Exemplary iRNA
agents 526 gaagucaucu ugcuaccagu auu 23 527 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 527 agucaucuug cuaccaguan n 21 528 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 528 uacugguagc aagaugacun n 21 529 23 RNA
Artificial Sequence Exemplary iRNA agents 529 aagucaucuu gcuaccagua
uuu 23 530 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 530 gucaucuugc
uaccaguaun n 21 531 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 531 auacugguag
caagaugacn n 21 532 23 RNA Artificial Sequence Exemplary iRNA
agents 532 agucaucuug cuaccaguau uua 23 533 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 533 ucaucuugcu accaguauun n 21 534 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 534 aauacuggua gcaagaugan n 21 535 23 RNA
Artificial Sequence Exemplary iRNA agents 535 gucaucuugc uaccaguauu
uag 23 536 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 536 caucuugcua
ccaguauuun n 21 537 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 537 aaauacuggu
agcaagaugn n 21 538 23 RNA Artificial Sequence Exemplary iRNA
agents 538 ucaucuugcu accaguauuu aga 23 539 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 539 aucuugcuac caguauuuan n 21 540 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 540 uaaauacugg uagcaagaun n 21 541 23 RNA
Artificial Sequence Exemplary iRNA agents 541 caucuugcua ccaguauuua
gaa 23 542 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 542 ucuugcuacc
aguauuuagn n 21 543 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 543 cuaaauacug
guagcaagan n 21 544 23 RNA Artificial Sequence Exemplary iRNA
agents 544 aucuugcuac caguauuuag aag 23 545 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 545 cuugcuacca guauuuagan n 21 546 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 546 ucuaaauacu gguagcaagn n 21 547 23 RNA
Artificial Sequence Exemplary iRNA agents 547 ucuugcuacc aguauuuaga
agc 23 548 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 548 uugcuaccag
uauuuagaan n 21 549 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 549 uucuaaauac
ugguagcaan n 21 550 23 RNA Artificial Sequence Exemplary iRNA
agents 550 cuugcuacca guauuuagaa gcc 23 551 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 551 ugcuaccagu auuuagaagn n 21 552 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 552 cuucuaaaua cugguagcan n 21 553 23 RNA
Artificial Sequence Exemplary iRNA agents 553 uugcuaccag uauuuagaag
cca 23 554 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 554 gcuaccagua
uuuagaagcn n 21 555 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 555 gcuucuaaau
acugguagcn n 21 556 23 RNA Artificial Sequence Exemplary iRNA
agents 556 ugcuaccagu auuuagaagc caa 23 557 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 557 cuaccaguau uuagaagccn n 21 558 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 558 ggcuucuaaa uacugguagn n 21 559 23 RNA
Artificial Sequence Exemplary iRNA agents 559 gcuaccagua uuuagaagcc
aac 23 560 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 560 uaccaguauu
uagaagccan n 21 561 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 561 uggcuucuaa
auacugguan n 21 562 23 RNA Artificial Sequence Exemplary iRNA
agents 562 cuaccaguau uuagaagcca acu 23 563 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 563 accaguauuu agaagccaan n 21 564 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 564 uuggcuucua aauacuggun n 21 565 23 RNA
Artificial Sequence Exemplary iRNA agents 565 uaccaguauu uagaagccaa
cua 23 566 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine
566 ccaguauuua gaagccaacn n 21 567 21 DNA Artificial Sequence
Exemplary iRNA agents misc_feature 20, 21 n = 2'-deoxy-thymidine
567 guuggcuucu aaauacuggn n 21 568 23 RNA Artificial Sequence
Exemplary iRNA agents 568 cuugcuucuu ucuagaaaga gaa 23 569 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 569 ugcuucuuuc uagaaagagn n 21 570 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 570 cucuuucuag aaagaagcan n 21 571 23 RNA
Artificial Sequence Exemplary iRNA agents 571 uugcuucuuu cuagaaagag
aaa 23 572 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 572 gcuucuuucu
agaaagagan n 21 573 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 573 ucucuuucua
gaaagaagcn n 21 574 23 RNA Artificial Sequence Exemplary iRNA
agents 574 ugcuucuuuc uagaaagaga aac 23 575 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 575 cuucuuucua gaaagagaan n 21 576 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 576 uucucuuucu agaaagaagn n 21 577 23 RNA
Artificial Sequence Exemplary iRNA agents 577 gcuucuuucu agaaagagaa
aca 23 578 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 578 uucuuucuag
aaagagaaan n 21 579 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 579 uuucucuuuc
uagaaagaan n 21 580 23 RNA Artificial Sequence Exemplary iRNA
agents 580 cuucuuucua gaaagagaaa cag 23 581 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 581 ucuuucuaga aagagaaacn n 21 582 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 582 guuucucuuu cuagaaagan n 21 583 23 RNA
Artificial Sequence Exemplary iRNA agents 583 uucuuucuag aaagagaaac
agu 23 584 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 584 cuuucuagaa
agagaaacan n 21 585 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 585 uguuucucuu
ucuagaaagn n 21 586 23 RNA Artificial Sequence Exemplary iRNA
agents 586 ucuuucuaga aagagaaaca guu 23 587 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 587 uuucuagaaa gagaaacagn n 21 588 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 588 cuguuucucu uucuagaaan n 21 589 23 RNA
Artificial Sequence Exemplary iRNA agents 589 cuuucuagaa agagaaacag
uug 23 590 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 590 uucuagaaag
agaaacagun n 21 591 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 591 acuguuucuc
uuucuagaan n 21 592 23 RNA Artificial Sequence Exemplary iRNA
agents 592 uuucuagaaa gagaaacagu ugg 23 593 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 593 ucuagaaaga gaaacaguun n 21 594 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 594 aacuguuucu cuuucuagan n 21 595 23 RNA
Artificial Sequence Exemplary iRNA agents 595 uucuagaaag agaaacaguu
ggu 23 596 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 596 cuagaaagag
aaacaguugn n 21 597 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 597 caacuguuuc
ucuuucuagn n 21 598 23 RNA Artificial Sequence Exemplary iRNA
agents 598 ucuagaaaga gaaacaguug gua 23 599 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 599 uagaaagaga aacaguuggn n 21 600 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 600 ccaacuguuu cucuuucuan n 21 601 23 RNA
Artificial Sequence Exemplary iRNA agents 601 cuagaaagag aaacaguugg
uaa 23 602 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 602 agaaagagaa
acaguuggun n 21 603 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 603 accaacuguu
ucucuuucun n 21 604 23 RNA Artificial Sequence Exemplary iRNA
agents 604 uagaaagaga aacaguuggu aac 23 605 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 605 gaaagagaaa caguugguan n 21 606 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 606 uaccaacugu uucucuuucn n 21 607 23 RNA
Artificial Sequence Exemplary iRNA agents 607 agaaagagaa acaguuggua
acu 23 608 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 608 aaagagaaac
aguugguaan n 21 609 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 609 uuaccaacug
uuucucuuun n 21 610 23 RNA Artificial Sequence Exemplary iRNA
agents 610 gaaagagaaa caguugguaa cuu 23 611 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 611 aagagaaaca guugguaacn n 21 612 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 612 guuaccaacu guuucucuun n 21 613 23 RNA
Artificial Sequence Exemplary iRNA agents 613 aaagagaaac aguugguaac
uuu 23 614 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 614 agagaaacag
uugguaacun n 21 615 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 615 aguuaccaac
uguuucucun n 21 616 23 RNA Artificial Sequence Exemplary iRNA
agents 616 aagagaaaca guugguaacu uuu 23 617 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 617 gagaaacagu ugguaacuun n 21 618 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 618 aaguuaccaa cuguuucucn n 21 619 23 RNA
Artificial Sequence Exemplary iRNA agents 619 agagaaacag uugguaacuu
uug 23 620 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 620 agaaacaguu
gguaacuuun n 21 621 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 621 aaaguuacca
acuguuucun n 21 622 23 RNA Artificial Sequence Exemplary iRNA
agents 622 gagaaacagu ugguaacuuu ugu 23 623 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 623 gaaacaguug guaacuuuun n 21 624 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 624 aaaaguuacc aacuguuucn n 21 625 23 RNA
Artificial Sequence Exemplary iRNA agents 625 agaaacaguu gguaacuuuu
gug 23 626 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 626 aaacaguugg
uaacuuuugn n 21 627 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 627 caaaaguuac
caacuguuun n 21 628 23 RNA Artificial Sequence Exemplary iRNA
agents 628 gaaacaguug guaacuuuug uga 23 629 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 629 aacaguuggu aacuuuugun n 21 630 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 630 acaaaaguua ccaacuguun n 21 631 23 RNA
Artificial Sequence Exemplary iRNA agents 631 aaacaguugg uaacuuuugu
gaa 23 632 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 632 acaguuggua
acuuuugugn n 21 633 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 633 cacaaaaguu
accaacugun n 21 634 23 RNA Artificial Sequence Exemplary iRNA
agents 634 aacaguuggu aacuuuugug aau 23 635 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 635 caguugguaa cuuuugugan n 21 636 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 636 ucacaaaagu uaccaacugn n 21 637 23 RNA
Artificial Sequence Exemplary iRNA agents 637 acaguuggua acuuuuguga
auu 23 638 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 638 aguugguaac
uuuugugaan n 21 639 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 639 uucacaaaag
uuaccaacun n 21 640 23 RNA Artificial Sequence Exemplary iRNA
agents 640 caguugguaa cuuuugugaa uua 23 641 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 641 guugguaacu uuugugaaun n 21 642 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 642 auucacaaaa guuaccaacn n 21 643 23 RNA
Artificial Sequence Exemplary iRNA agents 643 aguugguaac uuuugugaau
uag 23 644 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 644 uugguaacuu
uugugaauun n 21 645 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 645 aauucacaaa
aguuaccaan n 21 646 23 RNA Artificial Sequence Exemplary iRNA
agents 646 guugguaacu uuugugaauu agg 23 647 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 647 ugguaacuuu ugugaauuan n 21 648 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 648 uaauucacaa aaguuaccan n 21 649 23 RNA
Artificial Sequence Exemplary iRNA agents 649 uugguaacuu uugugaauua
ggc 23 650 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 650 gguaacuuuu
gugaauuagn n 21 651 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 651 cuaauucaca
aaaguuaccn n 21 652 23 RNA Artificial Sequence Exemplary iRNA
agents 652 ugguaacuuu ugugaauuag gcu 23 653 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 653 guaacuuuug ugaauuaggn n 21 654 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 654 ccuaauucac aaaaguuacn n 21 655 23 RNA
Artificial Sequence Exemplary iRNA agents 655 gguaacuuuu gugaauuagg
cug 23 656 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 656 uaacuuuugu
gaauuaggcn n 21 657 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 657 gccuaauuca
caaaaguuan n 21 658 23 RNA Artificial Sequence Exemplary iRNA
agents 658 guaacuuuug ugaauuaggc ugu 23 659 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 659 aacuuuugug aauuaggcun n 21 660 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 660 agccuaauuc acaaaaguun n 21 661 23 RNA
Artificial Sequence Exemplary iRNA agents 661 uaacuuuugu gaauuaggcu
gua 23 662 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 662 acuuuuguga
auuaggcugn n 21 663 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 663 cagccuaauu
cacaaaagun n 21 664 23 RNA Artificial Sequence Exemplary iRNA
agents 664 aacuuuugug aauuaggcug uaa 23 665 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 665 cuuuugugaa uuaggcugun n 21 666 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 666 acagccuaau ucacaaaagn n 21 667 23 RNA
Artificial Sequence Exemplary iRNA agents 667 acuuuuguga auuaggcugu
aac 23 668 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 668 uuuugugaau
uaggcuguan n 21 669 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 669 uacagccuaa
uucacaaaan n 21 670 23 RNA Artificial Sequence Exemplary iRNA
agents 670 cuuuugugaa uuaggcugua acu 23 671 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 671 uuugugaauu aggcuguaan n 21 672 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 672 uuacagccua auucacaaan n 21 673 23 RNA
Artificial Sequence Exemplary iRNA agents 673 uuuugugaau uaggcuguaa
cua 23 674 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 674 uugugaauua
ggcuguaacn n 21 675 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 675 guuacagccu
aauucacaan n 21 676 23 RNA Artificial Sequence Exemplary iRNA
agents 676 uuugugaauu aggcuguaac uac 23 677 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 677 ugugaauuag gcuguaacun n 21 678 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 678 aguuacagcc uaauucacan n 21 679 23 RNA
Artificial Sequence Exemplary iRNA agents 679 uugugaauua
ggcuguaacu acu 23 680 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 680 gugaauuagg
cuguaacuan n 21 681 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 681 uaguuacagc
cuaauucacn n 21 682 23 RNA Artificial Sequence Exemplary iRNA
agents 682 ugugaauuag gcuguaacua cuu 23 683 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 683 ugaauuaggc uguaacuacn n 21 684 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 684 guaguuacag ccuaauucan n 21 685 23 RNA
Artificial Sequence Exemplary iRNA agents 685 gugaauuagg cuguaacuac
uuu 23 686 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 686 gaauuaggcu
guaacuacun n 21 687 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 687 aguaguuaca
gccuaauucn n 21 688 23 RNA Artificial Sequence Exemplary iRNA
agents 688 ugaauuaggc uguaacuacu uua 23 689 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 689 aauuaggcug uaacuacuun n 21 690 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 690 aaguaguuac agccuaauun n 21 691 23 RNA
Artificial Sequence Exemplary iRNA agents 691 gaauuaggcu guaacuacuu
uau 23 692 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 692 auuaggcugu
aacuacuuun n 21 693 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 693 aaaguaguua
cagccuaaun n 21 694 23 RNA Artificial Sequence Exemplary iRNA
agents 694 aauuaggcug uaacuacuuu aua 23 695 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 695 uuaggcugua acuacuuuan n 21 696 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 696 uaaaguaguu acagccuaan n 21 697 23 RNA
Artificial Sequence Exemplary iRNA agents 697 auuaggcugu aacuacuuua
uaa 23 698 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 698 uaggcuguaa
cuacuuuaun n 21 699 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 699 auaaaguagu
uacagccuan n 21 700 23 RNA Artificial Sequence Exemplary iRNA
agents 700 uuaggcugua acuacuuuau aac 23 701 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 701 aggcuguaac uacuuuauan n 21 702 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 702 uauaaaguag uuacagccun n 21 703 23 RNA
Artificial Sequence Exemplary iRNA agents 703 uaggcuguaa cuacuuuaua
acu 23 704 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 704 ggcuguaacu
acuuuauaan n 21 705 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 705 uuauaaagua
guuacagccn n 21 706 23 RNA Artificial Sequence Exemplary iRNA
agents 706 aggcuguaac uacuuuauaa cua 23 707 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 707 gcuguaacua cuuuauaacn n 21 708 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 708 guuauaaagu aguuacagcn n 21 709 23 RNA
Artificial Sequence Exemplary iRNA agents 709 ggcuguaacu acuuuauaac
uaa 23 710 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 710 cuguaacuac
uuuauaacun n 21 711 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 711 aguuauaaag
uaguuacagn n 21 712 23 RNA Artificial Sequence Exemplary iRNA
agents 712 gcuguaacua cuuuauaacu aac 23 713 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 713 uguaacuacu uuauaacuan n 21 714 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 714 uaguuauaaa guaguuacan n 21 715 23 RNA
Artificial Sequence Exemplary iRNA agents 715 cuguaacuac uuuauaacua
aca 23 716 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 716 guaacuacuu
uauaacuaan n 21 717 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 717 uuaguuauaa
aguaguuacn n 21 718 23 RNA Artificial Sequence Exemplary iRNA
agents 718 uguaacuacu uuauaacuaa cau 23 719 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 719 uaacuacuuu auaacuaacn n 21 720 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 720 guuaguuaua aaguaguuan n 21 721 23 RNA
Artificial Sequence Exemplary iRNA agents 721 guaacuacuu uauaacuaac
aug 23 722 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 722 aacuacuuua
uaacuaacan n 21 723 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 723 uguuaguuau
aaaguaguun n 21 724 23 RNA Artificial Sequence Exemplary iRNA
agents 724 uaacuacuuu auaacuaaca ugu 23 725 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 725 acuacuuuau aacuaacaun n 21 726 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 726 auguuaguua uaaaguagun n 21 727 23 RNA
Artificial Sequence Exemplary iRNA agents 727 aacuacuuua uaacuaacau
guc 23 728 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 728 cuacuuuaua
acuaacaugn n 21 729 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 729 cauguuaguu
auaaaguagn n 21 730 23 RNA Artificial Sequence Exemplary iRNA
agents 730 acuacuuuau aacuaacaug ucc 23 731 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 731 uacuuuauaa cuaacaugun n 21 732 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 732 acauguuagu uauaaaguan n 21 733 23 RNA
Artificial Sequence Exemplary iRNA agents 733 cuacuuuaua acuaacaugu
ccu 23 734 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 734 acuuuauaac
uaacaugucn n 21 735 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 735 gacauguuag
uuauaaagun n 21 736 23 RNA Artificial Sequence Exemplary iRNA
agents 736 uacuuuauaa cuaacauguc cug 23 737 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 737 cuuuauaacu aacauguccn n 21 738 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 738 ggacauguua guuauaaagn n 21 739 23 RNA
Artificial Sequence Exemplary iRNA agents 739 acuuuauaac uaacaugucc
ugc 23 740 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 740 uuuauaacua
acauguccun n 21 741 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 741 aggacauguu
aguuauaaan n 21 742 23 RNA Artificial Sequence Exemplary iRNA
agents 742 cuuuauaacu aacauguccu gcc 23 743 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 743 uuauaacuaa cauguccugn n 21 744 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 744 caggacaugu uaguuauaan n 21 745 23 RNA
Artificial Sequence Exemplary iRNA agents 745 uuuauaacua acauguccug
ccu 23 746 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 746 uauaacuaac
auguccugcn n 21 747 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 747 gcaggacaug
uuaguuauan n 21 748 23 RNA Artificial Sequence Exemplary iRNA
agents 748 uuauaacuaa cauguccugc cua 23 749 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 749 auaacuaaca uguccugccn n 21 750 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 750 ggcaggacau guuaguuaun n 21 751 23 RNA
Artificial Sequence Exemplary iRNA agents 751 uauaacuaac auguccugcc
uau 23 752 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 752 uaacuaacau
guccugccun n 21 753 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 753 aggcaggaca
uguuaguuan n 21 754 23 RNA Artificial Sequence Exemplary iRNA
agents 754 auaacuaaca uguccugccu auu 23 755 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 755 aacuaacaug uccugccuan n 21 756 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 756 uaggcaggac auguuaguun n 21 757 23 RNA
Artificial Sequence Exemplary iRNA agents 757 uggcagaguu acaguucugu
ggu 23 758 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 758 gcagaguuac
aguucugugn n 21 759 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 759 cacagaacug
uaacucugcn n 21 760 23 RNA Artificial Sequence Exemplary iRNA
agents 760 ggcagaguua caguucugug guu 23 761 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 761 cagaguuaca guucuguggn n 21 762 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 762 ccacagaacu guaacucugn n 21 763 23 RNA
Artificial Sequence Exemplary iRNA agents 763 gcagaguuac aguucugugg
uuu 23 764 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 764 agaguuacag
uucuguggun n 21 765 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 765 accacagaac
uguaacucun n 21 766 23 RNA Artificial Sequence Exemplary iRNA
agents 766 uuucauguua guuaccuuau agu 23 767 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 767 ucauguuagu uaccuuauan n 21 768 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 768 uauaagguaa cuaacaugan n 21 769 23 RNA
Artificial Sequence Exemplary iRNA agents 769 uucauguuag uuaccuuaua
guu 23 770 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 770 cauguuaguu
accuuauagn n 21 771 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 771 cuauaaggua
acuaacaugn n 21 772 23 RNA Artificial Sequence Exemplary iRNA
agents 772 ucauguuagu uaccuuauag uua 23 773 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 773 auguuaguua ccuuauagun n 21 774 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 774 acuauaaggu aacuaacaun n 21 775 23 RNA
Artificial Sequence Exemplary iRNA agents 775 cauguuaguu accuuauagu
uac 23 776 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 776 uguuaguuac
cuuauaguun n 21 777 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 777 aacuauaagg
uaacuaacan n 21 778 23 RNA Artificial Sequence Exemplary iRNA
agents 778 auguuaguua ccuuauaguu acu 23 779 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 779 guuaguuacc uuauaguuan n 21 780 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 780 uaacuauaag guaacuaacn n 21 781 23 RNA
Artificial Sequence Exemplary iRNA agents 781 uguuaguuac cuuauaguua
cug 23 782 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 782 uuaguuaccu
uauaguuacn n 21 783 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 783 guaacuauaa
gguaacuaan n 21 784 23 RNA Artificial Sequence Exemplary iRNA
agents 784 guuaguuacc uuauaguuac ugu 23 785 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 785 uaguuaccuu auaguuacun n 21 786 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 786 aguaacuaua agguaacuan n 21 787 23 RNA
Artificial Sequence Exemplary iRNA agents 787 uuaguuaccu uauaguuacu
gug 23 788 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 788 aguuaccuua
uaguuacugn n 21 789 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 789 caguaacuau
aagguaacun n 21 790 23 RNA Artificial Sequence Exemplary iRNA
agents 790 uaguuaccuu auaguuacug ugu 23 791 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 791 guuaccuuau aguuacugun n 21 792 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20,
21 n = 2'-deoxy-thymidine 792 acaguaacua uaagguaacn n 21 793 23 RNA
Artificial Sequence Exemplary iRNA agents 793 aguuaccuua uaguuacugu
gua 23 794 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 794 uuaccuuaua
guuacugugn n 21 795 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 795 cacaguaacu
auaagguaan n 21 796 23 RNA Artificial Sequence Exemplary iRNA
agents 796 guuaccuuau aguuacugug uaa 23 797 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 797 uaccuuauag uuacugugun n 21 798 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 798 acacaguaac uauaagguan n 21 799 23 RNA
Artificial Sequence Exemplary iRNA agents 799 uuaccuuaua guuacugugu
aau 23 800 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 800 accuuauagu
uacuguguan n 21 801 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 801 uacacaguaa
cuauaaggun n 21 802 23 RNA Artificial Sequence Exemplary iRNA
agents 802 uaccuuauag uuacugugua auu 23 803 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 803 ccuuauaguu acuguguaan n 21 804 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 804 uuacacagua acuauaaggn n 21 805 23 RNA
Artificial Sequence Exemplary iRNA agents 805 accuuauagu uacuguguaa
uua 23 806 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 806 cuuauaguua
cuguguaaun n 21 807 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 807 auuacacagu
aacuauaagn n 21 808 23 RNA Artificial Sequence Exemplary iRNA
agents 808 ccuuauaguu acuguguaau uag 23 809 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 809 uuauaguuac uguguaauun n 21 810 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 810 aauuacacag uaacuauaan n 21 811 23 RNA
Artificial Sequence Exemplary iRNA agents 811 cuuauaguua cuguguaauu
agu 23 812 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 812 uauaguuacu
guguaauuan n 21 813 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 813 uaauuacaca
guaacuauan n 21 814 23 RNA Artificial Sequence Exemplary iRNA
agents 814 uuauaguuac uguguaauua gug 23 815 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 815 auaguuacug uguaauuagn n 21 816 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 816 cuaauuacac aguaacuaun n 21 817 23 RNA
Artificial Sequence Exemplary iRNA agents 817 uauaguuacu guguaauuag
ugc 23 818 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 818 uaguuacugu
guaauuagun n 21 819 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 819 acuaauuaca
caguaacuan n 21 820 23 RNA Artificial Sequence Exemplary iRNA
agents 820 auaguuacug uguaauuagu gcc 23 821 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 821 aguuacugug uaauuagugn n 21 822 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 822 cacuaauuac acaguaacun n 21 823 23 RNA
Artificial Sequence Exemplary iRNA agents 823 uaguuacugu guaauuagug
cca 23 824 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 824 guuacugugu
aauuagugcn n 21 825 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 825 gcacuaauua
cacaguaacn n 21 826 23 RNA Artificial Sequence Exemplary iRNA
agents 826 aguuacugug uaauuagugc cac 23 827 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 827 uuacugugua auuagugccn n 21 828 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 828 ggcacuaauu acacaguaan n 21 829 23 RNA
Artificial Sequence Exemplary iRNA agents 829 guuacugugu aauuagugcc
acu 23 830 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 830 uacuguguaa
uuagugccan n 21 831 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 831 uggcacuaau
uacacaguan n 21 832 23 RNA Artificial Sequence Exemplary iRNA
agents 832 uuacugugua auuagugcca cuu 23 833 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 833 acuguguaau uagugccacn n 21 834 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 834 guggcacuaa uuacacagun n 21 835 23 RNA
Artificial Sequence Exemplary iRNA agents 835 uacuguguaa uuagugccac
uua 23 836 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 836 cuguguaauu
agugccacun n 21 837 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 837 aguggcacua
auuacacagn n 21 838 23 RNA Artificial Sequence Exemplary iRNA
agents 838 acuguguaau uagugccacu uaa 23 839 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 839 uguguaauua gugccacuun n 21 840 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 840 aaguggcacu aauuacacan n 21 841 23 RNA
Artificial Sequence Exemplary iRNA agents 841 cuguguaauu agugccacuu
aau 23 842 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 842 guguaauuag
ugccacuuan n 21 843 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 843 uaaguggcac
uaauuacacn n 21 844 23 RNA Artificial Sequence Exemplary iRNA
agents 844 uguguaauua gugccacuua aug 23 845 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 845 uguaauuagu gccacuuaan n 21 846 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 846 uuaaguggca cuaauuacan n 21 847 23 RNA
Artificial Sequence Exemplary iRNA agents 847 guguaauuag ugccacuuaa
ugu 23 848 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 848 guaauuagug
ccacuuaaun n 21 849 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 849 auuaaguggc
acuaauuacn n 21 850 23 RNA Artificial Sequence Exemplary iRNA
agents 850 uguaauuagu gccacuuaau gua 23 851 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 851 uaauuagugc cacuuaaugn n 21 852 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 852 cauuaagugg cacuaauuan n 21 853 23 RNA
Artificial Sequence Exemplary iRNA agents 853 guaauuagug ccacuuaaug
uau 23 854 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 854 aauuagugcc
acuuaaugun n 21 855 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 855 acauuaagug
gcacuaauun n 21 856 23 RNA Artificial Sequence Exemplary iRNA
agents 856 uaauuagugc cacuuaaugu aug 23 857 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 857 auuagugcca cuuaauguan n 21 858 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 858 uacauuaagu ggcacuaaun n 21 859 23 RNA
Artificial Sequence Exemplary iRNA agents 859 aauuagugcc acuuaaugua
ugu 23 860 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 860 uuagugccac
uuaauguaun n 21 861 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 861 auacauuaag
uggcacuaan n 21 862 23 RNA Artificial Sequence Exemplary iRNA
agents 862 auuagugcca cuuaauguau guu 23 863 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 863 uagugccacu uaauguaugn n 21 864 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 864 cauacauuaa guggcacuan n 21 865 23 RNA
Artificial Sequence Exemplary iRNA agents 865 uuagugccac uuaauguaug
uua 23 866 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 866 agugccacuu
aauguaugun n 21 867 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 867 acauacauua
aguggcacun n 21 868 23 RNA Artificial Sequence Exemplary iRNA
agents 868 uagugccacu uaauguaugu uac 23 869 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 869 gugccacuua auguauguun n 21 870 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 870 aacauacauu aaguggcacn n 21 871 23 RNA
Artificial Sequence Exemplary iRNA agents 871 agugccacuu aauguauguu
acc 23 872 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 872 ugccacuuaa
uguauguuan n 21 873 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 873 uaacauacau
uaaguggcan n 21 874 23 RNA Artificial Sequence Exemplary iRNA
agents 874 gugccacuua auguauguua cca 23 875 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 875 gccacuuaau guauguuacn n 21 876 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 876 guaacauaca uuaaguggcn n 21 877 23 RNA
Artificial Sequence Exemplary iRNA agents 877 ugccacuuaa uguauguuac
caa 23 878 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 878 ccacuuaaug
uauguuaccn n 21 879 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 879 gguaacauac
auuaaguggn n 21 880 23 RNA Artificial Sequence Exemplary iRNA
agents 880 gccacuuaau guauguuacc aaa 23 881 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 881 cacuuaaugu auguuaccan n 21 882 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 882 ugguaacaua cauuaagugn n 21 883 23 RNA
Artificial Sequence Exemplary iRNA agents 883 ccacuuaaug uauguuacca
aaa 23 884 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 884 acuuaaugua
uguuaccaan n 21 885 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 885 uugguaacau
acauuaagun n 21 886 23 RNA Artificial Sequence Exemplary iRNA
agents 886 cacuuaaugu auguuaccaa aaa 23 887 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 887 cuuaauguau guuaccaaan n 21 888 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 888 uuugguaaca uacauuaagn n 21 889 23 RNA
Artificial Sequence Exemplary iRNA agents 889 acuuaaugua uguuaccaaa
aau 23 890 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 890 uuaauguaug
uuaccaaaan n 21 891 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 891 uuuugguaac
auacauuaan n 21 892 23 RNA Artificial Sequence Exemplary iRNA
agents 892 cuuaauguau guuaccaaaa aua 23 893 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 893 uaauguaugu uaccaaaaan n 21 894 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 894 uuuuugguaa cauacauuan n 21 895 23 RNA
Artificial Sequence Exemplary iRNA agents 895 aauaaauaua ucuaccccag
acu 23 896 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 896 uaaauauauc
uaccccagan n 21 897 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 897 ucugggguag
auauauuuan n 21 898 23 RNA Artificial Sequence Exemplary iRNA
agents 898 auaaauauau cuaccccaga cua 23 899 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 899 aaauauaucu accccagacn n 21 900 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 900 gucuggggua gauauauuun n 21 901 23 RNA
Artificial Sequence Exemplary iRNA agents 901 uaaauauauc uaccccagac
uag 23 902 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 902 aauauaucua
ccccagacun n 21 903 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 903 agucuggggu
agauauauun n 21 904 23 RNA Artificial Sequence Exemplary iRNA
agents 904 aaauauaucu accccagacu aga 23 905 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 905 auauaucuac cccagacuan n 21 906 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 906 uagucugggg uagauauaun n 21 907 23 RNA
Artificial Sequence Exemplary iRNA agents 907 aauauaucua ccccagacua
gau 23 908 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 908 uauaucuacc
ccagacuagn n 21 909 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 909 cuagucuggg
guagauauan n 21 910 23 RNA Artificial Sequence Exemplary iRNA
agents 910 auauaucuac cccagacuag aug 23 911 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 911 auaucuaccc cagacuagan n 21 912 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 912 ucuagucugg gguagauaun n 21 913 23 RNA
Artificial Sequence Exemplary iRNA agents 913 uauaucuacc ccagacuaga
ugu 23 914 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 914 uaucuacccc
agacuagaun n 21 915 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 915 aucuagucug
ggguagauan n 21 916 23 RNA Artificial Sequence Exemplary iRNA
agents 916 auaucuaccc cagacuagau gua 23 917 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 917 aucuacccca gacuagaugn n 21 918 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 918 caucuagucu gggguagaun n 21 919 23 RNA
Artificial Sequence Exemplary iRNA agents 919 uaucuacccc agacuagaug
uag 23 920 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 920 ucuaccccag
acuagaugun n 21 921 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 921 acaucuaguc
ugggguagan n 21 922 23 RNA Artificial Sequence Exemplary iRNA
agents 922 aucuacccca gacuagaugu agu 23 923 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 923 cuaccccaga cuagauguan n 21 924 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 924 uacaucuagu cugggguagn n 21 925 23 RNA
Artificial Sequence Exemplary iRNA agents 925 ucuaccccag acuagaugua
gua 23 926 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 926 uaccccagac
uagauguagn n 21 927 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 927 cuacaucuag
ucugggguan n 21 928 23 RNA Artificial Sequence Exemplary iRNA
agents 928 cuaccccaga cuagauguag uau 23 929 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 929 accccagacu agauguagun n 21 930 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 930 acuacaucua gucuggggun n 21 931 23 RNA
Artificial Sequence Exemplary iRNA agents 931 uaccccagac uagauguagu
auu 23 932 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 932 ccccagacua
gauguaguan n 21 933 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 933 uacuacaucu
agucuggggn n 21 934 23 RNA Artificial Sequence Exemplary iRNA
agents 934 accccagacu agauguagua uuu 23 935 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 935 cccagacuag auguaguaun n 21 936 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 936 auacuacauc uagucugggn n 21 937 23 RNA
Artificial Sequence Exemplary iRNA agents 937 ccccagacua gauguaguau
uuu 23 938 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 938 ccagacuaga
uguaguauun n 21 939 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 939 aauacuacau
cuagucuggn n 21 940 23 RNA Artificial Sequence Exemplary iRNA
agents 940 cccagacuag auguaguauu uuu 23 941 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 941 cagacuagau guaguauuun n 21 942 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 942 aaauacuaca ucuagucugn n 21 943 23 RNA
Artificial Sequence Exemplary iRNA agents 943 ccagacuaga uguaguauuu
uuu 23 944 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 944 agacuagaug
uaguauuuun n 21 945 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 945 aaaauacuac
aucuagucun n 21 946 23 RNA Artificial Sequence Exemplary iRNA
agents 946 cagacuagau guaguauuuu uug 23 947 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 947 gacuagaugu aguauuuuun n 21 948 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 948 aaaaauacua caucuagucn n 21 949 23 RNA
Artificial Sequence Exemplary iRNA agents 949 agacuagaug uaguauuuuu
ugu 23 950 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 950 acuagaugua
guauuuuuun n 21 951 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 951 aaaaaauacu
acaucuagun n 21 952 23 RNA Artificial Sequence Exemplary iRNA
agents 952 gacuagaugu aguauuuuuu gua 23 953 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 953 cuagauguag uauuuuuugn n 21 954 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 954 caaaaaauac uacaucuagn n 21 955 23 RNA
Artificial Sequence Exemplary iRNA agents 955 acuagaugua guauuuuuug
uau 23 956 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 956 uagauguagu
auuuuuugun n 21 957 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 957 acaaaaaaua
cuacaucuan n 21 958 23 RNA Artificial Sequence Exemplary iRNA
agents 958 cuagauguag uauuuuuugu aua 23 959 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 959 agauguagua uuuuuuguan n 21 960 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 960 uacaaaaaau acuacaucun n 21 961 23 RNA
Artificial Sequence Exemplary iRNA agents 961 uagauguagu auuuuuugua
uaa 23 962 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 962 gauguaguau
uuuuuguaun n 21 963 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 963 auacaaaaaa
uacuacaucn n 21 964 23 RNA Artificial Sequence Exemplary iRNA
agents 964 agauguagua uuuuuuguau aau 23 965 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 965 auguaguauu uuuuguauan n 21 966 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 966 uauacaaaaa auacuacaun n 21 967 23 RNA
Artificial Sequence Exemplary iRNA agents 967 gauguaguau uuuuuguaua
auu 23 968 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 968 uguaguauuu
uuuguauaan n 21 969 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 969 uuauacaaaa
aauacuacan n 21 970 23 RNA Artificial Sequence Exemplary iRNA
agents 970 auguaguauu uuuuguauaa uug 23 971 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 971 guaguauuuu uuguauaaun n 21 972 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 972 auuauacaaa aaauacuacn n 21 973 23 RNA
Artificial Sequence Exemplary iRNA agents 973 uguaguauuu uuuguauaau
ugg 23 974 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 974 uaguauuuuu
uguauaauun n 21 975 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 975 aauuauacaa
aaaauacuan n 21 976 23 RNA Artificial Sequence Exemplary iRNA
agents 976 guaguauuuu uuguauaauu gga 23 977 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 977 aguauuuuuu guauaauugn n 21 978 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 978 caauuauaca aaaaauacun n 21 979 23 RNA
Artificial Sequence Exemplary iRNA agents 979 uaguauuuuu uguauaauug
gau 23 980 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 980 guauuuuuug
uauaauuggn n 21 981 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 981 ccaauuauac
aaaaaauacn n 21 982 23 RNA Artificial Sequence Exemplary iRNA
agents 982 aguauuuuuu guauaauugg auu 23 983 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 983 uauuuuuugu auaauuggan n 21 984 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 984 uccaauuaua caaaaaauan n 21 985 23 RNA
Artificial Sequence Exemplary iRNA agents 985 guauuuuuug uauaauugga
uuu 23 986 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 986 auuuuuugua
uaauuggaun n 21 987 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 987 auccaauuau
acaaaaaaun n 21 988 23 RNA Artificial Sequence Exemplary iRNA
agents 988 uauuuuuugu auaauuggau uuc 23 989 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 989 uuuuuuguau aauuggauun n 21 990 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 990 aauccaauua uacaaaaaan n 21 991 23 RNA
Artificial Sequence Exemplary iRNA agents 991 auuuuuugua uaauuggauu
ucc 23 992 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 992 uuuuuguaua
auuggauuun n 21 993 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 993 aaauccaauu
auacaaaaan n 21 994 23 RNA Artificial Sequence Exemplary iRNA
agents 994 uuuuuuguau aauuggauuu ccu 23 995 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 995 uuuuguauaa uuggauuucn n 21 996 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 996 gaaauccaau uauacaaaan n 21 997 23 RNA
Artificial Sequence Exemplary iRNA agents 997 uuuuuguaua auuggauuuc
cua 23 998 21 DNA Artificial Sequence Exemplary iRNA agents
misc_feature 20, 21 n = 2'-deoxy-thymidine 998 uuuguauaau
uggauuuccn n 21 999 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 999 ggaaauccaa
uuauacaaan n 21 1000 23 RNA Artificial Sequence Exemplary iRNA
agents 1000 uuuuguauaa uuggauuucc uaa 23 1001 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1001 uuguauaauu ggauuuccun n 21 1002 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1002 aggaaaucca auuauacaan n 21 1003 23 RNA
Artificial Sequence Exemplary iRNA agents 1003 uuuguauaau
uggauuuccu aau 23 1004 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1004 uguauaauug
gauuuccuan n 21 1005 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1005 uaggaaaucc
aauuauacan n 21 1006 23 RNA Artificial Sequence Exemplary iRNA
agents 1006 uuguauaauu ggauuuccua aua 23 1007 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1007 guauaauugg auuuccuaan n 21 1008 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1008 uuaggaaauc caauuauacn n 21 1009 23 RNA
Artificial Sequence Exemplary iRNA agents 1009 uguauaauug
gauuuccuaa uac 23 1010 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1010 uauaauugga
uuuccuaaun n 21 1011 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1011 auuaggaaau
ccaauuauan n 21 1012 23 RNA Artificial Sequence Exemplary iRNA
agents 1012 guauuuggaa auaaagucag aug 23 1013 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1013 auuuggaaau aaagucagan n 21 1014 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1014 ucugacuuua uuuccaaaun n 21 1015 23 RNA
Artificial Sequence Exemplary iRNA agents 1015 uauuuggaaa
uaaagucaga ugg 23 1016 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1016 uuuggaaaua
aagucagaun n 21 1017 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1017 aucugacuuu
auuuccaaan n 21 1018 23 RNA
Artificial Sequence Exemplary iRNA agents 1018 auuuggaaau
aaagucagau gga 23 1019 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1019 uuggaaauaa
agucagaugn n 21 1020 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1020 caucugacuu
uauuuccaan n 21 1021 23 RNA Artificial Sequence Exemplary iRNA
agents 1021 uuuggaaaua aagucagaug gaa 23 1022 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1022 uggaaauaaa gucagauggn n 21 1023 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1023 ccaucugacu uuauuuccan n 21 1024 23 RNA
Artificial Sequence Exemplary iRNA agents 1024 uuggaaauaa
agucagaugg aaa 23 1025 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1025 ggaaauaaag
ucagauggan n 21 1026 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1026 uccaucugac
uuuauuuccn n 21 1027 23 RNA Artificial Sequence Exemplary iRNA
agents 1027 uggaaauaaa gucagaugga aaa 23 1028 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1028 gaaauaaagu cagauggaan n 21 1029 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1029 uuccaucuga cuuuauuucn n 21 1030 23 RNA
Artificial Sequence Exemplary iRNA agents 1030 ucccucccag
aggagccacc agu 23 1031 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1031 ccucccagag
gagccaccan n 21 1032 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1032 ugguggcucc
ucugggaggn n 21 1033 23 RNA Artificial Sequence Exemplary iRNA
agents 1033 cccucccaga ggagccacca guu 23 1034 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1034 cucccagagg agccaccagn n 21 1035 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1035 cugguggcuc cucugggagn n 21 1036 23 RNA
Artificial Sequence Exemplary iRNA agents 1036 ccucccagag
gagccaccag uuc 23 1037 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1037 ucccagagga
gccaccagun n 21 1038 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1038 acugguggcu
ccucugggan n 21 1039 23 RNA Artificial Sequence Exemplary iRNA
agents 1039 cucccagagg agccaccagu ucu 23 1040 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1040 cccagaggag ccaccaguun n 21 1041 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1041 aacugguggc uccucugggn n 21 1042 23 RNA
Artificial Sequence Exemplary iRNA agents 1042 ucccagagga
gccaccaguu cuc 23 1043 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1043 ccagaggagc
caccaguucn n 21 1044 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1044 gaacuggugg
cuccucuggn n 21 1045 23 RNA Artificial Sequence Exemplary iRNA
agents 1045 cccagaggag ccaccaguuc uca 23 1046 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1046 cagaggagcc accaguucun n 21 1047 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1047 agaacuggug gcuccucugn n 21 1048 23 RNA
Artificial Sequence Exemplary iRNA agents 1048 cuucucucca
gcugacuaaa cuu 23 1049 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1049 ucucuccagc
ugacuaaacn n 21 1050 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1050 guuuagucag
cuggagagan n 21 1051 23 RNA Artificial Sequence Exemplary iRNA
agents 1051 uucuguacca guuaauuuuu cca 23 1052 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1052 cuguaccagu uaauuuuucn n 21 1053 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1053 gaaaaauuaa cugguacagn n 21 1054 23 RNA
Artificial Sequence Exemplary iRNA agents 1054 ucuguaccag
uuaauuuuuc caa 23 1055 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1055 uguaccaguu
aauuuuuccn n 21 1056 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1056 ggaaaaauua
acugguacan n 21 1057 23 RNA Artificial Sequence Exemplary iRNA
agents 1057 cuguaccagu uaauuuuucc aac 23 1058 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1058 guaccaguua auuuuuccan n 21 1059 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1059 uggaaaaauu aacugguacn n 21 1060 23 RNA
Artificial Sequence Exemplary iRNA agents 1060 uguaccaguu
aauuuuucca acu 23 1061 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1061 uaccaguuaa
uuuuuccaan n 21 1062 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1062 uuggaaaaau
uaacugguan n 21 1063 23 RNA Artificial Sequence Exemplary iRNA
agents 1063 guaccaguua auuuuuccaa cua 23 1064 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1064 accaguuaau uuuuccaacn n 21 1065 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1065 guuggaaaaa uuaacuggun n 21 1066 23 RNA
Artificial Sequence Exemplary iRNA agents 1066 uaccaguuaa
uuuuuccaac uac 23 1067 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1067 ccaguuaauu
uuuccaacun n 21 1068 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1068 aguuggaaaa
auuaacuggn n 21 1069 23 RNA Artificial Sequence Exemplary iRNA
agents 1069 accaguuaau uuuuccaacu acu 23 1070 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1070 caguuaauuu uuccaacuan n 21 1071 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1071 uaguuggaaa aauuaacugn n 21 1072 23 RNA
Artificial Sequence Exemplary iRNA agents 1072 uaauagaaua
aaggcaguuu ucu 23 1073 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1073 auagaauaaa
ggcaguuuun n 21 1074 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1074 aaaacugccu
uuauucuaun n 21 1075 23 RNA Artificial Sequence Exemplary iRNA
agents 1075 aauagaauaa aggcaguuuu cua 23 1076 21 DNA Artificial
Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1076 uagaauaaag gcaguuuucn n 21 1077 21 DNA
Artificial Sequence Exemplary iRNA agents misc_feature 20, 21 n =
2'-deoxy-thymidine 1077 gaaaacugcc uuuauucuan n 21 1078 23 RNA
Artificial Sequence Exemplary iRNA agents 1078 auagaauaaa
ggcaguuuuc uaa 23 1079 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1079 agaauaaagg
caguuuucun n 21 1080 21 DNA Artificial Sequence Exemplary iRNA
agents misc_feature 20, 21 n = 2'-deoxy-thymidine 1080 agaaaacugc
cuuuauucun n 21 1081 21 DNA Artificial Sequence Synthetically
generated oligonucleotide misc_feature 20, 21 n =
2'-deoxy-thymidine 1081 gauuaugacc gucugaggcn n 21 1082 21 DNA
Artificial Sequence Synthetically generated oligonucleotide
misc_feature 20, 21 n = 2'-deoxy-thymidine 1082 gccucagucg
gucauaaucn n 21 1083 21 DNA Artificial Sequence Synthetically
generated oligonucleotide misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1083 ggaucuucgg aaugaugagn n 21 1084 21 DNA Artificial Sequence
Synthetically generated oligonucleotide misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1084 cucaucauuc cgaagauccn n 21 1085 21
DNA Artificial Sequence Synthetically generated oligonucleotide
misc_feature 20, 21 n = 2'-deoxy-thymidine 1085 agaccaaaga
cggagugagn n 21 1086 21 DNA Artificial Sequence Synthetically
generated oligonucleotide misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1086 cucacuccgu cuuuggucun n 21 1087 21 DNA Artificial Sequence
Synthetically generated oligonucleotide misc_feature 20, 21 n =
2'-deoxy-thymidine 1087 ugaagcagga gccgguaaan n 21 1088 21 DNA
Artificial Sequence Synthetically generated oligonucleotide
misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1088 uuuaccggcu
ccugcuucan n 21 1089 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 2, 3, 5, 6, 9, 11, 12,
13,19 2'- O-methyl modification corresponding base misc_feature 20,
n = 2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1089 gcuaccagua uuuagaagcn n 21 1090 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 6, 10, 16 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1090 gcuucuaaau
acugguagcn n 21 1091 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 2, 4, 5, 8, 10, 11, 12,
18, 19 2'- O-methyl modification corresponding base misc_feature 20
n = 2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1091 cuaccaguau uuagaagccn n 21 1092 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 7, 11, 17 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1092 ggcuucuaaa
uacugguagn n 21 1093 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 2, 3, 5, 8, 9, 11, 12, 13,
14, 16, 19 2'- O-methyl modification corresponding base
misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1093 gcuguaacua
cuuuauaacn n 21 1094 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 3, 5, 10, 14, 16 2'-
O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1094 guuauaaagu aguuacagcn n 21 1095 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 2, 3, 5, 6, 8, 10, 13, 14, 17, 19 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1095 guuacugugu aauuagugcn n 21 1096 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 5, 9, 11, 13, 16 2'- O-methyl modification
corresponding base misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1096 gcacuaauua cacaguaacn n 21 1097 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 1, 2, 4, 5,
6, 9, 11, 13, 15, 16, 18, 19 2'- O-methyl modification
corresponding base misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1097 ccacuuaaug uauguuaccn n 21 1098 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 3, 6, 8, 10,
13 2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1098 gguaacauac auuaaguggn n 21 1099 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 4, 5, 6, 7, 10, 13, 14, 15 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1099 cagcccugau aguuuagaan n 21 1100 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 4, 9, 12 2'- O-methyl modification corresponding base
misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1100 uucuaaacua
ucagggcugn n 21 1101 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 2, 3, 4, 5, 8, 11, 12, 13
2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1101 gcccugauag uuuagaaaan n 21 1102 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 6, 11, 14 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1102 uuuucuaaac
uaucagggcn n 21 1103 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 2, 3, 4, 7, 10, 11, 12,
19 2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1103 cccugauagu uuagaaaacn n 21 1104 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 7, 12, 15 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 20 n =
2'-deoxy-thymidine 1104 guuuucuaaa cuaucagggn n 21 1105 21 DNA
Artificial Sequence Synthetically generated oligonucleotide
modified_base 3, 6, 7, 8, 15, 17, 18, 19 2'- O-methyl modification
corresponding base misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1105 gauaguuuag
aaaacauccn n 21 1106 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 11, 16 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1106 ggauguuuuc uaaacuaucn n 21 1107 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 4, 5, 6, 13, 15, 16, 17, 18 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1107 uaguuuagaa aacaucccan n 21 1108 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 13, 18 2'- O-methyl modification corresponding base
misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1108 ugggauguuu
ucuaaacuan n 21 1109 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 5, 6, 10, 12, 15, 17,
18, 19 2'- O-methyl modification corresponding base misc_feature 20
n = 2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1109 cagacuagau guaguauuun n 21 1110 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 4, 7, 9, 13 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1110 aaauacuaca
ucuagucugn n 21 1111 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 2, 3, 4, 8, 9, 13, 15,
18 2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1111 ccccagacua gauguaguan n 21 1112 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 4, 6, 10 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1112 uacuacaucu
agucuggggn n 21 1113 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 2, 6, 7, 11, 13, 16, 18,
19 2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1113 ccagacuaga uguaguauun n 21 1114 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 3, 6, 8, 12 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1114 aauacuacau
cuagucuggn n 21 1115 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 2, 3, 7, 8, 12, 14, 17,
19 2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1115 cccagacuag auguaguaun n 21 1116 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 2, 5, 7, 11 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1116 auacuacauc
uagucugggn n 21 1117 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 3, 4, 6, 7, 8, 11, 13,
15, 17, 18 2'- O-methyl modification corresponding base
misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1117 ugccacuuaa
uguauguuan n 21 1118 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 4, 6, 8, 11, 18 2'-
O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1118 uaacauacau uaaguggcan n 21 1119 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 3, 4, 6, 7, 8, 10, 11, 14, 15, 16, 17 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1119 ugcuguuuau uaaucuuagn n 21 1120 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 2, 8, 11, 15, 18 2'- O-methyl modification
corresponding base misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1120 cuaagauuaa uaaacagcan n 21 1121 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 1, 2, 4, 6,
7, 10, 11, 13, 14, 15, 16, 18 2'- O-methyl modification
corresponding base misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1121 ucauguuagu uaccuuauan n 21 1122 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 1, 3, 8, 12,
15 2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1122 uauaagguaa cuaacaugan n 21 1123 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 2, 5, 6, 9, 10, 11, 12, 13,, 14, 15, 18, 19 2'-
O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1123 ccaguuaauu uuuccaacun n 21 1124 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 13 2'- O-methyl modification corresponding base
misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1124 aguuggaaaa
auuaacuggn n 21 1125 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 3, 4, 5, 10, 11, 13, 17,
18 2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1125 uaccuaagau uacaaaucan n 21 1126 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 8, 14, 18 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1126 ugauuuguaa
ucuuagguan n 21 1127 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 2, 3, 4, 6, 7, 9, 10,
13, 15, 16, 17 2'- O-methyl modification corresponding base
misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1127 ucuugcuacc
aguauuuagn n 21 1128 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 2, 6, 12, 15 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1128 cuaaauacug guagcaagan n 21 1129 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 3, 5, 8, 9, 12, 14, 15, 17, 18, 19 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1129 uguguaauua gugccacuun n 21 1130 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 7, 10, 14, 16, 18 2'- O-methyl modification
corresponding base misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1130 aaguggcacu aauuacacan n 21 1131 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 2, 3, 4, 5,
7, 8, 10, 11, 14, 16, 17, 18 2'- O-methyl modification
corresponding base misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1131 aucuugcuac caguauuuan n 21 1132 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 1, 5, 11, 14
2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1132 uaaauacugg uagcaagaun n 21 1133 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 2, 4, 7, 8, 10, 11, 12, 13, 15, 18, 19 2'-
O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1133 cuguaacuac uuuauaacun n 21 1134 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 4, 6, 11, 15, 17 2'- O-methyl modification
corresponding base misc_feature 20 n = 2'-deoxy-thymidine
misc_feature 21 n = 2'-deoxy-thymidine phosphorothioate linkages
1134 aguuauaaag uaguuacagn n 21 1135 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 2, 6, 7, 11,
12, 14, 17, 18 2'- O-methyl modification corresponding base
misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages 1135 gugaauuagg
cuguaacuan n 21 1136 21 DNA Artificial Sequence Synthetically
generated oligonucleotide modified_base 1, 5, 7, 12, 17, 2'-
O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1136 uaguuacagc cuaauucacn n 21 1137 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 2, 4, 5, 8, 10, 11, 12, 18, 19 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages, conjugated
1-{6-[cholester-3-yloxycarbonylamino]-
hexanoyl}-4-hydroxy-pyrrolidin-3-phosphorothioate diester 1137
cuaccaguau uuagaagccn n 21 1138 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 7, 11, 17 2'-
O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1138 ggcuucuaaa uacugguagn n 21 1139 21
DNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 1, 3, 4, 6, 7, 8, 10, 11, 14, 15, 16, 17 2'- O-methyl
modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages, conjugated
1-{6-[cholester-3-yloxycarbonylamino]-
hexanoyl}-4-hydroxy-pyrrolidin-3-phosphorothioate diester 1139
ugcuguuuau uaaucuuagn n 21 1140 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 2, 8, 11, 15,
18 2'- O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages 1140 cuaagauuaa uaaacagcan n 21 1141 46
DNA Rattus norvegicus 1141 ccatttttct gggatgtttt ctaaattttt
ctcttggaaa gaaagt 46 1142 45 DNA Rattus norvegicus 1142 acagaaatgc
ttgacttctg gagttttttc tcttggaaag aaagt 45 1143 41 DNA Rattus
norvegicus 1143 cttcaggttt taccggctcc tttttctctt ggaaagaaag t 41
1144 43 DNA Rattus norvegicus 1144 ctgtttgcca tatctctgcc tttttttctc
ttggaaagaa agt 43 1145 43 DNA Rattus norvegicus 1145 ttggtctttg
ctgaacactc catttttctc ttggaaagaa agt 43 1146 40 DNA Rattus
norvegicus 1146 cccgcgtcta gcttgcagat ttttctcttg gaaagaaagt 40 1147
44 DNA Rattus norvegicus 1147 aggatgatgg gcacatttgg tttttaggca
taggacccgt gtct 44 1148 45 DNA Rattus norvegicus 1148 gccttgtgtg
ctcatcattc ctttttaggc ataggacccg tgtct 45 1149 46 DNA Rattus
norvegicus 1149 tgcttcattt tggctaactc cctttttagg cataggaccc gtgtct
46 1150 44 DNA Rattus norvegicus 1150 tgtacccaaa agcgccaatc
tttttaggca taggacccgt gtct 44 1151 43 DNA Rattus norvegicus 1151
gcagctctcg tggccatctt ttttaggcat aggacccgtg tct 43 1152 44 DNA
Rattus norvegicus 1152 aggcaccccg actttttctt tttttaggca taggacccgt
gtct 44 1153 21 DNA Rattus norvegicus 1153 ctatcagggc tgtcgatgga a
21 1154 23 DNA Rattus norvegicus 1154 gaagatcctt cttgttccca act 23
1155 23 DNA Rattus norvegicus 1155 caaaaacctc tctcactccg tct 23
1156 41 DNA Rattus norvegicus 1156 ccagcttccc attctcagcc tttttctctt
ggaaagaaag t 41 1157 41 DNA Rattus norvegicus 1157 tctcgctcct
ggaagatggt tttttctctt ggaaagaaag t 41 1158 41 DNA Rattus norvegicus
1158 cccatttgat gttagcggga tttttctctt ggaaagaaag t 41 1159 42 DNA
Rattus norvegicus 1159 cggagatgat gacccttttg gtttttctct tggaaagaaa
gt 42 1160 44 DNA Rattus norvegicus 1160 gatgggtttc ccgttgatga
tttttaggca taggacccgt gtct 44 1161 47 DNA Rattus norvegicus 1161
gacatactca gcaccagcat cactttttag gcataggacc cgtgtct 47 1162 44 DNA
Rattus norvegicus 1162 cccagccttc tccatggtgg tttttaggca taggacccgt
gtct 44 1163 21 DNA Rattus norvegicus 1163 ttgactgtgc cgttgaactt g
21 1164 19 DNA Rattus norvegicus 1164 ccccaccctt caggtgagc 19 1165
17 DNA Rattus norvegicus 1165 ggcatcagcg gaagggg 17 1166 21 RNA
Artificial Sequence Synthetically generated oligonucleotide 21
conjugated 1-{6-[cholester-3-
yloxycarbonylamino]-hexanoyl}-4-hydroxy-pyrrolidin-3-
phosphorothioate diester 1166 ccacaugaag cagcacgacu u 21 1167 23
RNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 21 2'- O-methyl modification corresponding base
modified_base 22 2'- O-methyl modification corresponding base
phosphorothioate linkages modified_base 23 phosphorothioate
linkages corresponding base 1167 aagucgugcu gcuucaugug guc 23 1168
21 RNA Artificial Sequence Synthetically generated oligonucleotide
modified_base 20, 21, phosphorothioate linkages corresponding base
1168 ccacaugaag cagcacgacu u 21 1169 23 RNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 21 2'-
O-methyl modification corresponding base modified_base 22 2'-
O-methyl modification corresponding base phosphorothioate linkages
modified_base 23 phosphorothioate linkages corresponding base 1169
aagucgugcu gcuucaugug guc 23 1170 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 1, 2, 3, 5,
7, 8, 12, 14, 15, 16, 17 2'- O-methyl modification corresponding
base misc_feature 20 n = 2'-deoxy-thymidine misc_feature 21 n =
2'-deoxy-thymidine phosphorothioate linkages, conjugated
1-{6-[cholester-3-yloxycarbonylamino]-
hexanoyl}-4-hydroxy-pyrrolidin-3-phosphorothioate diester 1170
cuuacgcuga guacuucgan n 21 1171 21 DNA Artificial Sequence
Synthetically generated oligonucleotide modified_base 7, 11, 16 2'-
O-methyl modification corresponding base misc_feature 20 n =
2'-deoxy-thymidine misc_feature 21 n = 2'-deoxy-thymidine
phosphorothioate linkages, conjugated
1-{6-[cholester-3-yloxycarbonylamino]-
hexanoyl}-4-hydroxy-pyrrolidin-3-phosphorothioate diester 1171
ucgaaguacu cagcguaagn n 21
* * * * *